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Alleles at the HLA-DRB1, -DQA1 and -DQB1 loci confer the greatest genetic predisposition to 
type 1 diabetes (T1D). However, details linking HLA-DQ-mediated predisposition and T cell 
autoreactivity in T1D are scant. An attractive explanation lies in the discovery of a novel form 
of modified peptide generated by covalent crosslinking of proinsulin peptides to other 
pancreatic β-cell peptides, termed hybrid insulin peptides (HIPs). To date, HIPs have been 
identified in b-cells by mass spectrometry (MS) and HIP-reactive CD4+ T cells detected in the 
islets and peripheral blood mononuclear cells (PBMCs) of patients with T1D. I hypothesise that 
the hybrid peptides that have been reported derive from antigen-presenting cell (APC)-
dependent processing of an immunogenic hybrid polypeptide. To address this, I optimised an 
antigen delivery system by conjugating synthetic peptides to carrier proteins, permitting peptide 
targeting to the APC surface and internalisation. Pulsing of Epstein-Barr virus-transformed B 
(EBV B) cell lines homozygous for high-risk HLA alleles with a pokeweed mitogen (PWM)-
peptide conjugate results in HLA-restricted presentation of a GAD65 epitope and T cell 
activation. This effect was not observed using peptide-conjugated anti-DEC205 antibody 
despite evidence of efficient internalisation. Large-scale EBV B cell cultures were pulsed with 
PWM conjugated to a C-peptide:WE14 hybrid polypeptide and HLA-DR and -DQ peptide 
complexes isolated for immunoaffinity purification. MS analysis of eluted peptides from HLA-
DR4, -DR3, -DQ8 and -DQ2 molecules did not identify hybrid epitopes although evidence of 
class II processing was observed. Using FluoroSpot to investigate immunogenicity in T1D 
patient-derived PBMCs, I present data to suggest that immunological processing of hybrid 
polypeptides to generate a cognate hybrid epitope is limited. Together these findings indicate 
hybrid epitopes may not be generated through conventional processing and presentation of a 
long hybrid polypeptide. This project provides novel insight into the mechanism(s) of hybrid 
peptide generation, highlighting unconventional antigen presentation pathways in T1D. 
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CHAPTER 1: INTRODUCTION   
1.1 Type 1 diabetes: an autoimmune disease 
Diabetes mellitus (DM) is a chronic metabolic disorder caused by either insulin deficiency or 
insulin resistance, or both (Kerner et al., 2014). The two most common forms of DM are type 
1 and type 2 diabetes (T1D and T2D, respectively). T1D is an autoimmune disease 
characterised by destruction of insulin-producing b-cells within the pancreas. As a 
consequence, patients present with persistent hyperglycaemia (fasting blood glucose ≥126 
mg/dL, random plasma glucose ≥200 mg/dL, haemoglobin A1C [HbA1c] ≥6.5%) (American 
Diabetes, 2018) resulting in a high risk of metabolic and vascular complications (Bhattarai et 
al., 2019). The absolute requirement for exogenous insulin is a defining feature of T1D 
compared with non-insulin-dependent T2D. Age at diagnosis and the presence of 
autoantibodies in the peripheral blood against glutamic acid decarboxylase (GAD65), zinc 
transporter 8 (ZnT8), insulinoma-associated antigen-2 (IA-2) and insulin (IAA) (Couper and 
Donaghue, 2009; Vermeulen et al., 2011) are also important hallmarks distinguishing T1D from 
T2D. The appearance of autoantibodies in the serum can predate clinical onset of the disease 
by months or even years (Krischer et al., 2003; Riley et al., 1990), thus the role of these 
autoantibodies in disease pathogenesis is still not yet clear. 
 
1.2 Epidemiology 
Onset of T1D most commonly occurs in childhood (van Belle et al., 2011) with a peak incidence 
between 10-14 years of age. However, T1D is no longer considered to be restricted to children 
and adolescents as the disease can manifest at almost any age from early infancy to late 
adulthood (Maahs et al., 2010; Rogers et al., 2017; Thunander et al., 2008). T1D is thought to 
be one of the most common endocrine/metabolic diseases diagnosed in children, representing 
80-90% of diabetic children (Craig et al., 2009). The global incidence of T1D is unknown 
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however, up to 3 million T1D patients were estimated in the USA in 2010 (Chiang et al., 2014), 
equivalent to 1 in 300 by 18 years of age (Shojaeian and Mehri-Ghahfarrokhi, 2018). 
Interestingly, wide variations exist between the incidence rates of different populations with 
China and Venezuela bearing the lowest incidence rates (0.1 per 100 000 per year) and the 
highest incidence observed in Finland and Sardinia (37 per 100 000 per year) (Soltesz et al., 
2007). In general, the incidence rate of T1D is higher in populations in Europe or in populations 
of European origin (e.g. USA, Canada, Australia and New Zealand) (Diamond Project Group, 
2006). Incidence rates in Europe follow a north-south gradient (EURODIAB ACE Study 
Group, 2000; Green et al., 1992) with Sardinia as an exception, being south of Finland and 
having a similarly high incidence rate.  
 
This global variation in incidence can be explained in part by variation between populations in 
the distribution of human leukocyte antigen-DQ (HLA-DQ) genotypes conferring high-risk for 
T1D (Ronningen et al., 2001). Additionally, differences in environmental risk factors such as 
nutrition and lifestyle may be an important determinant of incidence rates (Patterson et al., 
2001) in combination with genetic susceptibility markers. Worldwide epidemiological data 
suggests the incidence of T1D is increasing by 2-5% annually (Shojaeian and Mehri-
Ghahfarrokhi, 2018) therefore the need to better understand the genetic and environmental 
factors involved in the pathogenesis continues to grow.  
 
1.3 Aetiology: genetic and environmental risk factors 
T1D is a multifactorial disease arising from a complex interaction of genetic and environmental 
factors. This is evident by the observation that 90-95% of T1D children carry high-risk HLA 
haplotypes, yet in the general population only 5% or less bearing the haplotype develop T1D 
(Maahs et al., 2010). Genome-wide association studies (GWAS) have identified >60 loci 
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associated with risk of developing T1D (Pociot, 2017). However, the strongest association is 
with genes mapping to the HLA region, specifically those mapping to the HLA class II region, 
with odds ratios ranging from 0.02 to >11 for specific HLA-DR-DQ haplotypes (Erlich et al., 
2008). Class II genes encoding either the HLA-DR4-DQ8 (HLA-DRB1*04–DQA1*03:01–
DQB1*03:02) or HLA-DR3-DQ2 (HLA-DRB1*03:01–DQA1*05:01–DQB1*02:01) 
haplotypes confer the greatest disease risk (odds ratios = ~5) and the risk is ~5-fold higher again 
in individuals who are heterozygous for HLA-DR3-DQ2/DR4-DQ8 haplotypes (Pociot and 
McDermott, 2002). On the contrary, dominant protection from T1D is conferred by possession 
of the HLA-DQ6 (HLA-DQA1*01:02–DQB1*06:02) haplotype. Although associated with 
lower odds ratios (~2-4), class I HLA genes are also implicated in T1D risk (Nejentsev et al., 
2007) with CD8+ T cells shown to kill human β-cells in vitro by recognition of HLA-A2 (HLA-
A*02:01) and HLA-A24 (HLA-A*24:02)-restricted preproinsulin epitopes (Knight et al., 2013; 
Skowera et al., 2008). 
 
Polymorphism in the promoter region of the insulin gene (odds ratio = 2.4) yields the strongest 
genetic association besides HLA (Pociot et al., 2010) and is thought to result in lower levels of 
proinsulin gene expression in the thymus, thus shaping negative selection (Nokoff and Rewers, 
2013). Only two other loci, protein tyrosine phosphatase nonreceptor type 22 (PTPN22) and 
interleukin 2 receptor alpha (IL2RA) have consistently reported odds ratios greater than 1.5 
(Pociot, 2017). The latter is associated with lower levels of forkhead box P3 (FOXP3) 
expression by regulatory T cells (Tregs) and a reduction in their ability to suppress effector T 
cells (Garg et al., 2012).  
 
It is most likely that T1D arises in genetically susceptible individuals due to an environmental 
trigger (van Belle et al., 2011). This is strengthened by a discordance of age of T1D 
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development between monozygotic twins, suggestive of an unshared environmental factor 
(Redondo et al., 1999). Several environmental factors have been proposed, of which viral 
infection has gathered the strongest evidence. Enteroviral infection such as group B 
coxsackieviruses (CBV) have been strongly implicated with one study reporting 67% of 
children diagnosed with T1D exhibit CBV IgM responses (Friman et al., 1985). Equally, of 
fourteen serum samples taken from children diagnosed with new-onset T1D, 64% (9/14) 
showed evidence of enteroviral RNA particularly coxsackie B3 and B4 viruses (Clements et 
al., 1995).  Further evidence was provided by reports suggesting coxsackievirus B1 increases 
the risk of disease development in children at high-risk or recently diagnosed T1D (Laitinen et 
al., 2014; Oikarinen et al., 2014). Mouse models have suggested a potentially causative 
relationship with inoculation of mice with a coxsackievirus (CVB4E2) isolated from a child 
with diabetic ketoacidosis shown to induce diabetes (Yoon et al., 1979). Furthermore, 
maternally transferred CVB-specific antibodies in the non-obese diabetic (NOD) mouse reduce 
the risk of CVB infection in the offspring and protect them from T1D development (Larsson et 
al., 2013). The exact mechanism by which viral infection contributes to b-cell destruction is yet 
to be elucidated although molecular mimicry, b-cell dysfunction and bystander activation of T 
cells have been proposed (Dunne et al., 2019; Xia et al., 2019). Nevertheless, as studies in 
humans have largely been epidemiological, a conclusive link between viral infection and human 
T1D development is still lacking.  
 
1.4 T cell mediated immune tolerance 
In order to understand autoimmunity and autoimmune disease, it is important to appreciate the 
mechanisms by which the risk of T cell recognition of self-antigens is, for the most part, held 
in check. Immature T cells, termed thymocytes, are subject to a selection process in the thymus 
with the outcome being dependent upon the affinity of the T cell receptor (TCR) for self-
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peptide–major histocompatibility complex (MHC) complexes (Hogquist et al., 2005). The 
essence of thymic self-representation is embodied by the autoimmune regulator transcription 
factor (AIRE) which permits ectopic expression of tissue-specific antigens (e.g. insulin) by 
medullary thymic epithelial cells (mTECs) (Anderson et al., 2002). T cells bearing a TCR with 
high affinity for self-peptide–MHC complexes undergo deletion by negative selection, 
conversely those TCRs that have no detectable affinity for peptide–MHC ligands are subject to 
death by neglect. Thymocytes that recognise self-peptide–MHC complexes with low affinity 
induce positive selection, promoting thymocyte maturation, survival and release into the 
periphery. Thymic Tregs are generated in response to intermediate-affinity interactions with 
self-antigen (Klein et al., 2014).  
 
However, not all self-antigens that T cells need to be tolerant to are expressed in the thymus, 
and thus central tolerance mechanisms are not 100% efficient. The result is the release of 
potentially autoreactive T cells into the periphery. Peripheral tolerance mechanisms serve to 
restrain activation and expansion of these self-reactive T cells after their exit from the thymus. 
These mechanisms include immunological ignorance, i.e. an autoreactive T cell is kept in 
ignorance by sequestration of the self-antigen behind anatomical barriers such that it never 
encounters its cognate self-antigen in vivo. In addition, encounter of the self-antigen can lead 
to activation-induced cell death (apoptosis) via the Fas and Fas ligand (FasL) pathway or induce 
anergy (a state of unresponsiveness), potentially involving interaction of the T cell molecules 
CTLA-4 or PD-1 with their respective ligands (CD80/86, PD-L1/2) (Walker and Abbas, 2002). 
In addition, Tregs can directly supress autoreactive T cells in the periphery by producing 
inhibitory cytokines such as IL-10 and transforming growth factor-β (TGF-β) (O'Garra et al., 
2004). A failure to maintain self-tolerance mechanisms results in self-antigens being targeted 
by the immune system causing chronic inflammation and autoimmunity.   
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1.5 The dominant role of the adaptive immune system in T1D pathogenesis 
Most evidence implicate the adaptive immune system (T and B lymphocytes) as being central 
to b-cell destruction in T1D (Roep, 2003). That being said, knowledge of the mechanisms by 
which tolerance to b-cell autoantigens is inadequate or unsuccessful is scant. To date, a model 
constructed from human and mouse studies, suggests a yet unidentified initiating event results 
in damage to the islet of Langerhans (Roncarolo and Battaglia, 2007). The inflammation that 
ensues stimulates the release of b-cell autoantigens which are endocytosed by professional 
antigen-presenting cells (APCs) e.g. dendritic cells (DCs). Following migration of the APC to 
the local lymph node, peptides derived from the b-cell autoantigen are presented via HLA class 
I and II molecules to CD8+ and CD4+ T cells, respectively, culminating in T cell activation.  
 
Functionally impaired Tregs are unable to constrain activation of islet-reactive T cells (Lindley 
et al., 2005) allowing them to home to the pancreas where CD8+ T cells can directly kill b-cells 
(Bulek et al., 2012; Kronenberg et al., 2012; Skowera et al., 2008) through release of cytolytic 
granules containing perforin and granzymes, as well as through Fas–FasL interactions. CD4+ T 
cells produce pro-inflammatory cytokines such as interferon-g (IFN-γ) and tumour necrosis 
factor-a (TNF-α) which promote M1 macrophages resident in the islets to produce reactive 
oxygen species, TNF-α and IL-1β which in turn augment damage to b-cells (Burrack et al., 
2017). Additionally, T follicular helper (Tfh) cells can activate islet antigen-specific B cells, 
stimulating their differentiation into antibody-producing plasma cells (Serr and Daniel, 2018). 
Within the inflammatory environment of the islet, activated B cells can function as APCs; 
antibodies can bind β-cells to mediate antibody dependent cell-mediated cytotoxicity (ADCC) 
and complement dependent cytotoxicity (CDC), further enhancing the autoimmune response 
(Wallberg and Cooke, 2013). Due to their ability to concentrate antigen manyfold by virtue of 
the specificity of the BCR (Wong et al., 2004), B cells have been utilised as APCs to identify 
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epitopes by elution from HLA class II molecules (Arif et al., 2004; Peakman et al., 1999). 
However, it is important to appreciate the existence of other APCs such as macrophages and 
DCs, which may be present at the earlier stages of diabetes (Carrero et al., 2017; Ferris et al., 
2014) and may process antigen differently to B cells (van Lummel et al., 2016a).  
 
Increasing evidence exists that innate immune cells also play a critical role in T1D 
pathogenesis. (Diana et al., 2013) showed in NOD mice that physiological β-cell death induces 
the recruitment and activation of B-1a cells, neutrophils and plasmacytoid DCs to the pancreas. 
This infiltration occurs in the first postnatal weeks and innate immune cell crosstalk takes place 
which is crucial for the development of T1D. A reduction in circulating neutrophils has also 
been documented in T1D patients and in autoantibody-positive at-risk individuals (Valle et al., 
2013). Furthermore, neutrophils are observed at disease onset and at later stages, in the exocrine 
pancreas of patients with T1D but not in that of T2D or nondiabetic controls. Cytotoxic 
substances released by neutrophils during maturation, including cytokines, reactive oxygen 
species and extracellular traps may cause damage to the islet (Huang et al., 2016). Although 
data on innate immune cells in T1D pathogenesis remains limited, the role of these cells in the 
initiation and development of T1D will undoubtedly garner further interest in the future.  
 
Importantly, any proposed pathobiological model has to take into consideration that HLA genes 
at DRB1, DQA1 and DQB1 loci encode the highest genetic predisposition to T1D (Pociot and 
McDermott, 2002). A study by (Miyadera et al., 2015) suggested instability of HLA-DQ protein 
may be important and/or biased binding of specific host or infectious agent-derived antigenic 
peptides by disease-associated HLA molecules (Nepom and Kwok, 1998). Overall, however, a 
lack of convincing explanations for HLA-DQ-mediated predisposition exists within the current 
model.    
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1.6 The major targets: b-cell autoantigens 
This consensus model outlined above suggests that the anti-b-cell immune response is 
concentrated onto distinct molecular targets for which discovery was largely guided by the 
recognition of native proteins by islet cell autoantibodies (Roep and Peakman, 2012). Insulin, 
GAD65, IA-2 and ZnT8 are well established as major autoantigens, due to prognostic and 
diagnostic features of disease-associated autoantibodies (Achenbach et al., 2009; Ziegler et al., 
2013). In recent years, evidence of recognition of several additional antigens has been obtained 
in human T1D, for example islet-specific glucose-6-phosphatase catalytic subunit-related 
protein (IGRP) (Mallone et al., 2007; Yang et al., 2006) which was discovered by reverse 
translation, chromogranin A (ChgA) (Gottlieb et al., 2014; Li et al., 2015) and islet amyloid 
polypeptide (IAPP) (Denroche and Verchere, 2018; Panagiotopoulos et al., 2003; Standifer et 
al., 2006) (Table 1.1). Many of the autoantigens are components of secretory granules which 
upon release by the b-cell, may facilitate their uptake by APCs and delivery to the HLA class 
II processing machinery (Pugliese, 2017). 
 







detected in patients 
CD4+ T cell 
responses 
CD8+ T cell 
responses 
Insulin b-cell Secretory granule + + + 
ZnT8 b-cell Secretory granule + + + 
IA-2 Neuroendocrine Secretory granule + + + 
GAD65 Neuroendocrine Synaptic-like 
microvesciles 
+ + + 
IGRP b-cell Endoplasmic 
reticulum 
 + + 
IAPP b-cell Secretory granule + + + 
ChgA Neuroendocrine Secretory granule  + + 
†ZnT8, zinc transporter 8; IA-2, insulinoma-associated antigen-2; GAD65, glutamic acid 
decarboxylase 65; IGRP, islet-specific glucose-6-phosphatase catalytic subunit-related protein; 
IAPP, islet amyloid polypeptide; ChgA, chromogranin A. Adapted from (Purcell et al., 2019b). 
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1.7 Classical antigen processing and presentation 
In canonical antigen presentation via MHC class I, antigenic peptides presented to CD8+ T cells 
are generated in the cytosol by a multi-catalytic complex called the proteasome (Groettrup et 
al., 2010). The proteasome degrades cellular proteins into peptide fragments. The peptides are 
then transported into the endoplasmic reticulum (ER) lumen by the transporter associated with 
antigen processing 1 and 2 (TAP-1 and TAP-2). In the ER, these peptides are further trimmed 
to approximately 8-10 amino acids in length by ER aminopeptidases (ERAPs). With the help 
of the peptide loading complex, peptides are loaded onto the MHC class I heavy chain-β2m 
complex in the ER and the peptide–MHC complex is transported to the cell surface. 
 
Conversely, exogenous antigens destined for presentation by HLA class II molecules enter the 
endocytic pathway of APCs by multiple mechanisms (Roche and Furuta, 2015). An example 
of one such process is receptor-mediated endocytosis via clarithin-coated pits which requires 
antigen binding to receptors present on the APC surface, e.g. lectin receptors, resulting in 
internalisation of the antigen-receptor complex and delivery into early endosomes. 
Macropinocytosis represents another mechanism, dependent on the actin cytoskeleton to 
mediate the non-selective uptake of solute molecules giving rise to large endocytic vacuoles 
called macropinosomes (Lim and Gleeson, 2011). Arguably the most important mechanism of 
antigen uptake is phagocytosis, whereby opsonised antigens bind to various cell surface 
receptors to stimulate re-organisation of the actin cytoskeleton surrounding the antigen (Stuart 
and Ezekowitz, 2005). By this process, antigens are delivered into the cell in membrane-derived 
phagosomes. In each of the aforementioned processes, the internalised early endosomes fuse 
with late endosomal–lysosomal compartments rich in proteolytic enzymes that are active in the 
low pH environment maintained within this compartment for antigen proteolysis (Blum et al., 
2013). It is in these late endosomal–lysosomal compartments where peptide–MHC class II 
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complex formation occurs. The process by which membranes encapsulate cytosolic antigens to 
form an autophagosome, termed autophagy, is also an important mechanism of antigen 
acquisition (Schmid et al., 2007). In a similar manner to the other mechanisms of antigen 
uptake, the autophagosome eventually fuses with lysosomal compartments to form an 
autophagolysosome where peptide–MHC class II complexes are generated.  
 
In the ER, newly synthesised MHC class II αβ dimers associate with the invariant chain (Ii), 
transit through the Golgi apparatus and are targeted to the plasma membrane by signal 
sequences present in the Ii chain (Figure 1.1) (Cresswell, 1996). At the cell surface, Ii:MHC 
class II complexes undergo clathrin-mediated internalisation into early endosomes which 
eventually fuse with late endosomal–lysosomal compartments containing antigenic proteins 
and peptides. Proteolytic cleavage of the Ii chain generates a fragment of Ii, termed class II-
associated invariant chain peptide (CLIP), which remains bound in the peptide binding groove 
of the MHC class II molecule. Removal of CLIP is mediated by the enzyme HLA-DM allowing 
the nascent MHC class II molecule to bind antigenic peptides. The activity of HLA-DM is 
regulated by HLA-DO (Denzin et al., 2005). Peptide–MHC class II complexes are transported 
via vesicles which deposit peptide–MHC class II directly into the membrane for CD4+ T cell 
recognition. If recognition by CD4+ T cells does not occur, surface peptide–MHC class II 
complexes can be internalised by clathrin-independent endocytosis and are targeted for 
lysosomal degradation or via recycling endosomes back to the plasma membrane (Cho and 

















Figure 1.1 MHC class II presentation pathway. ER, endoplasmic reticulum; ILV, intraluminal 
vesicles; Ii, invariant chain. Taken from (Roche and Furuta, 2015). 
 
1.8 Non-conventional epitope generation 
The inadequacy of the consensus model – the lack of a convincing explanation for HLA-DQ-
mediated susceptibility – has fostered novel insights into the mechanisms of loss of b-cell 
tolerance. The discovery of neo-epitopes, also termed non-conventional epitopes (an epitope 
that is derived after modification of the germline sequence), as T cell targets in T1D has 
gathered much attention in recent years and may account for the disease association with 
specific HLA alleles.  
 
1.8.1 Post-translational modification of autoantigens 
Post-translational modification (PTM) of self-proteins could generate neo-antigens which can 
engage actively with the peripheral immune system due to insufficient thymic education. Thus, 
PTM of antigens has been extensively studied in autoimmune/chronic inflammatory diseases 
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such as rheumatoid arthritis (RA) (Trouw et al., 2017) and coeliac disease (CD) (Koning et al., 
2015; Sollid and Jabri, 2011). A list of common PTMs associated with autoimmune diseases is 
provided in Table 1.2. Of particular importance, is the enhanced MHC binding capacity 
described for many post-translationally modified peptides. In RA, citrullination of aggrecan 
and vimentin epitopes enhances binding of these peptides to disease-associated HLA-DR4 
molecules (Scally et al., 2013). Equally, deamidation of gluten-derived peptides by tissue 
transglutaminase in CD increases binding affinity to disease-associated HLA-DQ2 and -DQ8 
molecules, increasing their dwell-time and as a consequence results in a strong T cell response 
(Molberg et al., 1998; van de Wal et al., 1998). T1D shares similar HLA associations with RA 
and CD, thus it is plausible that autoantigen modification may have a similar role in T1D 
pathogenesis.  
 
Table 1.2 Common post-translational modifications of self-antigens associated with 
autoimmune disease.  
†MBP, myelin basic protein; GFAP, glial fibrillary acidic protein; PLP, myelin proteolipid 
protein; GAD65, glutamic acid decarboxylase 65. Taken from (Harbige et al., 2017). 
Autoimmune disease Modification Antigen Reference 






(Bradford et al., 2014) 
(Zamvil et al., 1986) 
 
(Greer et al., 2001) 




(Scally et al., 2013) 






RNA splicing factors 
Histones 
(Neugebauer et al., 2000) 
(Dwivedi et al., 2014) 
Celiac disease Deamidation Gluten (gliadin) (Arentz-Hansen et al., 2000) 
Psoriasis Endoprotease cleavage Pso27 (Iversen et al., 2011) 














(van Lummel et al., 2014) 
 
(Mannering et al., 2005) 
 
(McGinty et al., 2014) 
 
(Strollo et al., 2017) 
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T cell responses to a disulphide-modified insulin A chain epitope (A1-13) restricted by HLA-
DR4, was the first evidence that post-translationally modified peptides could be relevant in T1D 
(Mannering et al., 2005). Since then additional evidence has come from the identification of a 
transglutaminated ChgA peptide which exhibited increased antigenicity to NOD mouse-derived 
diabetogenic CD4+ T cell clones (Delong et al., 2012). Furthermore, deamidation of islet 
peptides by the tissue transglutaminase enzyme enhances their binding affinity to HLA-DQ8 
and HLA-DQ8trans molecules (van Lummel et al., 2014). Isolation of a T cell clone from a 
new-onset T1D patient capable of recognising a deamidated proinsulin peptide presented by 
HLA-DQ8 provides a priori evidence that such modifications could be relevant in vivo. HLA-
DR4-restricted citrullinated and transglutaminated GAD65 epitopes have also been described 
with T cells reactive against these modified epitopes present at significantly higher frequencies 
in T1D patients than HLA-matched controls (McGinty et al., 2014). Altogether the data indicate 
that immune recognition of enzymatically-modified epitopes does occur in T1D although the 
link to disease pathogenesis is yet to be uncovered.  
 
Unlike RA and CD, the PTM model in T1D is yet to be firmly consolidated into our 
understanding of disease pathogenesis. The field has therefore sought new insights into how 
non-conventional epitopes are generated and their relevance to the conventional peptide 
repertoire. The discovery of hybrid insulin peptides (HIPs) as a novel form of modified peptide 
containing non-germline encoded epitope sequences, inspired new thinking around the 
mechanisms of epitope generation in T1D (Delong et al., 2016). HIPs represent peptides formed 
not by modification of amino acids (discussed above) but fusion of amino acids sequences. 
Although in the context of T1D several reports implicate this more complex modification to be 
involved in the generation of MHC class II epitopes, it has also been reported to give rise to 
MHC class I-restricted peptides (spliced peptides) (Faridi et al., 2018; Liepe et al., 2016). To 
date only one report of a HLA class I-restricted IAPP fusion peptide with potential relevance 
 32 
to T1D has been demonstrated (Gonzalez-Duque et al., 2018). Yet another example which 
brought non-conventional epitopes into the limelight was the discovery of a defective ribosomal 
insulin gene product that is targeted by T cells in T1D patients (Kracht et al., 2017). Low or 
absent expression of these non-conventional epitopes in the thymus may bypass central 
tolerance and in certain circumstances may be able to explain the highly predisposing HLA-DQ 
gene effect. 
 
1.8.2 Hybrid insulin peptides 
First identified in the NOD mouse (Stadinski et al., 2010a) and later in T1D patients (Gottlieb 
et al., 2014), the natural ChgA-processed peptide, WE14, is a weak agonist for several ChgA-
reactive T cell clones derived from NOD mice including the archetypal Barbara Davis Centre 
(BDC)-2.5 clone (Stadinski et al., 2010a). By modelling the interaction of the WE14 peptide 
with IA-g7 (NOD mouse MHC II molecule) the authors were able to show that WE14 occupies 
only half of the IA-g7 peptide binding groove. Thus, it was proposed that the natural ligand 
recognised by these islet antigen-reactive CD4+ T cell clones in vivo may be a modified form 
of the WE14 peptide. In line with this hypothesis, (Jin et al., 2015) described that addition of 
RLGL to the N-terminus of WE14 (RLGLWSRMDQLAKELTAE) places the WSRMD motif 
in the correct position in the IA-g7 peptide binding groove. The N-terminally extended WE14 
peptide was demonstrated to be much more potent than unmodified WE14 in T cell stimulation 
and activates a diverse set of ChgA-reactive T cell clones. Later, a hybrid peptide formed by 
the fusion of a proinsulin C-peptide fragment on the N-terminal side to WE14 on the C-terminal 
side, significantly increases activation of the BDC-2.5 T cell clone compared to native WE14 
(Delong et al., 2016). It was this discovery which brought HIP formation to the forefront of 
T1D research, generating an unconventional type of neo-epitope potentially of great relevance 
to disease pathogenesis. 
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Currently, HIPs that have been described originate from the covalent crosslinking of proinsulin 
C-peptide to a peptide from another β-cell secretory granule protein. It is therefore reasonable 
to surmise that HIP formation occurs preferentially in a protein-dense environment such as 
within the b-cell granule, currently estimated to contain 50–100 distinct proteins (Brunner et 
al., 2007; Hickey et al., 2009; Schvartz et al., 2012) many of which have unknown functions 
(Suckale and Solimena, 2010). The identification of hybrid peptides containing different 
peptide species, but all derivates of proteins present within the granule (Delong et al., 2016) 
would support this notion.  
 
Initially, hybrid peptides formed by the fusion of C-peptide with WE14 and IAPP2 (islet 
amyloid polypeptide propeptide 2) were found to elicit an IFN-g response using a set of NOD 
mouse-derived BDC T cell clones and this response was stronger than that of the unmodified 
epitope. Up until now BDC T cell clones have been reported to have defined reactivities, with 
these findings now suggesting that HIPs may represent the natural ligands for these clones. To 
show that HIPs exist in vivo within b-cells, mass spectrometric analysis of the granule fraction 
of insulinoma cells revealed the presence of a HIP containing the DLQTLAL C-peptide 
sequence fused to the WSRM WE14 sequence (Delong et al., 2016). T cells reactive against 
these HIPs were consequently isolated from the residual islets of deceased donors with T1D. In 
this case, the islet-derived T cell clones responded to HIPs formed by the fusion of C-peptide 
to IAPP2 and neuropeptide Y (NPY) but native C-peptide stimulated these T cells weakly. 
Intriguingly, these T cells only recognised HIPs presented by APCs in the context of HLA-
DQ8, suggesting HIPs may provide the missing link for HLA-DQ-mediated susceptibility. Two 
hybrid peptides (C-peptide:IAPP2 and insulin-2 C-peptide:insulin-1 C-peptide) were later 
independently identified in the granule fraction of NOD mouse b-cells providing further 
confirmation of the existence of HIPs in vivo (Wan et al., 2018). 
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In a study by (Babon et al., 2016), CD4+ T cell lines expanded from islets of cadaveric donors 
with T1D were shown to respond to some of the same hybrid epitopes described by (Delong et 
al., 2016) by production of IFN-g. T cell reactivity was observed to HIPs containing C-peptide 
fused with IAPP2, IAPP1 (islet amyloid polypeptide propeptide 1) and the A chain of insulin. 
Whether or not these islet-derived T cell lines cross-react with the unmodified peptide and 
whether the response to the HIP is different to that of the unmodified version was not elucidated. 
The capacity of C-peptide:IAPP HIPs to stimulate the IAPP-specific BDC-6.9 T cell clone was 
shown by (Wiles et al., 2017) to be dependent on residues from both insulin and IAPP 
components, since N- or C- terminal truncation abolished IFN-g secretion by the BDC-6.9 
clone. In addition, modification of the hybrid sequence revealed that negatively charged amino 
acid side chains are preferred at the C-terminus and that this may be necessary for optimal T 
cell activation. Similar to HLA-DQ8 molecules, IA-g7 preferentially binds peptides with C-
terminal negatively charged amino acids (Suri et al., 2005). Thus, hybrid peptides containing 
negatively charged amino acids at anchor positions may provide optimal binding to HLA 
molecules.  
 
(Baker et al., 2018) advanced our knowledge of HIPs in T1D by using IA-g7 tetramers loaded 
with HIPs to track HIP-reactive T cells over the progression of the disease. Both nondiabetic 
and diabetic NOD mice harbour high frequencies of T cells reactive to a C-peptide:WE14 
hybrid peptide in the pancreas, with T cells reactive to a C-peptide:IAPP2 HIP also being 
present in the pancreas of NOD mice. An important finding was that antigen-experienced HIP-
reactive T cells were detected in the pancreatic lymph nodes well in advance of their infiltration 
the pancreas (as early as 3 weeks of age). This suggests that HIP-reactive T cells acquire this 
phenotype early on in the disease process and are amongst the first antigen-specific CD4+ T 
cells to be activated in the pancreatic lymph nodes. After shedding L-selectin (CD62L) and exit 
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from the lymph nodes, they can be detected in peripheral blood with increasing frequency 
throughout disease progression. In this manner, T cells reactive to HIPs may be useful 
biomarkers of disease and it would be curious to determine if this is also true in humans.  
 
Interestingly, very few HIP-reactive T cells express FOXP3 in the pancreas at the time of 
disease onset (Baker et al., 2018). Conversely, a large frequency (>20%) of insulin B9-23-
reactive T cells in the pancreas expressed FOXP3 indicating that these cells might be involved 
in immune regulation. These findings were later confirmed by (Ito et al., 2018) and (Spence et 
al., 2018) who reported that islet-infiltrating Tregs express TCRs specific for B9-23 but not for 
HIPs. The former study also observed that HIP-reactive T cells were skewed towards a Th1 
phenotype upon antigen encounter, secreting both TNF-α and IFN-γ (Ito et al., 2018). Overall, 
these studies suggest differences, which may lie at the level of thymic education, in CD4+ T 
cell regulation to conventional and non-conventional epitopes. Restoring a lack of regulatory 
function in HIP-reactive T cells could therefore be useful in immunotherapeutic approaches.   
 
As research on HIPs in T1D has gathered momentum, an important question is whether 
individuals that do not develop diabetes also form HIPs. Criteria for the accurate identification 
of these peptides by mass spectrometry was developed (Wiles et al., 2019) and the presence of 
HIPs confirmed in primary NOD mouse and human islets. Surprisingly, HIPs were also 
identified in islets from non-diabetes prone BALB/c mice and islets from human donors without 
T1D. This indicates that the presence of HIPs alone is not sufficient to cause disease. It is likely 
that in predisposed individuals, differences in the immune response could precipitate disease 
development. Such differences include how efficiently HIPs are presented by HLA molecules, 
how efficient tolerance to HIPs is established and the degree to which they are generated (Baker 
et al., 2019a; Wiles et al., 2019). 
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Evidence for the existence of HIPs in human islets has become an increasingly important 
research focus. Further to the presence of HIP-reactive T cells in the islets of T1D patients, 
HIP-reactive T cells can also be detected in the peripheral blood of newly diagnosed patients 
(Baker et al., 2019b). Approximately 30% of T1D patients elicit an IFN-g response to at least 
one HIP with responses to up to seven HIPs detected in some patients. In contrast, in HLA-
matched controls T cells responses to HIPs were less frequent, of lower magnitude and seldom 
to more than one HIP. Longitudinal data from one patient indicated that T cell responses to 
HIPs can continue up to 1 year after diagnosis. Subsequent isolation of T cell clones with 
different HIP-specificities showed reactivity to target HIPs at low nanomolar concentrations 
but not to native epitopes, confirming the findings of (Delong et al., 2016). One T cell clone 
was isolated from the same patient at two different time points, indicating that HIP-reactive T 
cells traffic in the blood for a prolonged period after onset of T1D. Given that most C-peptide-
specific T cell clones derived from the peripheral blood of T1D patients are HLA-DQ-restricted 
(So et al., 2018), it would be of interest to investigate whether these clones also cross-react with 
putative HIPs recently identified in human islets (Wiles et al., 2019). Overall, the unearthing of 
HIPs as T cell targets in T1D has questioned current concepts of disease pathogenesis. 
 
There are, however, limitations which need to be resolved before non-conventional epitopes 
such as HIPs can be accommodated into our dogma of disease development. Although HIPs 
have been identified in vivo in human islets (Wiles et al., 2019), whether naturally processed 
and presented HIP epitopes are generated via HLA class II (and class I) processing pathways is 
undetermined. Furthermore, their relationship to the natural peptide repertoire is also unknown. 
For example, it is possible that an early autoimmune response is primed against conventional 
epitopes of C-peptide and/or WE14 but this is insufficient for autoimmunity to be initiated. 
Encounter with a non-conventional epitope such as a HIP subsequently acts as a super-agonist, 
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stimulating expansion of diabetogenic T cell clones which drive disease (Figure 1.2). In this 
two-step model, a breakdown of tolerance would precede an event (e.g. local inflammation) 
which results in the formation of non-conventional epitopes. Conversely, the initial autoreactive 
response is primed to non-conventional epitopes de novo (tolerance breaker). Such activated T 
cells may cross-react with germline epitopes, opening up further opportunities for TCR 
engagement. The importance of higher HLA binding and/or TCR recognition of HIPs compared 
with germline epitopes is also an unknown at this stage as is the initial cue responsible for their 
generation. Such an event may arise under different circumstances such as viral infection or 
weaning where the islet undergoes significant b-cell re-modelling (Gunasekaran et al., 2012) 












Figure 1.2 Non-conventional epitopes: tolerance breakers () or disease drivers () in 
autoimmune diabetes. The initial autoreactive T cell response is primed to non-conventional 
epitopes such as HIPs (tolerance breaker). Alternatively, non-conventional epitopes 
complement a pre-existing autoimmune response to conventional epitopes to drive disease. 























1.8.3 Spliced peptides 
Peptide splicing warrants extensive discussion here as it is a relatively novel extension of the 
conventional view of processing through the canonical HLA class I pathway. Since its first 
discovery, peptide splicing has been shown to be relevant to cancer pathology and infectious 
disease (Mishto and Liepe, 2017). For these reasons, it is illustrative of some of the important 
questions surrounding hybrid peptides in T1D, i.e. mechanism of generation and the complexity 
of the processes (requiring computational power because of all of the combinatorial 
possibilities). 
 
Spliced peptides represent an additional domain of non-conventional epitope generation 
whereby a non-germline sequence is formed by the fusion of two peptide fragments. Such 
peptides can originate from splicing of two distinct regions within the same protein (cis-spliced 
peptides) or the fusion of peptide fragments from two distinct proteins (trans-spliced peptides). 
Both mechanisms of spliced peptide generation have been described to be operative in the 
generation of novel class I epitopes. Furthermore, spliced peptides have been shown to be the 
result of a post-translational event (Hanada et al., 2004); either fusing two peptide fragments 
end-to-end (Vigneron et al., 2004) or in reverse order (Michaux et al., 2014; Warren et al., 
2006). 
 
By generating a database restricted to peptides generated by cis-splicing, (Liepe et al., 2016) 
showed that cis-splicing of peptides, specifically proteasome-catalysed peptide splicing is not 
scarce within the human immunopeptidome. Analysis of the HLA class I immunopeptidome of 
cell lines and primary human fibroblasts by mass spectrometry revealed that up to one-third of 
uniquely identified epitopes are derivatives of spliced species. Interestingly, spliced epitopes 
constituent one-fourth of the total peptide repertoire in terms of abundance, indicating 
 39 
comparable efficiency in the generation of non-spliced and spliced epitopes. Indeed, 
comparable abundance of spliced and non-spliced epitopes has also been suggested by (Ebstein 
et al., 2016) using CD8+ T cell clones specific for melanoma antigens. Spliced epitopes should 
therefore be equally likely to trigger CD8+ T cell responses as non-spliced epitopes. 
Intriguingly, (Liepe et al., 2016) also showed that some proteins were exclusively represented 
by spliced peptides and not non-spliced peptides. These proteins may not possess linear 
peptides with sufficient HLA binding capacity and/or generate smaller peptides, and thus 
splicing is a way to generate peptides of sufficient length and motif for HLA class I loading 
(Vigneron et al., 2017).      
 
Until recently, trans-splicing was predicted to occur at a low frequency simply because two 
distinct protein substrates can hardly fit inside the proteasome simultaneously, coupled with the 
low chances of having two protein substrates repeatedly degraded at the same time within the 
proteasome. As a result, only a handful of HLA class I trans-spliced peptides had been shown 
to occur in vitro and in vivo (Dalet et al., 2010) but due to increases in computational power, 
(Faridi et al., 2018) were able to report a considerable contribution of trans-spliced peptides to 
the immunopeptidome. The unexpected proportion of trans-spliced peptides highlights 
additional complexity of the immunopeptidome beyond that previously described by (Liepe et 
al., 2016). The authors propose that for trans-splicing it is not necessary that each of the two 
peptide fragments consistently originate from a particular region of a protein. In the case of 
short fragments of spliced peptides, the proteasome could ligate identical polypeptides 
generated from a multitude of donor proteins. They therefore argue that despite the low 
probability of an individual trans-splicing reaction, a high abundance of “trans-donors” could 
increase the probability.   
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Peptide joining does not appear to be a random process but represents a finely tuned mechanism 
which has increased efficiency when the splice reactants bear specific properties (Berkers et 
al., 2015). For example, the C-terminal splice reactant involved in the generation of one specific 
spliced epitope was required to be at least three amino acids in length (Michaux et al., 2014). 
The N-terminal splice reactant is also likely to have a minimal length although N-terminally 
elongated spliced peptides can be trimmed in the ER by ERAPs (Vigneron et al., 2017). 
Furthermore, another spliced epitope was shown to be generated with reduced efficiency as the 
length of the intervening sequence (the sequence excised between two splice-reactants) 
increased (Dalet et al., 2010). However, studies involving analysis of the entire HLA class I 
immunopeptidome did not identify a correlation between the frequency at which the spliced 
peptide is generated and the intervening sequence length (Liepe et al., 2016). In breast and 
colon cancer cell lines, spliced peptides make up approximately 20% of the class I 
immunopeptidome with source antigens being preferentially long, hydrophobic and basic 
(Liepe et al., 2019). An explanation as to why these antigens possess such properties is not yet 
clear but it is possible to speculate that short antigens are less able to generate spliced peptides 
simply due to less combinational possibilities.  
 
The implication from the above studies is that peptide splicing is subject to regulation. Precisely 
how cis- and trans-spliced peptides are generated and how they contribute to T cell selection 
in unknown. Both standard and the immunoproteasome have the capacity to splice peptides 
(Dalet et al., 2011) as does the yeast proteasome (Mishto et al., 2012). Thus, because spliced 
peptides are by-products of proteasomal activity, any type of proteasome including the 
thymoproteasome should be capable of generating spliced peptides (Vigneron et al., 2019).  
Therefore, spliced peptides may not be intrinsically more immunogenic than non-spliced 
peptides as central tolerance mechanisms may exist. Indeed, a large proportion of spliced 
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peptides are presented at the cell surface and are immunologically silent (Vigneron et al., 2019). 
Furthermore, (Liepe et al., 2019) and (Faridi et al., 2018) show overall similarity in the 
sequence motifs (amino acid preference and anchor residues) of spliced and non-spliced 
epitopes.  This is unsurprising as spliced peptides obey the same antigen processing pathway 
as non-spliced peptides and are selected based on their affinity for the class I peptide binding 
groove downstream of the proteasome. Where spliced epitopes may differ to non-spliced 
epitopes is when spliced peptides escape central tolerance, for example because the source 
protein is not adequately expressed in the thymus or because the proteasome isoform is 
inefficient in generating these peptides.  
 
Undoubtedly, the combined actions of cis- and trans-spliced peptides enable a greater breath 
of antigen-derived epitopes to be displayed for recognition by T cells, especially important 
during bacterial or viral infection (Faridi et al., 2018; Liepe et al., 2016). Indeed, there is 
evidence for the immunogenicity of pathogen-derived spliced epitopes during Listeria 
monocytogenes infection (Platteel et al., 2016; Platteel et al., 2017a). Splicing may also be 
particularly important for the host upon infection with pathogens with small genomes. Such 
genomes may not encode adequate class I ligands, thus peptide ligation with other antigens may 
enhance immunosurveillance. More recently, peptide splicing has been shown to have a role in 
limiting viral escape and control of HIV-1 replication (Paes et al., 2019). Furthermore, T cell 
responses against spliced epitopes are documented in cancer, with melanoma gp100 (gp100mel)-
derived spliced epitopes triggering activation of CD8+ T cells found in the peripheral blood of 
half of melanoma patients (Ebstein et al., 2016). It is not therefore surprising that in silico-in 
vitro pipelines are being developed to identify tumour-specific spliced epitope candidates 
which can be subsequently validated as putative targets for anti-cancer therapies (Mishto et al., 
2019). 
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To summarise, data on the relevance of cis- and trans-spliced peptides in immunopeptidomes 
on autoimmunity and T1D in particular is limited, with this being an area of discovery in the 
future. Recently, a HLA-A2-restricted fusion epitope was found to be naturally processed and 
presented by β-cells, formed via the fusion of IAPP15-17 with IAPP5-10 (Gonzalez-Duque et al., 
2018). However, a pathogenic role of the CD8+ T cells recognising this epitope remains to be 
definitively established. Based on this, it is not unreasonable to speculate that in an 
inflammatory milieu, ER stress in β-cells may trigger an upregulation of proteasome-mediated 
protein degradation which could augment spliced peptide generation.  
 
1.8.4 Generation of hybrid and spliced peptides 
The mechanism by which hybrid peptides are generated in vivo is not fully understood although 
it is currently thought to involve transpeptidation (Delong et al., 2016), namely the process by 
which two peptide fragments are ligated together to form a hybrid peptide (Berkers et al., 2009). 
The secretory granule represents a candidate organelle for this reaction to occur due to high 
concentrations of enzymes and b-cell proteins such as insulin (Rorsman and Renstrom, 2003), 
ChgA and IAPP, which promote the transpeptidation reaction (Delong et al., 2016). The degree 
of enzymatic involvement, or whether this process occurs spontaneously within the b-cell 
granule due to the sheer abundance of secretory proteins (molecular crowding) is unknown at 
present. It is possible to envisage that if an enzyme responsible for HIP formation did exist, it 
would likely reside in the secretory compartment where MHC class II peptides are produced 
(Vigneron et al., 2017). The proteasome has been shown to catalyse transpeptidation during the 
production of epitopes for HLA class I presentation (see below), therefore there is the prospect 




The mechanism by which class I spliced peptides are generated has been well-established as a 
proteasome-dependent mechanism. Until a few years ago, only a handful of human spliced 
epitopes derived from tumour-associated antigens had been reported (Dalet et al., 2011; Hanada 
et al., 2004; Michaux et al., 2014; Vigneron et al., 2004; Warren et al., 2006), thus tagging 
proteasome-catalysed peptide splicing as a rare event. The mechanism, however, has been 
recognised to involve a transpeptidation reaction (Dalet et al., 2010; Mishto et al., 2012; 
Vigneron et al., 2004; Warren et al., 2006). The reaction begins with breakage of the peptide 
bond between a residue (termed P1) of the N-terminal splice reactant and the succeeding 
intervening sequence (Figure 1.3). This generates an acyl-enzyme intermediate between the P1 
residue and a catalytic residue of the proteasome facilitating the release of the intervening 
sequence. In conventional antigen processing, the acyl-enzyme intermediate reacts with a water 
molecule (hydrolysis) to release the N-terminal peptide fragment. During transpeptidation, the 
free amino group of a C-terminal splice reactant reacts with the acyl-enzyme intermediate 
resulting in the joining of the N- and C-terminal splice reactants. Within the proteasome’s 
catalytic pockets, it has been suggested that substrate-specific binding sites exist which mediate 
peptide splicing (Michaux et al., 2014) but it is not known whether the same binding sites are 














Figure 1.3 Schematic mechanism of proteasome-catalysed peptide splicing by 
transpeptidation. Adapted from (Jin et al., 2015).  
Due to bioinformatic approaches and novel database search strategies, (Liepe et al., 2016) were 
able to identify thousands of cis-spliced peptides in the HLA I immunopeptidome and (Faridi 
et al., 2018) later showed that trans-spliced peptides are as frequently identified as cis-spliced 
peptides found bound to a number of different HLA-A and HLA-B alleles. Thus, the generation 
of spliced peptides represents a key source of antigenic epitopes. This phenomenon of 
proteasome-catalysed peptide splicing has to date only been described for class I peptides. 
Peptide splicing can also give rise to class II epitopes as is the case for hybrid peptides in T1D. 
These peptides are identified by the ligation of peptide fragments originating from two different 
secretory granule proteins (by definition trans-splicing). The T1D field should proceed with 
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caution in mixing those class II results with the occurrence of spliced peptides in class I. The 
generation of trans-spliced class II peptides involves a different pathway and may involve 
different mechanisms to proteasome-mediated peptide splicing of class I epitopes e.g. 
endosome- or lysosome-based (Harbige et al., 2017). It is possible to envisage that if a pool of 
spliced species exists in the cytoplasm for HLA class I loading, b-cell death may facilitate their 
uptake by APCs delivering them into the HLA class II processing and presentation pathway. 
Alternatively, extracellular proteasomes (Dianzani et al., 2017) may generate epitopes 
independently of APC processing.  
 
Involvement of a membrane-bound organelle in the formation of fusion peptides has also been 
suggested by (Wang et al., 2019). This study utilised the B9-23 epitope which is known to 
require C-terminal modification for efficient binding and presentation by IA-g7 (Crawford et 
al., 2011; Stadinski et al., 2010b) and HLA-DQ8 (Nakayama et al., 2015; Yang et al., 2014). 
The authors advance this theory by identifying potential donor peptides from mouse or human 
C-peptide for fusion by transpeptidation to insulin B9-23 derived peptides. These fusion 
peptides create super-agonists, stimulating T cell activation as strongly or if not stronger than 
mutations to the C-terminal end of the B9-23 peptide. The authors suggest transpeptidation in 
the lysosome could be responsible for such fusions in vivo although proof that transpeptidation 
of these motifs is operative in vivo and produces relevant neo-epitopes is lacking. Speculation 
remains on the sub-cellular compartment in which transpeptidation occurs as granule 
purification from whole β-cells is likely to yield crude preparations which may also contain 
lysosomes. 
 
Alternatively, other mechanisms may exist which also culminate in the generation of non-
germline peptide sequences. These include translocation, interstitial deletion and chromosomal 
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inversion of genes to generate gene fusions documented predominately in cancer cells 
(Campbell et al., 2008; Mitelman et al., 2007). The identification of novel tumour epitopes 
generated as a result of gene translocation and point mutations is an exciting research area 
which may be fruitful in cancer immunotherapy if these epitopes can be selectively targeted 
(Yarchoan et al., 2017). Indeed, following checkpoint blockade tumour regression is correlated 
with CD8+ T cells specific for mutation-induced neo-epitopes (Gubin et al., 2014) and these 
neo-epitopes have been efficacious as vaccines for melanoma (Kreiter et al., 2015). Chimeric 
RNAs have also been described in cancer cells to generate non-germline sequences by cis- and 
trans-splicing of RNA (Jia et al., 2016). Peptide elution from human b-cell lines has identified 
HLA-A2-restricted neo-antigenic peptides formed by mRNA splice variants of b-cell antigens 
(Gonzalez-Duque et al., 2018). Thus, there is evolving evidence that such mechanisms occur in 
autoimmunity and in theory, hybrid peptides could be generated by trans-splicing of RNA. 
 
1.8.5 Defective ribosomal products (DRiPs) 
During protein homeostasis, proteins can assume the incorrect conformation despite translation 
from the correct start codon. In this event, these misfolded proteins (defective ribosomal 
products, DRiPs) traffic to the proteasome where they are degraded and epitopes generated for 
loading onto class I molecules (Yewdell, 2011). An additional class of DRiPs is generated by 
translation initiation at an out-of-frame start codon, translating a novel amino acid sequence 
(Anton and Yewdell, 2014). In tumour and virally infected cells, such pathways play an 
important role in generating non-conventional class I epitopes for immunosurveillance (Starck 
and Shastri, 2011). 
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In the context of T1D, this additional class of DRiPs is involved in the generation of class I and 
II epitopes (Kracht et al., 2017). Initiation of translation at an alternative start codon within the 
mRNA of preproinsulin (PPI) defines an alternative open reading frame which bypasses the 
original PPI stop codon. A neopolypeptide is generated, the amino acid sequence of which is 
different from PPI and is hence termed a defective ribosomal insulin gene product (INS-DRiP) 
(Figure 1.4). A 9-mer epitope of this INS-DRiP polypeptide (INS-DRiP1–9) is presented by 
HLA-A2 as well as the highest-T1D-risk HLA-DQ8trans molecules and INS-DRiP1–9-specific 
CD8+ T cells shown to kill human b-cells in vitro. The expression of the DRiP polypeptide is 
increased under ER stress with increased b-cell death observed by preconditioning islets with 
high glucose and pro-inflammatory cytokines (IL-1β and IFN-γ). Whether central tolerance 
exists against DRiPs, and when responses to the INS-DRiP arise during the course of T1D 
development, will be vital questions to be addressed. 
  
 
Figure 1.4 Sites of non-conventional epitope generation within the pancreatic β-cell. Epitopes 
can be generated by errors in translation, peptide splicing by the proteasome and during 
cleavage of polypeptide cargoes within the granule. DRiP, defective ribosomal product; HIP, 















1.9 Implications of non-conventional epitopes on the consensus model 
Non-conventional epitope generation perturbs our notion of self and non-self, promoting re-
evaluation of the targeting of self-antigens in autoimmune diseases e.g. T1D. A key question is 
whether hybrid peptides have a physiological role within b-cells which provides a rationale for 
their generation. The generation of chimeric fusion RNAs, not only in tumour cells but also in 
non-cancer cells, have been shown to be functional and are required for cellular activities 
(Babiceanu et al., 2016) although it is yet unclear whether hybrid peptides can be generated via 
this route. Proteasome-generated spliced peptides have been scrutinised thus far as T cell 
targets, but they may also have additional functions. For example, spliced peptides may be 
beneficial for cells to expand the diversity of functional peptides derivable from a single parent 
protein (Dianzani et al., 2017). 
 
The N- and C-terminal ligation partners involved in proteasome-catalysed peptide splicing 
appear to be subject to splicing rules. Attempts to identify a HLA-A2-restricted splicing pattern 
has yielded markedly different results (Berkers et al., 2015; Liepe et al., 2016). (Liepe et al., 
2016) eluted spliced peptides from various cell lines and showed substantial differences in the 
nature of the junctional amino acids, suggesting this is influenced partly by the HLA molecule 
to which these peptide bind. Equally, (Faridi et al., 2018) report only subtle preferences at the 
junctional amino acids with no obvious splicing rules. The challenge in identifying splicing 
rules is likely underpinned by the wide specificity of different proteasome isoforms e.g. 
constitutive, immunoproteasomes and intermediate proteasomes, which preferentially regulate 
specific pathways in different cell types (Mishto and Liepe, 2017). Contingent on the expressed 
isoform, different peptide products can predominant in the peptide repertoire which can 
determine whether a specific T cell response is primed (Platteel et al., 2017b). Importantly, 
although not yet established, if presentation of spliced peptides is restricted to specific HLA 
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alleles, then this has implications for T1D and autoimmune diseases in general. High overlap 
between self and non-self may facilitate the generation of cross-reactive T cells due to 
molecular mimicry of pathogen-derived and self-peptides (Cusick et al., 2012).  
 
Cell or tissue-specific restriction of spliced peptides, and whether such epitopes are available 
for T cell selection in the thymus, will be critical to our understanding of their role in T1D 
pathogenesis. Low or absent expression of non-conventional epitopes in the thymus may lead 
to a lack of clonal deletion and thus, escape of non-conventional-reactive T cells into the 
periphery likely characterised by a more diverse T cell repertoire (Anderson et al., 2000). 
Within this T cell repertoire, high affinity TCRs to the non-conventional epitope are more likely 
to exist (Mohan et al., 2010) increasing the opportunity for autoreactive responses. Indeed, 
MHC II-islet peptide-specific tetramer staining in the NOD mouse has shown that CD4+CD25–
(Tconv) T cells display higher reactivity to HIPs than insulin B chain peptides (Holohan et al., 
2019). This finding is consistent with the notion that insulin-reactive T cells would undergo 
thymic deletion while HIPs represent peripherally generated neo-epitopes that escape thymic 
selection. 
 
Additionally, the modifications present in non-conventional epitopes may also cause a 
heteroclitic effect whereby modification of key anchor residues enhances peptide binding to 
HLA molecules and/or TCR docking compared to the conventional epitope (Borbulevych et 
al., 2005; Cole et al., 2010). Alterations in HLA register usage may also come into play, 
permitting non-conventional epitopes to be presented as neo-epitopes if in the thymus the 
epitope was not presented in the same register (Pugliese, 2017), as described for the insulin B 
chain (Mohan et al., 2011). Regardless of the mechanism, tetramer staining could be useful in 
pre-diabetic phases to elucidate if these peptides do indeed have the potential to break tolerance. 
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It is also possible that a reduced pool of thymic-derived Tregs is resident in the periphery due 
to low or absent expression of non-conventional epitopes in the thymus (Kieback et al., 2016). 
In support of this, evidence in the NOD mouse suggests that the Treg compartment within the 
islet is largely comprised of thymically-derived Tregs; islet Tregs isolated from NOD mice do 
not react with C-peptide:IAPP2 or C-peptide:WE14 HIP tetramers (Holohan et al., 2019). 
These results suggest that there might not be a substantial proportion of HIP-reactive thymic 
Tregs resident in the islets overall. It is, however, known that DCs can acquire antigens present 
in the periphery and traffic them to the thymus to mediate T cell selection (Bonasio et al., 2006; 
Hadeiba et al., 2012) therefore the thymic Treg repertoire against non-conventional epitopes 
may be dependent on the stage of disease.  
 
The role of non-conventional epitopes in the context of the disease-protective HLA-DQ6 
haplotype is also yet to be determined. HLA-DQ6 may bind these epitopes in a different register 
than disease-susceptible alleles leading to the induction of Tregs as reported for an epitope of 
type IV collagen in Goodpasture disease (Ooi et al., 2017). Using HIPs as an example, an 
increased frequency of HIP-reactive Tregs in individuals with the HLA-DQ6 haplotype would 
be speculative at this stage, however a recent publication by (Wen et al., 2020) provides some 
evidence to support this notion. In this study, GAD65- and IGRP-specific effector and 
CD25+CD127–FOXP3+ regulatory CD4+ T cells were found to be present in high frequencies 
in individuals with the protective HLA-DQ6 haplotype than those with susceptible or neutral 
haplotypes. Alternatively, HLA-DQ6 may bind non-conventional epitopes in a competing 
HLA-binding register (epitope stealing) than disease-susceptible HLA alleles (van Lummel et 
al., 2019) directing the T cell response away from the epitope presented by disease-susceptible 
HLA molecules.   
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1.10 Aims and significance of the thesis 
Efforts to induce immunological tolerance in T1D patients using antigen-specific therapies e.g. 
peptide immunotherapy (Alhadj Ali et al., 2017) have focused on the use of conventional 
epitopes. The studies discussed above highlight the relevance of non-conventional epitopes in 
T1D and utilising HIPs for tolerance induction has already shown promise in the NOD mouse 
(Jamison et al., 2019). In order to understand whether non-conventional epitope generation can 
be targeted at a therapeutic level, this requires a more comprehensive understanding of peptide 
generation. For example, the pathways through which hybrid peptides are loaded onto HLA 
class II molecules are not clear. Equally, hybrid peptides have thus far been identified by 
proteolytic digestion of b-cell granule extracts prior to mass spectrometric analysis. It is 
therefore unclear whether the granule extract contains these hybrid peptide species or whether 
they derive from a larger species e.g. a hybrid polypeptide that requires immunological 
processing. This is an important question since a better understanding of the antigen processing 
pathway and its cellular location would potentially foster novel therapeutic approaches to 
countering these events. 
 
The hypothesis to be tested in this thesis is that epitopes from hybrid polypeptides undergo 
immunological processing by conventional antigen-presenting cells and presentation by high-
risk HLA molecules. The aims of the study are given below with the experimental objectives: 
 
1. Identify novel naturally processed and presented epitopes (NPPEs) derived from 
hybrid polypeptides generated by the HLA class II processing pathway 
• Optimisation of an antigen delivery system (ADS) 
• APC pulsing and pHLA elution to identify novel hybrid epitopes 
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2. Investigate immunogenicity of hybrid polypeptides 







CHAPTER 2: MATERIALS AND METHODS  
2.1 Antigens and peptides 
All peptides were obtained lyophilised and re-constituted in dimethyl sulfoxide (DMSO). 
Peptides utilised in antigen delivery experiments and the synthetic pokeweed peptide used to 
verify the spectra of the natural peptide, were purchased from Thermo Fisher Scientific 
(Rockford, IL, USA) or Almac Sciences (Edinburgh, Scotland). Peptides were synthesised by 
Fmoc (9-fluorenylmethoxycarbonyl) solid-phase chemistry to more than 95% purity using mass 
spectrometry as well as reversed-phase high-performance liquid chromatography (RP-HPLC) 
to confirm identity and for purification of crude peptides. The amino acid sequence of each 
peptide is shown in Table 2.1. The control peptide contains the HLA-DR4-restricted 
GAD65(274-286) epitope embedded into the intersection of the C-peptide:WE14 sequence. 41- 
mer peptides were synthesised with an added cysteine residue at the C-terminus and a biotin 
moiety at the N-terminus.  
 
Table 2.1 Amino acid sequence of synthetic pokeweed peptide and peptides used for antigen 
delivery.  
†Highlighted sequence represents GAD65(274-286) epitope. Italicised and underlined 




Peptide MW (g/mol) Amino acid sequence 
GAD65(274-286) 1504    IAFTSEHSHFSLK 
C-peptide:WE14 4467 Biotin-EAEDLQVGQVELGGGPGAGSLQPLALWSKMDQLAKELTAEC 
Control 4584 Biotin-GGPGAGSLQPLALIAFTSEHSHFSLKWSKMDQLAKELTAEC 
PWM lectin-B (47-58) 1289 REASGKVCPDDL 
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Peptides used for FluoroSpot assays were synthesised by GL Biochem (Shanghai, China) to 
more than 95% purity using Fmoc-Glu(OtBu)-Wang resin (Table 2.2). Infanrix-hexa, a 
hexavaccine consisting of diphtheria, tetanus, pertussis, inactivated poliomyelitis, Haemophilus 
influenzae type b and hepatitis B was obtained from GlaxoSmithKline and used at 2 µL/mL per 
well as a positive control. Lyophilised Candida albicans antigen was purchased from Greer 
Laboratories (strain #10231, cat no: XPLM73X1A2), re-constituted to 1 mg/mL in phosphate 
buffered saline (PBS) and used at a final concentration of 2 µg/mL as a positive control for IL-
17A responses.  
 
Table 2.2 List of peptides used for FluoroSpot assays.  
 
†Highlighted sequences represent C-peptide components of HIPs. Blue and red represent 
WE14- and IAPP2-containing sequences, respectively. HIP, hybrid insulin peptide. 
2.2 Cell lines 
Table 2.3 lists the Epstein–Barr virus (EBV)-transformed B-lymphoblastoid cell lines (BLCLs) 
used in this study obtained from Public Health England (PHE)/European Collection of 
Authenticated Cell Cultures (ECACC). B cell lines were maintained in R10 medium (RPMI-
1640 GlutaMAX [Thermo Fisher Scientific], 100 U/mL penicillin, 100 μg/mL streptomycin 
[penicillin-streptomycin 100X stock solution, Thermo Fisher Scientific] and 10% [v/v] heat-
inactivated FCS) at a density of 0.3–0.6 × 106 cells/mL. To heat-inactivate, FCS was heated at 
56°C for 30 minutes in a water bath with occasional shaking. 
Peptide Amino acid sequence 
hEL:ChgA-WE14  
 






   WSKMDQLAKELTAEEAEDLQVGQVELGGGPGAGSLQPLAL 
 hEL:IAPP2  
 
            SLQPLALNAVEVLK 
C-peptide:IAPP2 
 
  EAEDLQVGQVELGGGPGAGSLQPLALNAVEVLKREPLNYLPL 





Table 2.3 EBV-transformed B-lymphoblastoid cell lines. 
 
Cell line DNA typing profile 
DRB1* DQA1* DQB1* 
WT51 04:01 03:01 03:02 
PF04015 03:01 05:01 02:01 
 
The murine T cell hybridoma T33 was donated by Dr Linda Wicker (University of Cambridge, 
Cambridge, UK). The hybridoma was generated in a HLA-DR4 transgenic mouse and 
recognises the GAD65(274-286) epitope presented by HLA-DR4 (Wicker et al., 1996). T33 
hybridoma cells were seeded in D10 medium (Dulbecco's Modified Eagle Medium [Thermo 
Fisher Scientific], 100 U/mL penicillin, 100 μg/mL streptomycin and 10% [v/v] heat-
inactivated  FCS) at a density of 0.1 × 106 cells/mL and split 1:10 every 2-3 days. 
 
2.3 Chapter 3  
2.3.1 DEC205 surface expression 
For all experiments, cells were used when split the day prior to assure good quality. WT51 cells 
were harvested and washed with 4 mL of FACS buffer (FB) comprised of 1X PBS and 3% (v/v) 
FCS and centrifuged (300g, 5 minutes, 20°C). After washing the tube for staining, the 
supernatant was decanted, cells were re-suspended in 100 µL of FB and 5 µL of Human 
TruStain FcX Fc receptor blocking solution (BioLegend, UK) added for 10 minutes on ice. 
WT51 cells were subsequently incubated with 2 μL of anti-human DEC205 antibody (BD 
Biosciences, PE-conjugated IgG2b, MG38 clone) or corresponding isotype control on ice for 
30 minutes in the dark. Cells were washed twice with 4 mL of FB, centrifuged (300g, 5 minutes, 
20°C) and the supernatant discarded. A 100 µL residual volume remained and 1 µL of 7-AAD 
Viability Staining Solution (eBioscience) was added for 5 minutes at room temperature in the 
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dark before analysis on a BD FACSCanto (BD Biosciences, San Jose, CA, USA). Unless 
otherwise stated, flow cytometry was performed by gating on live single cells (Figure 2.1) and 
FACS data analysed using FlowJo 10.1 software (FlowJo LLC). 
Figure 2.1 Representative gating strategy of FACS analysis. Gating was performed by first 
gating for the cell population based on forward and side scatter (far left). Doublets were then 
excluded and 7-AAD negative live cells gated (far right).  
 
2.3.2 Generation of pokeweed mitogen and anti-DEC205 conjugates 
Purified mouse anti-human DEC205 antibody was purchased (Bio-Rad, non-conjugated IgG2b, 
MG38 clone, cat no: MCA2258EL) at 1 mg/mL in PBS. Lectin from Phytolacca americana 
(pokeweed mitogen) was obtained from Sigma-Aldrich (cat no: L9379) as a lyophilised powder 
and re-constituted in PBS to 1 mg/mL. The extinction co-efficient of pokeweed mitogen (E1% 
= 18.5) was used to accurately determine the protein concentration by a NanoDrop 1000 
spectrophotometer (Thermo Fisher Scientific).  
 
Prior to conjugation, both proteins were prepared in Conjugation Buffer (1X PBS + 2 mM 
EDTA [0.5 M stock, Sigma-Aldrich]). Pokeweed mitogen and anti-DEC205 antibody were 
treated with a molar excess of sulfosuccinimidyl 4-(N-maleimidomethyl)cyclohexane-1 
carboxylate (10 mg/mL stock solution in double-distilled water; sulfo-SMCC from Thermo 
Fisher Scientific) crosslinker. Depending on the protein concentration, the molar excess of 
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crosslinker ranged from twenty-fold (protein concentration of 1-4 mg/mL) to fifty-fold (protein 
concentration of <1 mg/mL). After 30 minutes of incubation at room temperature with moderate 
agitation on an orbital shaker, excess crosslinker (MW: 436.37 g/mol) was removed using 7K 
MWCO Zeba Desalting Columns (Thermo Fisher Scientific). The concentration of sulfo-
SMCC activated carrier protein was determined after desalting using a NanoDrop 
spectrophotometer by measuring absorbance at 280 nm. The instrument uses the Beer-Lambert 
law (A = " c l; where A is absorbance, ε is molar extinction co-efficient, c is concentration and 
l is light path length) with the appropriate extinction co-efficients (IgG: 13.7 and pokeweed 
mitogen: 18.5) to determine protein concentration. Subsequently, peptide containing a C-
terminal cysteine and a N-terminal biotin group was added to sulfo-SMCC activated proteins. 
Peptides were added in Conjugation Buffer at a peptide/protein molar ratio of 5:1 (activated 
anti-DEC205 antibody; MW: 150 kDa) or 2:1 (activated pokeweed mitogen; MW: 32 kDa). 
Following 30 minutes of incubation at room temperature with moderate agitation on an orbital 
shaker, the generated conjugates were stored at -20°C until use. After thawing, conjugates were 
stored at 4°C. 
 
2.3.3 Pulsing of EBV-transformed B cells with crosslinked GAD65(274-286)-containing 
control peptide 
B cell lines were seeded at 10 × 106 cells/mL in R10 in sterile 1.5 mL Eppendorf tubes and 
pulsed with conjugates at a concentration of 2.18 or 0.218 µM for 30 minutes on ice. As a 
control, at the same time cells were pulsed with activated pokeweed mitogen or anti-DEC205 
antibody or peptide (biotin-labelled) alone comparable with the amount present in the 
conjugate. Where indicated, control EBV-transformed B cells were also pulsed with the 
equivalent concentration of DMSO peptide diluent or non-conjugated activated pokeweed 
mitogen and GAD65(274-286)-containing 41-mer. After 30 minutes, R10 (37ºC) was added to 
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adjust the cell concentration to 0.5 × 106 cells/mL (final ADS concentration of either 0.1 or 
0.01 µM) and cells incubated at 37ºC, 5% CO2 for 16 hours in a 12-well plate (Corning) to 
permit uptake. In a few experiments, non-pulsed cells were seeded in R10 at 0.5 × 106 cells/mL 
and three concentrations (2.18, 0.218 and 0.0218 µM) of control peptide (41-mer containing 
GAD65[274-286] epitope) added directly to the culture for 16 hours at 37ºC, 5% CO2.  
 
EBV-transformed B cells were harvested, washed with 8 mL of R10 and centrifuged (300g, 5 
minutes, 20°C). The supernatant was discarded and cells were counted (using Trypan blue 
[Sigma-Aldrich]) before co-culture with T33 hybridoma cells at a B cell-T cell ratio of 1:1. In 
each case, 100 µL of cells were added per well at a concentration of 1 × 106 cells/mL in a 96-
well plate (200 µL final volume per well). As a control, WT51 cells (DR4/DQ8) were pulsed 
at 1 × 106 cells/mL (100 000 cells/100 µL) for 30 minutes at 37ºC with the GAD65(274-286) 
epitope before subsequent co-culture with the T33 hybridoma (1:1 B cell-T cell ratio as above). 
GAD65(274-286) was used at equimolar (2.18 µM) to that of the 41-mer peptide in the ADS. 
T33 cells cultured with untreated EBV B cells and both cell lines cultured alone were used at 
negative controls. Following 6 hours of co-culture at 37°C, 5% CO2, supernatants were 
harvested for an IL-2 ELISA. IL-2 production was evaluated using the Mouse IL-2 ELISA 
Ready-SET-Go Kit (eBioscence, San Diego, CA, USA) according to the manufacturer’s 
instructions. 
 
2.3.4 Detection of conjugates at the cell surface 
EBV-transformed B cells were pulsed in multiples of 10 × 106 cells/mL as in (2.3.3) with 2.18 
µM of pokeweed-peptide conjugate, equivalent concentrations of activated pokeweed or 
peptide (biotin-labelled) alone and incubated at 37°C, 5% CO2 for 0–6 hours before being 
placed on ice to stop further internalisation. Samples were washed with 4 mL of FB, centrifuged 
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(300g, 5 minutes, 4°C) and the supernatant taken off. Cells were re-suspended in 100 µL of FB 
and 5 µL of Human TruStain FcX Fc receptor blocking solution added for 10 minutes on ice 
prior to the addition of 1 µL of anti-biotin antibody (BioLegend, PE-conjugated IgG2a, 1D4-
C5 clone) or corresponding isotype control. Following 30 minutes of incubation on ice in the 
dark, cells were washed twice with 4 mL of FB, centrifuged (300g, 5 minutes, 4°C) and the 
supernatant decanted. 1 µL of 7-AAD Viability Staining Solution was added in 100 µL 
suspension volume for 5 minutes at room temperature in the dark before acquisition on a flow 
cytometer. Cells pulsed with 2.18 µM of anti-DEC205-peptide conjugate were incubated at 
37°C, 5% CO2 over a shorter time period (0–2 hours) before biotin surface staining. In this case, 
staining was performed as above except 1 µL of APC-conjugated streptavidin (1 mg/mL; 
Invitrogen) in 100 µL was used to detect biotinylated peptide at the cell surface after pulsing.  
 
In some experiments it was necessary to confirm binding of the anti-DEC205-peptide conjugate 
to the cell surface. WT51 cells were pulsed at 10 × 106 cells/mL in R10 for 30 minutes on ice 
with either non-activated anti-DEC205, sulfo-SMCC activated anti-DEC205 or anti-DEC205-
peptide conjugate ensuring incubation with the same amount of antibody in each condition.  
Control cells were also pulsed with a mouse IgG2b negative control antibody (Bio-Rad, cat no: 
MCA691). After washing with 4 mL of FB and adding Fc receptor block solution, 1 µL of anti-
mouse IgG2b antibody (BioLegend, PE-conjugated IgG1, RMG2b-1 clone) was added in 100 
µL staining volume for 30 minutes on ice in the dark. Samples were washed twice with 4 mL 
of FB, centrifuged (300g, 5 minutes, 4°C) and the supernatant discarded. 1 µL of 7-AAD 
Viability Staining Solution was added in 100 µL suspension volume for 5 minutes at room 




2.3.5 Detection of biotinylated peptide within anti-DEC205 conjugate  
Anti-mouse Ig κ CompBeads (BD Biosciences, San Jose, CA) were washed once with 4 mL of 
FB, spun at 300g for 5 minutes (20°C) and the supernatant discarded before addition of 2.18 
µM of anti-DEC205-peptide conjugate for 20 minutes at room temperature. As a control, 
CompBeads were also incubated with activated anti-DEC205 antibody and peptide alone equal 
to that present in the conjugate. After 20 minutes beads were washed twice with 4 mL of FB, 
centrifuged (300g, 5 minutes, 20°C) and the supernatant discarded before adding 1 µL of APC-
conjugated streptavidin for 30 minutes on ice in the dark. Samples were washed twice with 4 
mL of FB, centrifuged (300g, 5 minutes, 4°C) and the supernatant decanted prior to acquisition 
on a flow cytometer by gating on the bead population. 
 
2.3.6 Imaging flow cytometry 
WT51 cells were pulsed at 10 × 106 cells/mL with either 10 µg/mL of fluorophore-conjugated 
anti-human DEC205 antibody (BD Biosciences, PE-conjugated IgG2b, MG38 clone) or 5 
µg/mL of APC-conjugated pokeweed mitogen for 30 minutes on ice. Pokeweed mitogen was 
pre-conjugated with APC using an APC conjugation kit (Abcam ab201807), following the 
provided protocol. Cells were also pulsed with either an anti-human HLA-DR antibody 
(BioLegend, APC-conjugated IgG2a, L243 clone) or an anti-human HLA-DQ antibody 
(BioLegend, PE-conjugated IgG1, HLADQ1 clone) as a positive control for surface staining. 
After pulsing, cells were seeded at 0.5 × 106 cells/mL in R10 at 37°C, 5% CO2 in a 12-well 
plate. At specific time points as indicated in the figure legend, cells were harvested into sterile 
1.5 mL Eppendorf tubes and placed on ice. Samples were washed three times with 1 mL of FB 
(4°C), centrifuged (300g, 5 minutes, 4°C) and the supernatant removed by aspiration. Cells 
were re-suspended in 50 µL of FB (4°C) and analysed on the ImageStream X MKII (Amnis-
Luminex) imaging flow cytometer at 40X magnification. A minimum of 20 000 pre-gated cells 
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were acquired per sample. Channel 1 (PE-conjugated anti-DEC205 monoclonal antibody) or 9 
(APC-conjugated pokeweed mitogen) detects brightfield. Channel 11 and 3 was used for APC 
and PE, respectively. Channel 6 was used for side scatter. All other channels were turned off 
during acquisition. Laser powers were set to the maximum. 
 
For data analysis, Amnis® IDEAS version 6.2 (Luminex Corporation) was used. Cells were 
analysed using the gating strategy shown in Figure 2.2: single cells (brightfield area versus 
aspect ratio), cells in focus (histogram of gradient RMS) and cells positive for either APC or in 
some cases PE. For the measurement of internalisation, an object mask based on the brightfield 
cell image (channel 1/9) was first created and then eroded by 4-5 pixels to exclude the cell 
membrane. The internalisation score was then calculated on this eroded object mask as well as 
the fluorescent image of the relevant channel in the Internalisation feature provided in the 
IDEAS software. The internalisation score is defined as the ratio of the intensity inside the cell 
to the intensity of the entire cell. Samples pulsed for 0 hours were used as imaging controls. 
Figure 2.2 Gating strategy for ImageStream analysis. Single cells were first identified based 
on a dot plot of brightfield area versus aspect ratio (far left). Using this population, cells are 
then gated based on focus using gradient RMS (middle). To gate PWM-APC-positive cells, a 
dot plot of the side scatter intensity (Intensity_Ch06) versus the fluorescence intensity of APC 
(Intensity_Ch11) was used (far right). APC+ gate was set using an unstained control. This 
population was used for all downstream analyses. 
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2.3.7 Fixation of EBV-transformed B cells pulsed with crosslinked GAD65(274-286)-
containing control peptide 
EBV-transformed B cells were pulsed with 2.18 µM of pokeweed-peptide conjugate or 
activated pokeweed mitogen alone as described previously (2.3.3) and incubated at 37°C, 5% 
CO2 for specific time periods (indicated in figure legend). After being removed from culture 
cells were washed once with 1X PBS (no serum), centrifuged (200g, 3 minutes, 20°C) and the 
supernatant removed before gentle fixation with 2 mL of 0.1% (v/v) paraformaldehyde in PBS 
(16% stock solution, Electron Microscopy Sciences) for 30 minutes at room temperature in the 
dark. Samples were then washed twice with 1X PBS-5% (v/v) FCS, centrifuged (200g, 3 
minutes, 20°C) and the supernatant decanted. Cells were counted and cultured at a 1:1 ratio 
(100 000 cells each) in a 96-well plate with the T33 hybridoma at 37°C, 5% CO2. T33 cells 
were also cultured alone or with PMA (50 ng/mL) and ionomycin (1 μg/mL) as negative and 
positive controls, respectively. Supernatants were harvested after 16 hours of incubation for 
determination of IL-2 as mentioned previously (2.3.3). 
 
2.4 Chapter 4 
2.4.1 Pulsing of EBV-transformed B cells with pokeweed mitogen crosslinked to C-
peptide:WE14 
For each pulsing experiment, 100–150 × 106 B cells were pulsed at the same time, with multiple 
rounds of pulsing being performed. EBV-transformed B cells were centrifuged at 500g for 8 
minutes at room temperature. All subsequent centrifugation steps were performed at 4°C. The 
cell pellet was washed first with 50 mL of room temperature 1X PBS and then with 1X PBS 
(4°C) by centrifugation at 400g for 5 minutes. Cells were re-suspended in 1X PBS (4°C) to 20 
× 106 cells/mL and placed on ice. Crosslinked pokeweed-hybrid polypeptide was diluted to 
4.36 µM in 1X PBS (4°C) and mixed in a 1:1 ratio with the cell suspension giving an ADS final 
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concentration of 2.18 µM. Following 30 minutes of incubation on ice, R10 medium (37°C) was 
added to adjust cells to 0.5 × 106 cells/mL (final ADS concentration 0.1 µM) and seeded in 
multiple T175 flasks (Corning) for 16 hours laid flat in the incubator at 37°C, 5% CO2. Pulsed 
cells were harvested, pooled and washed twice with 50 mL of 1X PBS (4°C) by centrifugation 
(400g, 5 minutes, 4°C). A final wash step was performed (600g, 5 minutes, 4°C) to give a dense 
cell pellet. The supernatant was aspirated and the cell pellet stored at -80°C for immunoaffinity 
purification.  
 
2.4.2 Anti-biotin and HLA class II surface staining of EBV-transformed B cells pulsed with 
crosslinked C-peptide:WE14 
After pulsing with the pokeweed-C-peptide:WE14 conjugate, EBV-transformed B cells were 
stained with an anti-biotin antibody following the protocol described previously (2.3.4). To 
detect surface HLA-DR and -DQ expression, Fc block was performed and cells stained for 30 
minutes on ice with 10 µg/mL of anti-DQ antibody (Bio-Rad, non-conjugated IgG2a, SPVL3 
clone, cat no: MCA279G) or negative control mouse IgG2a antibody (Dako Cytomation, cat 
no: X0943). After washing twice with 4 mL of FB, cells were stained for 30 minutes on ice in 
the dark with 1 µL of anti-mouse IgG2a secondary antibody (BioLegend, PE-conjugated IgG, 
RMG2a-62 clone) and 1 µL of anti-human HLA-DR antibody (BioLegend, APC-conjugated 
IgG2a, L243 clone). Samples were also stained with the corresponding HLA-DR isotype 
control antibody. Afterward, cells were washed twice with 4 mL of FB, centrifuged (300g, 5 
minutes, 20°C) and the supernatant discarded. 1 µL of 7-AAD Viability Staining Solution was 
added in 100 µL for 5 minutes at room temperature in the dark before acquisition on a BD 




2.4.3 Purification of anti-DR (L243) and anti-DQ (SPVL3) antibodies 
Murine ascites fluid containing the L243 monoclonal antibody was generated previously by 
Harlan Sera-Lab (Loughborough, UK). SPVL3 ascites was produced by ProMab 
Biotechnologies (Richmond, CA, USA) by firstly priming BALB/c mice with 0.5 mL pristine 
for 1-2 weeks before injecting 1-2 × 106 viable hybridoma cells per mouse. The ascites fluid 
was harvested after 4 weeks and centrifuged to remove particles. L243 and SPVL3 antibodies 
were purified from ascitic fluid using the Melon Gel Monoclonal IgG Purification Kit (Thermo 
Fisher Scientific) according to the manufacturer’s instructions. Briefly, the ascites fluid was 
treated with Ascites Conditioning Reagent (Thermo Fisher Scientific, cat no: 45219) before 
dialysing into 1X Melon Gel Purification Buffer. The dialysed sample is added to a column 
containing a proprietary resin which binds non-IgG proteins and pure IgG is recovered in the 
flow through fraction. Purified antibodies were buffer-exchanged into PBS for downstream 
applications using 7K MWCO Zeba Delating Columns. The concentration and purity of the 
recovered antibodies were analysed by a NanoDrop spectrophotometer and SDS-PAGE, 
respectively.  
 
2.4.4 Confirmation of HLA binding capacity of in-house purified antibodies 
WT51 cells were washed with 4 mL of FB, centrifuged (300g, 5 minutes, 20°C) and the 
supernatant removed before re-suspending in 100 µL of FB and incubating with 5 µL of Human 
TruStain FcX Fc receptor blocking solution for 10 minutes on ice. Cells were stained with a 
titration (0.01 – 10 µg/mL) of either in-house purified antibodies, commercially available L243 
(LEAF Purified anti-human HLA-DR Antibody, BioLegend)/SPVL3 (Anti-HLA-DQ antibody 
[SPV-L3] ab23632, Abcam) or 10 µg/mL of negative control mouse IgG2a antibody for 30 
minutes on ice. After washing twice with 4 mL of FB, samples were stained with 1 µL of PE-
conjugated anti-mouse IgG2a secondary antibody for a further 30 minutes on ice in the dark. 
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Cells were washed twice with 4 mL of FB, centrifuged (300g, 5 minutes, 20°C) and the 
supernatant decanted before acquisition on a BD FACSCanto flow cytometer.  
 
2.4.5 Crosslinking of antibodies to Protein A Sepharose 
One millilitre of Protein A Sepharose beads (Fast Flow; GE Healthcare) was added to a Poly-
Prep Chromatography column (BioRad), washed with 10 resin volumes (RV) of a solution 
containing 0.1M boric acid and 0.1M KCl (borate buffer; pH 8.0) and subsequently incubated 
with 5 (SPVL3) to 10 mg (L243) of purified anti-HLA-class II antibody with moderate rotation 
for 1 hour at room temperature. The beads were then washed with 10 RV of 0.2 M 
triethanolamine (pH 8.2; Sigma-Aldrich) and the bound antibody was crosslinked by using 40 
mM dimethyl pimelimidate dihydrochloride (DMP; Sigma-Aldrich) (pH 8.3) for 1 hour at room 
temperature. The crosslinking reaction was terminated by the addition of 10 RV ice-cold 0.2 
Tris buffer (pH 8.0). Any unbound antibody was removed by using 0.1M citrate buffer (pH 3.0) 
and the column stored in borate buffer supplemented with 0.02% (w/v) sodium azide (Sigma-
Aldrich) at 4°C until use.  
 
2.4.6 Isolation of peptide-HLA complexes and peptide purification 
Cell pellets were thawed on ice and dissociated using 2 mL (per 100 × 106 cells) of cell lysis 
buffer (150 mM NaCl, 20 mM Tris [pH 8.0], 1 mM EDTA, 6 mM Sodium deoxycholate 
detergent [Sigma-Aldrich], 34 mM Octyl β-D-glucopyranoside [Sigma-Aldrich] and protease 
inhibitors [Complete Protease Inhibitor Cocktail tablets, Roche Life Science, Indianapolis, 
IN]). Cell membranes were further disrupted by sonication (QSonica, Newtown, CT) using five 
(100 ms/s) pulses at 20% amplitude until all the visible precipitates were solubilised. Lysates 
were pre-cleared using microfuge centrifugation (20 000g, 30 minutes, 4°C). Soluble cell 
lysates were loaded by gravity flow onto a series of pre-equilibrated immunoaffinity columns 
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set up in tandem at 4°C. To remove non-specific binding proteins, the lysate was first passed 
over a column containing Protein A Sepharose beads without crosslinked antibody. The flow 
through from this pre-column was set up to drip directly onto affinity columns with crosslinked 
L243 and SPVL3 antibodies. Lysate loading onto the affinity columns was repeated three times 
before separating the columns for washing steps of 20 RV with low salt buffer (150 mM NaCl, 
20 mM Tris, pH 8.0), high salt buffer (450 mM NaCl, 20 mM Tris, pH 8.0), low salt buffer and 
no salt buffer (10 mM Tris, pH 8.0). The peptides were subsequently eluted with 5 RV of 10 % 
(v/v) acetic acid (Acetic Acid, Glacial Optima LC/MS Grade [Fisher Chemical]).  
 
After elution, HLA molecules and HLA-binding peptides were separated using a Sep Pak C18 
cartridge (Waters, Milford, MA, USA). The cartridge was wetted twice with 1 mL 50% (v/v) 
acetonitrile (ACN):double-distilled water (ddH2O) and rinsed twice with 1 mL 0.1% (v/v) 
trifluoroacetic acid (TFA):ddH2O. After equilibrating the cartridge twice with 1 mL 2% (v/v) 
ACN:0.1% TFA:ddH2O, the sample was loaded onto the cartridge and the flow through 
collected. The cartridge was washed twice with 1 mL 2% (v/v) ACN:0.1% TFA:ddH2O and 
peptides eluted with 400 µL 30% (v/v) ACN:0.1% TFA:ddH2O into a Protein LoBind 
Eppendorf tube (Sigma-Aldrich). HLA molecules were eluted using 400 µL 80% (v/v) 
ACN:0.1% TFA:ddH2O. Eluates were vacuum concentrated to complete dryness before being 
delivered to the Proteomics Core Facility at Denmark Hill (King’s College London).  
 
2.4.7 Liquid chromatography-tandem mass spectrometry (LC-MS/MS) method and database 
search 
Samples were re-constituted in 2% (v/v) ACN-0.1% formic acid (FA) loading buffer and 
approximately 50% used for LC-MS/MS analysis. Chromatographic separation was performed 
using an Ultimate 3000 NanoLC system (Thermo Fisher Scientific). Peptides were resolved by 
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reversed phase chromatography on a 75 µm × 50 cm C18 column using a four-step linear 
gradient of water in 0.1% (v/v) formic acid (A) and 80% (v/v) acetonitrile in 0.1% formic acid 
(B). The gradient was delivered to elute the peptides at a flow rate of 250 nL/minutes over 90 
minutes. The eluate was ionised by electrospray ionisation using an Orbitrap-Fusion-Lumos 
(Thermo Fisher Scientific) operating under Xcalibur v4.1. The instrument was programmed to 
acquire using a “Universal” method by defining a 3s cycle time between a full MS scan and 
MS/MS fragmentation. The MS/MS analyses were conducted using collision energy profiles 
that were chosen based on the mass-to-charge ratio (m/z) and the charge state of the peptide. 
 
Raw mass spectrometry data were processed into peak list files using both Proteome Discoverer 
(ThermoScientific; v2.2) (PD 2.2) and Peakstudio 7.5. Processed data was then searched using 
both Mascot search algorithm (www.matrixscience.com) embedded in PD 2.2 and Peaks DB 
search, against the current version of the reviewed Swissprot Homo sapiens database 
downloaded from Uniprot (http://www.uniprot.org/uniprot/) combined with in-house created 
sequences of the C-peptide:WE14 polypeptide and synthetic pokeweed peptide (Table 2.1).  
 
2.4.8 SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and Western blot 
Samples were boiled at 95°C in Laemmli sample buffer (Bio-Rad) containing 355 mM β-
mercaptoethanol (Sigma-Aldrich) for 10 minutes and loaded alongside a Color Prestained 
Protein Standard (Broad Range 10-250 kDa, New England Biolabs) on denaturing 
polyacrylamide gels (either 10% or 4-20% w/v) purchased from Bio-Rad. Gels were run in a 
mini-gel apparatus (Bio-Rad) in Tris/Glycine/SDS running buffer (Bio-Rad) at 100V until the 
dye front reached the end of the gel. After electrophoresis, gels were either used for 
immunoblotting or stained with Coomassie blue (Coomassie Brilliant Blue R-250 Staining 
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Solution, Bio-Rad) overnight with moderate agitation. Gels were de-stained in several changes 
of 10% (v/v) acetic acid (Sigma-Aldrich) until the background was clear.  
 
For Western blotting, gels were transferred onto a nitrocellulose membrane (GE Healthcare) 
and blocked with 5% (w/v) nonfat dry milk in Tris Buffered Saline (TBS) with 0.1% (v/v) 
Tween-20 (TBST) for 1 hour at room temperature. The membrane was incubated with either 
an anti-HLA-DR primary antibody (1:200 dilution; TAL 1B5, Santa Cruz Biotechnology) or 
an anti-HLA-DQA1 antibody (1:10 000 dilution; EPR7300, ab128959, Abcam) at 4°C 
overnight. After washing with TBST, a goat anti-mouse or anti-rabbit secondary antibody 
conjugated to a DyLight 680 fluorescent dye (1:10 000 dilution; Cell Signalling) was added at 
room temperature for 1 hour. Membranes were washed with TBS and the antibody signals 
imaged using the Li-Cor Odyssey CLx imaging system. 
 
2.5 Chapter 5 
2.5.1 Subjects  
Cryopreserved peripheral blood mononuclear cell (PBMC) samples from twenty T1D patients 
(age range 18-38 yrs, median: 26 yrs; disease duration range 1-11 months, median: 5 months) 
were obtained from the T1D Biobank (Dr Timothy Tree, King’s College London). The Biobank 
contains a collection of PBMCs from patients considered to have T1D by the local diabetes 
team (based upon clinical presentation and/or the presence of islet autoantibodies) with an 
intention to start or has already started on insulin therapy. Diagnosis made within the last 12 
months.  
 
Patients were recruited onto the “T cell studies in Type 1 diabetes” study at Guy’s and St 
Thomas’ Hospital and Bristol Royal Infirmary. This study was carried out with the approval of 
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the UK National Research Ethics Service (REC reference 08/H0805/14) and informed consent 
was obtained from all participants. PBMCs were isolated from fresh heparinised blood on 
density gradients before being frozen in heat-inactivated 90% foetal calf serum (FCS; 
Gibco)/10% (v/v) DMSO (Sigma-Aldrich) or in some cases CryoStor (Sigma-Aldrich) and 
samples stored in liquid nitrogen. Basic demographic information of each patient is shown in 
Table 2.4. HLA-DRB1 and -DQB1 genotyping was performed by the Clinical Transplantation 
Laboratory (Guy’s Hospital, London, UK). 
Table 2.4 Patient demographics.  
Patient Sex Age (y) T1D (m) DRB1* DQB1* 
Allele 1 Allele 2 Allele 1 Allele 2 
G695  M 20 9 03:01 13:02 02:01 06:04 
G697 F 24 6 03:01 04:01 02:01 03:02 
G705 M 27 9 04:01 13:01 03:02 06:03 
G712 F 18 5 03:01 04:01 02:01 03:02 
G713 F 23 8 04:01 04:01 03:02 03:02 
G716 F 18 1 04:01 13:01 03:02 06:03 
G729  M 24 3 04:01 13:01 03:01 06:03 
G732 F 30 5 03:01 03:01 02:01 02:01 
G733 M 32 6 07:01 13:02 02:01 06:04 
G772 M 26 3 03:01 04:01 02:01 03:02 
G804 M 26 4 04:01 13:02 03:02 06:04 
G817 F 20 <1 04:01 13:01 03:02 05:01 
G819 M 27 11 07:01 15:01 02:01 06:02 
G832 M 26 2 03:01 07:01 02:01 02:01 
NDB115  M 26 1 04:01 04:01 03:01 03:02 
NDB116  F 18 3 01:01 04:01 03:01 05:01 
NDB118  M 24 1 01:01 03:01 02:01 05:01 
NDB119  M 38 7 04:01 13:02 03:02 06:04 
NDB121 M 30 8 01:01 04:01 03:01 05:01 
NDB129 F 26 9 03:01 08:01 02:01 04:01 
†A high-resolution typing result is given for DRB1*04:01. Other results reported to four digits 
in this table represent the first allele in a string of alleles, as only low to medium resolution 
typing was performed. F, female; M, male; G, patients recruited at Guy’s Hospital; NDB, 
patients recruited at Bristol Royal Infirmary. Patient age was rounded down. 
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2.5.2 FluoroSpot assay 
FluoroSpot assays were carried out using an IFN-g, IL-22, IL-17A FluoroSpot kit (FSP-
011803-10, Mabtech, Sweden). Cryopreserved PBMCs from T1D patients were thawed and 
washed twice with thawing media (RPMI-1640 GlutaMAX, 100 U/mL penicillin, 100 μg/mL 
streptomycin, 2.5 µg/mL amphotericin B [Fungizone, Thermo Fisher Scientific] and 10% [v/v] 
heat-inactivated FCS) before centrifugation (first wash: 200g, 10 minutes, 20°C; second wash: 
400g, 5 minutes, 20°C). Cells were seeded in a 48-well plate at a density of 2 × 106 cells/mL 
in 0.5 mL complete media (RPMI-1640 GlutaMAX, 100 U/mL penicillin, 100 μg/mL 
streptomycin and 2.5 µg/mL amphotericin B) supplemented with 10% (v/v) heat-inactivated 
human AB serum (Sigma-Aldrich) supplemented with peptide at a final concentration of 6.64 
µM. Control wells contained PBMCs stimulated with an equivalent concentration of DMSO 
peptide diluent or Infanrix-hexa and Candida albicans antigen. After 48 hours, non-adherent 
cells from each well (1 × 106/well) were harvested using complete media/2% (v/v) human AB 
serum, centrifuged (400g, 10 minutes, 20°C) and the supernatant decanted. Cells were re-
suspended in complete media/10% (v/v) human AB serum at a concentration of 3.3 × 106/mL 
and 100 µL of cells aliquoted into triplicate wells of a pre-coated FluoroSpot plate (mAbs 1-
D1K, 9D7 and MT44.6) pre-blocked with complete media/10% (v/v) human AB serum for 2 
hours at room temperature.  
 
Plates were incubated for 21 hours at 37°C, 5% CO2 prior to spot development. Cells were 
discarded and plates washed five times with 1X PBS (200 µL/well). Bound cytokines were 
detected using BAM-peptide tagged mAb 7-B6-1, WASP-peptide tagged mAb MT504 and 
biotin-labelled mAb 12G8 diluted according to the manufacturer’s instructions and 100 µL 
added to each well for 2 hours of incubation at room temperature. Plates were then washed five 
times with 1X PBS (200 µL/well) before adding the fluorophore conjugates: anti-BAM-490, 
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streptavidin-550 or anti-WASP-640 (each diluted 1:200 in 1X PBS/0.1% [v/v] BSA), followed 
by a 1 hour incubation at room temperature. Plates were washed with 1X PBS (200 µL/well) 
and 50 µL/well of fluorescence enhancer added for a 15 minute incubation at room temperature. 
After discarding the fluorescence enhancer, the underdrain (plastic attached to the bottom 
surface of the plate) was removed before leaving the plates to dry in the dark. The numbers of 
spot forming units (SFU) were determined using a Mabtech IRIS FluoroSpot reader (Mabtech, 
Sweden) with software enabling overlay analysis of cells secreting all three cytokines. 
Stimulation index (SI) was calculated as follows: SI = total sum of SFUs in peptide-containing 
wells/total sum of SFU in negative control (DMSO) wells. To identify responders, Receiver 
Operating Characteristic (ROC) curve analysis performed previously using ELISpot data (Arif 
et al., 2004) indicated an optimal SI cut-off of 3.0 for IFN-g. For consistency, a cut-off of 3.0 
was also applied to IL-17A and IL-22.  
 
2.5.3 Statistical analysis  
The number of individuals eliciting a positive cytokine response was compared between 
different peptides using Fisher’s exact test (QuickCalcs GraphPad). Analyses of paired SI IFN-
γ responses to short and long hybrid peptides were carried out using the Wilcoxon signed rank 
test for pairing (GraphPad Prism). A 2x2 contingency table was also used to compare hybrid 
polypeptide responders and non-responders firstly, to that of the corresponding reversed 
orientation sequence and secondly, to the short epitope sequence and a p-value computed using 
Fisher’s exact test. Differences were considered statistically significant at p <0.05. 
 
2.6 In silico data analysis 
Peptides with a FDR less than 1% were discarded and duplicate peptides deleted. For binding 
motif prediction, the standard sequence logo option of the programme Icelogo (Colaert et al., 
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2009) was used. Subcellular location of the human proteome was matched to source proteins 
of eluted peptides. Human proteome data was retrieved from the UniProt database (UniProt 
Consortium, 2012) using only reviewed records that have subcellular location annotations. For 
binding affinity prediction of eluted peptides and overlapping 15-mers the NetMHCII 2.3 
algorithm (Jensen et al., 2018) was used. The NetMHCII 2.3 Server was also used for binding 
core sequence prediction. The program SitePrediction (Verspurten et al., 2009) was used to 
identify cathepsin cleavage sites in the C-peptide:WE14 sequence.  
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CHAPTER 3: OPTIMISATION OF AN ANTIGEN DELIVERY SYSTEM 
3.1 Background to the Chapter  
The hypothesis to be tested is that the hybrid peptides that have been described (Baker et al., 
2018; Baker et al., 2019b; Delong et al., 2016; Wiles et al., 2019) derive from a larger species 
i.e., a hybrid polypeptide which requires immunological processing via canonical antigen 
presentation pathways. To address this hypothesis, I aim to identify novel naturally processed 
and presented epitopes (NPPEs) derived from a hybrid polypeptide, generated by the HLA class 
II processing pathway. In order to do so, the polypeptide antigen needs to be targeted to the 
surface of APCs for uptake, processing and presentation. This chapter explores the use of two 
methods of antigen delivery, pokeweed mitogen (PWM) and DEC205 (CD205) to optimise 
delivery of a long peptide containing a known epitope.  
 
Initial attempts to study epitopes of exogenous antigens naturally presented by APCs adopted 
pulsing of EBV B cells with recombinant autoantigen in the context of Goodpasture disease 
(Phelps et al., 1996). Insufficient peptide material was obtained to identify epitopes bound to 
HLA-DR15, likely due to poor passive uptake by B cells (Chicz et al., 1992). Hence, the need 
for an antigen delivery system (ADS) is critical to overcome this issue. (Peakman et al., 1999) 
pioneered development of a lectin-based ADS to identify NPPEs derived from the intracellular 
domain of insulinoma-associated antigen-2 (IA-2ic) presented by HLA-DR4. Here the authors 
target antigen onto the surface of EBV B cells by incubation sequentially on ice with 
biotinylated pokeweed mitogen (bPWM), avidin-D and biotinylated IA-2ic. bPWM binds 
preferentially to carbohydrate moieties on cell surface receptors with immunoglobulin-like 
domains e.g. the BCR (Chilson and Kelly-Chilson, 1989). Avidin is then used as a bridge 
between bPWM bound to the cell surface and biotinylated IA-2ic permitting rapid 
internalisation, processing and presentation following incubation at 37°C. Synthetic peptides 
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of IA-2ic based on NPPEs identified by elution were found to bind HLA-DR4 and stimulate T 
cell proliferation in HLA-DR4-positive patients but not in controls. More recently, epitopes of 
GAD65 have also been eluted by pulsing of EBV B cells with PWM crosslinked to whole 
GAD65 (Peakman, unpublished). Presumably, efficient delivery of antigen in these systems is 
due to the ability of PWM to enhance APC function, because it is a polyclonal activator. 
Altogether, these findings support the use of a PWM-based ADS in directing antigens into the 
class II processing pathway and the generation of disease-relevant epitopes.  
 
3.2 Use of DEC205 for APC targeting 
DEC205 is a C-type multilectin transmembrane receptor expressed preferentially by DCs and 
thymic epithelial cells (Jiang et al., 1995). C-type lectin receptors are a diverse group of 
receptors originally identified as Ca2+-dependent proteins capable of binding carbohydrate 
moieties of endogenous and exogenous origin to trigger phagocytic responses (Figdor et al., 
2002). In DCs, the DEC205 receptor is endocytosed into clathrin-coated pits and recycled 
through late endosomal/lysosomal compartments rich in MHC class II molecules, leading to 
efficient antigen presentation to CD4+ T cells (Mahnke et al., 2000). B cells express low levels 
of DEC205 but this increases significantly upon activation (Kamphorst et al., 2010). Thus, 
given its potent role in antigen presentation in DCs, DEC205-targeted antigen delivery in B 
cells has also gathered interest (Gurer et al., 2008; Leung et al., 2013). 
 
Leung and colleagues (2013) were able to show that EBV-transformed B cells express similar 
levels of DEC205 to DCs and are capable of processing and presenting DEC205-targeted EBV 
antigens to peptide-specific CD4+ and CD8+ T cell clones. To target EBV antigens to the 
DEC205 receptor the authors cloned and purified fusion antibodies containing the COOH 
terminus of a monoclonal anti-human DEC205 antibody fused to cDNA encoding a sequence 
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of amino acids derived from different EBV antigens. Interestingly, incubation of anti-DEC205 
fusion antibodies with EBV B cells stimulated higher IFN-g secretion by T cells than targeting 
DEC205 on monocyte-derived DCs. The authors propose that EBV B cells retain antigen 
targeted by DEC205 for longer than DCs therefore prolonging T cell activation. Undoubtedly, 
targeting of DEC205 posed an additional method of antigen delivery to be investigated in the 
current study.  
 
To first confirm expression of DEC205 on an EBV B cell line harbouring the T1D-associated 
HLA-DR4-DQ8 haplotype, WT51 cells were stained with an anti-DEC205 monoclonal 
antibody (aDEC205) and analysed by flow cytometry (Figure 3.1). Consistent with the findings 
of (Leung et al., 2013), DEC205 was expressed at high levels prompting further exploration as 












Figure 3.1 Cell surface expression of DEC205 on WT51 B cell line. WT51 cells were analysed 





3.3 Construction of antigen delivery strategies  
To evaluate PWM and DEC205 as putative delivery systems, optimisation studies focused on 
processing and presentation of a 41-mer peptide containing a HLA-DR4-restricted 
GAD65(274-286) epitope embedded within a hybrid polypeptide (control peptide in Table 2.1). 
The presence of a C-terminal sulfhydryl group (-SH) permits covalent conjugation of the 41-
mer peptide to amine-containing (-NH2) proteins such as PWM or an anti-human DEC205 
antibody via a heterobifunctional crosslinker (Figure 3.2). PWM- and aDEC205-peptide 
conjugates were used to pulse WT51 cells for 30 minutes on ice at high cell density to increase 
fractional saturation (number of receptors occupied by ligand). To adjust the cell concentration 
to a suitable density for overnight culture at 37°C, fresh culture medium was added, thus 
diluting the peptide conjugate. T33.1 hybridoma cells (recognise the GAD65[274-286] epitope 
in the context of HLA-DR4) (Wicker et al., 1996) were used as a readout of antigen presentation 
by co-culture with pulsed B cells (Figure 3.3). 
Figure 3.2 Crosslinking of peptide to carrier protein. Sulfo-SMCC activates amine groups 
within the carrier protein to form a maleimide-activated intermediate. This intermediate 
spontaneously reacts with free sulfhydryl groups of cysteine residues within the peptide to form 
a stable covalent linkage. Adapted from SMCC and sulfo-SMCC product instructions 













Figure 3.3 Schematic of ADS pulsing. As presentation of the GAD65(274-286) epitope is 
restricted to HLA-DR4, an EBV B lymphoblastoid cell line (BLCL) expressing HLA-DR4 was 
used for pulsing experiments.   
 
3.4 Assessing ADS efficiency of antigen presentation  
To be an efficient ADS, covalent conjugation to a carrier protein should enhance delivery of 
the GAD65(274-286)-containing 41-mer peptide. This was assessed by comparing activation 
of the T33 hybridoma by co-culture with either WT51 cells pulsed with conjugated peptide or 
co-incubated with 41-mer peptide for 16 hours in the absence of pulsing (Figure 3.4A). As a 
positive control, prior to co-culture WT51 cells were pulsed with the short 13-mer GAD65(274-
286) epitope for 30 minutes at 37°C at equimolar concentration to the 41-mer peptide. The 
GAD65(274-286) epitope binds externally to HLA-DR4 molecules present on the APC 
therefore directly stimulating the T33 hybridoma. IL-2 production by T33 cells during co-
culture with B cells pulsed with 41-mer peptide or activated PWM alone was also measured. In 
the case of activated PWM, addition of the crosslinker to crude PWM has generated a stable 
maleimide-activated intermediate but deprived of peptide for conjugation.  
 78 
The data show that co-incubation of B cells with a titration of 41-mer peptide for 16 hours 
induced dose-dependent IL-2 secretion by the T cell hybridoma (Figure 3.4B, C). This indicated 
that the GAD65(274-286) epitope can be generated from the 41-mer peptide and passive uptake 
by the WT51 B cell line is possible. Pulsing with 2.18 µM of PWM-conjugated peptide for 30 
minutes followed by twenty-fold dilution of the peptide (0.1 µM final), results in a similar level 
of T cell activation (approximately 60%, normalised to the GAD65[274-286] positive control) 
to co-incubation with 2.18 µM of 41-mer peptide for 16 hours. Similar T cell activation (3-5%) 
was also observed following pulsing with 0.218 µM of PWM-peptide conjugate (0.01 µM final) 
and co-incubation with 0.218 µM of 41-mer peptide, although IL-2 levels appear 
indistinguishable from the activated PWM alone control. Moreover, B cells pulsed with the 41-
mer peptide alone did not stimulate the T33 hybridoma and co-culture with activated PWM-
pulsed B cells produced a low background level of IL-2. These data indicate that the 41-mer 
peptide lacks the capacity to bind directly to HLA-DR4 present on the APC surface and then 
present GAD65(274-286); and that activated PWM does not have a direct mitogenic effect on 
the T33 hybridoma. Thus, individually the components within the PWM-peptide conjugate do 
not cause activation of the T cell hybridoma.  
 
In further support of the need for conjugation, pulsing of WT51 B cells with non-conjugated 
activated PWM and 41-mer peptide stimulates IL-2 secretion above background (7% of 
GAD65[274-286] response) but this does not reach the same level of T cell activation achieved 
if the two components are conjugated (~60%). Most likely this response is due to spontaneous 
conjugation of the two components, even at 4°C, albeit at a low level. Surprisingly, pulsing 
with an aDEC205-peptide conjugate yielded no T cell response at either of the concentrations 
tested. Taken together, these findings suggest that twenty-fold more peptide is necessary for 16 
hours’ incubation to reach a similar T cell activation compared with a PWM-based ADS, 
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demonstrating enhancement in the delivery of the 41-mer peptide into the APC for processing. 
All downstream pulsing experiments were performed using the peptide molarity shown in 


















Figure 3.4 Pulsing with PWM-peptide conjugate enhances delivery of a 41-mer peptide 
containing an immunodominant T cell epitope from GAD65. A depicts a schematic of the 
experimental strategy. IL-2 production by the GAD65(274-286)-specific T33 hybridoma was 
measured following co-culture with WT51 EBV B cells (APC) either co-incubated with a 41-
mer GAD65(274-286)-containing peptide for 16 hours or pulsed with an ADS. Within the ADS, 
the 41-mer peptide is conjugated to either PWM or aDEC205. A hyphen signifies conjugation 
of ADS components. B and C show data from a representative experiment and combined data 
from three independent experiments expressed as percentage of stimulation with GAD65(274-
286) peptide (positive control), respectively. For experiments involving pulsing with conjugate, 
the final molarity of 41-mer peptide in the culture medium for overnight incubation at 37°C is 
indicated in brackets. Graphs indicate mean ± SD as well as individual data points representing 













Figure 3.4 Pulsing with PWM-peptide conjugate enhances delivery of a 41-mer peptide containing an immunodominant T cell epitope from 
GAD65. A depicts a schematic of the experimental strategy. IL-2 production by the GAD65(274-286)-specific T33 hybridoma was measured 
following co-culture with WT51 EBV B cells (APC) either co-incubated with a 41-mer GAD65(274-286)-containing peptide for 16 hours or pulsed 
with an ADS. Within the ADS, the 41-mer peptide is conjugated to either PWM or aDEC205. A hyphen signifies conjugation of ADS components. 
B and C show data from a representative experiment and combined data from three independent experiments expressed as percentage of stimulation 
with GAD65(274-286) peptide (positive control), respectively. For experiments involving pulsing with conjugate, the final molarity of 41-mer 
peptide in the culture medium for overnight incubation at 37°C is indicated in brackets. Graphs indicate mean ± SD as well as individual data 

















Figure 3.4 Pulsing with PWM-peptide conjugate enhances delivery of a 41-mer peptide containing an immunodominant T cell epitope from 
GAD65. A depicts a schematic of the experimental strategy. IL-2 production by the GAD65(274-286)-specific T33 hybridoma was measured 
following co-culture with WT51 EBV B cells (APC) either co-incubated with a 41-mer GAD65(274-286)-containing peptide for 16 hours or pulsed 
with an ADS. Within the ADS, the 41-mer peptide is conjugated to either PWM or aDEC205. A hyphen signifies conjugation of ADS components. 
B and C show data from a representative experiment and combined data from three independent experiments expressed as percentage of stimulation 
with GAD65(274-286) peptide (positive control), respectively. For experiments involving pulsing with conjugate, the final molarity of 41-mer 
peptide in the culture medium for overnight incubation at 37°C is indicated in brackets. Graphs indicate mean ± SD as well as individual data 
points representing either a separate T cell-B cell co-culture (B) or an independent experiment (C).   
C 
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3.5 HLA-restriction of presented epitopes derived from ADS  
To eliminate the possibility that the response to the PWM-peptide conjugate occurs 
independently of the presence of HLA-DR4, T33 hybridoma cells were co-cultured with pulsed 
EBV B cells expressing either HLA-DR4 or HLA-DR3 (Figure 3.5A). Both B cell lines were 
also pulsed with activated PWM, peptide alone or prior to T cell-B cell co-culture, the short 
GAD65(274-286) epitope. Since preceding experiments (Figure 3.4) established that the 
response is due to the peptide and not DMSO (peptide vehicle), non-pulsed cells were used as 
a control. Consistent with previous findings, pulsing of a HLA-DR4+ EBV B cell line with 
PWM-peptide conjugate followed by T33 co-culture provoked significant IL-2 secretion 
(>2000 pg/mL). The amount of IL-2 however, was variable between two independent 
experiments (Figure 3.5B, C) due to inherent variability in the ability of the T33 hybridoma to 
respond between experiments. Importantly, this IL-2 response is abolished upon co-culture of 
the T33 hybridoma with a HLA-DR3-expressing B cell line pulsed with the PWM-based ADS. 
B cells pulsed with the 41-mer peptide alone did not activate the T33 hybridoma above 
background regardless of the HLA type of the B cell. Interestingly, pulsing of the HLA-DR3+ 
cell line with activated PWM produced a higher IL-2 response in both experiments than pulsing 
with the PWM-peptide conjugate, suggesting that the presence of the peptide may interfere with 
binding of the lectin.  
 
A T cell response to the short GAD65(274-286) epitope was only observed by co-culture with 
an EBV B cell line expressing the HLA-DR4 haplotype. The response to the short epitope was 
lower in both experiments than pulsing with the conjugate; inconsistent with prior experiments. 
The likely explanation for this lies in the fact that the proportion of peptide within the conjugate 
that is conjugated to PWM is unknown and may vary between batches. Overall, these data 
indicate that the response to the PWM-peptide conjugate is HLA-restricted but also peptide-
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specific, as the peptide repertoire that is selected and presented by the HLA-DR3+ line will be 
different to that of the HLA-DR4+ line driven largely by differing anchor residues between 





























Figure 3.5 The response to the PWM-peptide conjugate is restricted by 
HLA type. A depicts a schematic of the experimental strategy. IL-2 
production by the GAD65(274-286)-specific T33 hybridoma was 
measured following co-culture with a HLA-DR4 or HLA-DR3-
expressing EBV B cell line (APC) pulsed with PWM-peptide conjugate. 
B and C show data from two independent experiments. Graphs indicate 
mean ± SD as well as individual data points representing a separate T 
cell-B cell co-culture. 
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3.6 Internalisation of labelled PWM 
It was necessary to provide evidence that the PWM-peptide conjugate was being internalised 
rather than undergoing cell surface processing, reported to occur in the case of a fragment of 
tetanus toxin (Moss et al., 2007). Initial experiments to infer internalisation utilised the biotin 
moiety attached to the N-terminus of the 41-mer peptide. In this way, an anti-biotin antibody 
can be used to monitor the presence of 41-mer peptide at the surface of the APC by FACS. 
EBV B cells were pulsed with PWM-peptide conjugate, activated PWM or peptide alone and 
incubated at 37°C for 0, 1, 3 and 6 hours before placing the cells on ice (to stop further 
internalisation) followed by anti-biotin staining (Figure 3.6A).  
 
Pulsing with activated PWM or peptide alone revealed a staining pattern similar to the isotype 
control, demonstrating an absence of peptide at the cell surface (Figure 3.6B). This further 
supports a lack of direct binding of the 41-mer peptide. The staining pattern of cells pulsed with 
PWM-peptide conjugate shows a gradual shift from 0 to 6 hours, indicated by a reduction in 
biotin median fluorescence intensity (MFI) (Figure 3.6C). Additionally, there appears to be a 
reduction in the number of positive events between 0 and 6 hours. The rate of reduction in biotin 
MFI was greatest between 0 and 1 hour, stabilising between 1 and 3 hours preceding further 
decline between 3 and 6 hours. Taken together, these results show that peptide is present at the 
cell surface after pulsing with PWM-peptide conjugate and decreases over time suggesting 



























Figure 3.6 Biotinylated peptide is targeted to the cell surface after pulsing and disappears over 
time. A depicts a schematic of the experimental strategy. EBV B cells were pulsed with 
activated PWM, peptide alone or PWM-peptide conjugate and stained with an anti-biotin 
antibody at specific time points following incubation at 37°C. B shows representative flow 
cytometry histograms illustrating the biotin staining pattern with black histograms denoting 
isotype control-stained cells. Biotin MFI values across the four time points are plotted from two 





Although from the anti-biotin staining presented in Figure 3.6 it is compelling to speculate 
internalisation is occurring, an alternative explanation is that the peptide is simply falling off 
the surface of the cell over time. To confirm that this was not the case, imaging flow cytometry 
(ImageStream) was employed to visualise and quantify internalisation. In order to assess 
internalisation, PWM was conjugated to an allophycocyanin fluorescent label (PWM-APC) via 
available amine groups, thus replicating the same chemistry utilised by the sulfo-SMCC 
crosslinker in conjugating PWM to the 41-mer peptide. EBV B cells were pulsed with PWM-
APC, incubated at 37°C and localisation of the fluorescent PWM compared at 0 and 6 hours 
(Figure 3.7A). The gating strategy applied for the ImageStream analysis is shown in Figure 2.2 
(Materials and Methods).   
 
To measure whether the localisation of PWM-APC was intracellular or surface-bound, a mask 
was designed that excludes the cell membrane and an internalisation score computed, reflecting 
the ratio of the amount of fluorescence located in the mask versus the total amount of 
fluorescence. Due to the focal depth, fluorescence from the top and the bottom of the cell will 
be out of focus thus contributing very little to the overall fluorescence. Internalisation scores 
around 0 have a mix of internalisation and membrane intensity. The higher the score, the greater 
the concentration of intensity inside the cell, as previously reported (Garcia-Vallejo et al., 
2015). At 0 hours after pulsing with PWM-APC, the majority of cells present with a uniform 
staining pattern in a ring around the cell (Figure 3.7D, left) indicative of localisation at the 
plasma membrane. Because there is a degree of overlap in the fluorescence signal between 
inside and outside the cell, a median internalisation score of 0.3178 was observed at 0 hours. In 
contrast, after 6 hours of incubation at 37°C, a greater frequency of cells with significant 
intracellular staining are observable (Figure 3.7D, right). This is reflected by an increase in the 
median internalisation score from 0.3178 to 1.269 between 0 and 6 hours (Figure 3.7B, C). 
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These findings indicate a greater concentration of PWM-APC intensity inside the cell at 6 hours 











Figure 3.7 Internalisation of PWM-APC. A depicts a schematic of the experimental strategy. EBV B cells were pulsed with PWM-APC and the 
degree of internalisation measured using ImageStream X. Single focused and cells positive for APC were gated. Internalisation scores were 
calculated, reflecting the ratio of cytoplasmic to total brightness intensity. B and C show histogram plots of internalisation scores for cells 
immediately after pulsing and after incubation for 6 hours at 37°C, respectively. Representative cell images captured by the Amnis ImageStream 
Flow Cytometer are also provided (D). Selected cell images were chosen to be well above and below the median with the first column showing 
brightfield images (Ch01) and the second column showing images of fluorescence of PWM (Ch11). Dotted green lines indicated in C correspond 






















Figure 3.7 Internalisation of PWM-APC. A depicts a schematic of the experimental strategy. EBV B cells 
were pulsed with PWM-APC and the degree of internalisation measured using ImageStream X. Single 
focused and cells positive for APC were gated. Internalisation scores were calculated, reflecting the ratio 
of cytoplasmic to total brightness intensity. B and C show histogram plots of internalisation scores for 
cells immediately after pulsing and after incubation for 6 hours at 37°C, respectively. Representative cell 
images captured by the Amnis ImageStream Flow Cytometer are also provided (D). Selected cell images 
were chosen to be well above and below the median with the first column showing brightfield images 
(Ch01) and the second column showing images of fluorescence of PWM (Ch11). Dotted green lines 
indicated in C correspond to the location on the histogram where representative images were chosen.  
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3.7 Changes in epitope density following PWM-mediated peptide delivery 
Identification of naturally processed epitopes requires putative epitopes to be present on the cell 
surface at a reasonable abundance. It was therefore important to establish the time point after 
pulsing which lead to the maximal epitope density. To determine this using the GAD65(274-
286)-containing 41-mer peptide, HLA-DR4-expressing EBV B cells were pulsed with PWM-
peptide conjugate and incubated at 37°C for 0-6 hours before gentle fixation with 0.1% 
paraformaldehyde (Figure 3.8A). The fixation procedure terminates further processing by the 
B cell and co-culture with the T33 hybridoma provides an indication of the number of epitopes 
present at the cell surface at a given time point. In parallel, EBV B cells were also pulsed with 
activated PWM and fixed over the same time course as it is plausible to speculate that the 
response to activated PWM is reduced over time as PWM is internalised, hence providing less 
stimulation.  
 
The data show a gradual increase in the number of epitopes present at the cell surface, indicated 
by an increase in IL-2 secretion, every 2 hours for the first 6 hours after pulsing with PWM-
peptide conjugate (Figure 3.8B, C). This increase in T cell activation over time also provides 
additional evidence of processing and presentation which is known to be a highly dynamic 
process (Croft et al., 2013). On the other hand, pulsing with activated PWM and fixation at the 
various time points results in a level of IL-2 secretion which remains relatively unchanged 
throughout the time course, supporting the peptide-specific nature of the response to the 
conjugate. Interestingly, IL-2 secretion was observed by co-culture with B cells fixed 
immediately after pulsing with PWM-peptide conjugate. Given that the amount of IL-2 
produced in this case (200 pg/mL) surpassed that of the activated PWM alone, it is unlikely that 
the response at 0 hours is due to low background stimulation by PWM. It is more likely that the 
fixation procedure is not completely efficient in rendering the cell incapable of processing. 
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Furthermore, one of the ligands PWM binds is the BCR, at which site internalisation has been 
described to commence within minutes after removal from ice (Hou et al., 2006). Thus, amongst 
the incubation steps there is the potential for epitope generation to occur at an early stage.  
 
Of note, production of IL-2 by the T33 hybridoma is greatest upon co-culture with non-fixed B 
cells pulsed with PWM-peptide conjugate. This indicates the potential for a greater level of 
epitope density to be reached beyond 6 hours. For this reason, the time course was extended, 
incubating pulsed cells for 12-18 hours at 37°C before gentle fixation and co-culture with T33 
hybridoma cells. Consistent between two independent experiments, the consequence of fixation 
either 14 or 16 hours after pulsing is a similar level of T cell activation (Figure 3.9A, B). A 
trend towards greater T cell activation is observed following fixation at 12 hours relative to 14-
16 hours; however, the error bars rule overlap suggesting there is not a significant difference 
between the conditions. Overall, the data suggest that the epitope density on the cell surface 
remains relatively constant 12-18 hours after pulsing with the PWM-based delivery system. To 
ensure feasibility of downstream pulsing experiments involving hybrid polypeptides, 16 hours 


















Figure 3.8 Epitope density on the cell surface increases 0-6 hrs after pulsing with PWM-peptide conjugate. A depicts a schematic of the 
experimental strategy. EBV B cells were pulsed with either PWM-peptide conjugate or activated PWM and gently fixed every 2 hours. Fixed cells 
were co-cultured with the T33 hybridoma and IL-2 measured in the supernatant. B and C show data from two independent experiments. PMA and 
ionomycin was used as a positive control for IL-2 production in both experiments; mean values obtained for B and C were 60012 ± 7038 pg/mL 































Figure 3.9 Epitope density on the cell surface remains constant 12-18 hrs after pulsing with 
PWM-peptide conjugate. EBV B cells were pulsed with either PWM-peptide conjugate or 
activated PWM and gently fixed at 2 hour intervals, commencing 12 hours after pulsing. Fixed 
cells were co-cultured with the T33 hybridoma and IL-2 measured in the supernatant. A and B 
show data from two independent experiments. PMA and ionomycin was used as a positive 
control for IL-2 production in both experiments; mean values obtained for A and B were 81710 
± 9377 pg/mL and 41281 ± 5451 pg/mL, respectively. Graphs show mean ± SD as well as 




3.8 Conjugation and cell surface binding of aDEC205-peptide conjugate 
The lack of T cell response observed after pulsing with aDEC205-peptide conjugate is curious 
given a previous report using DEC205 to successfully target antigens for processing in EBV B 
cells (Leung et al., 2013). To explore this, it was first necessary to confirm conjugation of the 
41-mer peptide to the anti-DEC205 antibody. Anti-mouse IgG beads bind any mouse kappa 
light chain-bearing immunoglobulin and were incubated with either activated aDEC205, 41-
mer peptide or aDEC205-peptide conjugate (Figure 3.10A). To remove unbound antibody the 
beads were washed and subsequently incubated with streptavidin-APC. As the 41-mer peptide 
bears a biotin-label, providing the conjugate contains 41-mer peptide crosslinked to the 
antibody one would expect the beads to be APC-positive when analysed by flow cytometry. 
Indeed, as shown in Figure 3.10C, beads incubated with the conjugate stain positive for APC 
while beads incubated with the activated aDEC205 antibody do not due to the absence of 41-
mer peptide. Beads incubated with the 41-mer peptide alone also stain negative for APC 
indicating that the 41-mer peptide does not bind to the anti-mouse IgG beads.  
 
It was also necessary to exclude the possibility that conjugation to the 41-mer peptide disrupts 
the antigen-binding site of the antibody. This was investigated by pulsing WT51 cells with 
either aDEC205-peptide conjugate, activated aDEC205, non-activated aDEC205 or a negative 
control mouse IgG2b antibody. Pulsed cells were then stained with an anti-mouse IgG2b 
secondary antibody and analysed by flow cytometry (Figure 3.10B). Non-activated and 
activated aDEC205 show similar binding to the DEC205 antigen on the surface of the WT51 
cells, while binding of the aDEC205-peptide conjugate is marginally reduced in comparison 
(Figure 3.10D). This reduction in binding was consistent across three independent experiments 
and carries the caveat that this could be due to the presence of the peptide interfering with the 
binding of aDEC205 to the cell surface. Alternatively, the presence of the peptide may interfere 
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with binding of the secondary antibody to aDEC205. Nevertheless, together these data 
demonstrate that biotinylated 41-mer peptide is detectable within the conjugate which still binds 


















Figure 3.10 The aDEC205-peptide conjugate binds to the cell surface and contains biotinylated 41-mer peptide. A and B depict schematics of the 
experimental strategies. Anti-mouse IgG beads were incubated first with activated aDEC205, aDEC205-peptide conjugate or peptide alone and 
subsequently with streptavidin-APC. Beads were run on a flow cytometer and gated for APC staining (C). Histograms in D illustrate cells stained 
with an anti-mouse IgG2b secondary antibody after pulsing with non-activated aDEC205, activated aDEC205 or aDEC205-peptide conjugate to 
detect cell surface binding. Cells pulsed with a negative control mouse IgG2b antibody were also included (filled grey histogram). Data shown in 







3.9 Internalisation of labelled anti-DEC205 monoclonal antibody  
A failure of the aDEC205-peptide conjugate to be internalised would provide an explanation 
for the absence of a T cell response. To establish whether this was the case, EBV B cells were 
pulsed with either activated aDEC205, aDEC205-peptide conjugate or peptide alone and 
incubated at 37°C. At specific time points cells were removed from culture, placed on ice to 
stop further internalisation and stained with streptavidin-APC to detect the 41-mer peptide 
(biotin-labelled) on the APC surface (Figure 3.11A). Pulsing with activated aDEC205 resulted 
in a staining pattern identical to non-pulsed cells due to the absence of 41-mer peptide, whereas 
analysis of cells pulsed with peptide alone revealed a very low level of direct binding (Figure 
3.11B). A striking reduction in the amount of biotin-labelled peptide present at the cell surface 
was observed between 0 and 1 hour post-pulse with the conjugate, falling to a level comparable 
to the staining seen with peptide alone. No further change in biotin MFI was observed beyond 
1 hour (Figure 3.11C). These findings suggest rapid internalisation of the aDEC205-peptide 
conjugate within 1 hour at 37°C. However, this experiment merely suggests internalisation, 
therefore imaging flow cytometry was applied to be conclusive.  
 
To examine internalisation of aDEC205 by imaging flow cytometry, a commercially available 
antibody labelled with phycoerythrin (aDEC205-PE) was used to pulse EBV B cells. Given 
that previous data suggest rapid internalisation of the aDEC205-peptide conjugate, cells were 
pulsed with aDEC205-PE and fluorescence localisation visualised immediately after pulsing 
and after 2 hours of incubation at 37°C (Figure 3.12A). In line with the ImageStream analysis 
performed with PWM-APC, the gating strategy outlined in Figure 2.2 (Materials and Methods) 
was applied but in this case PE-positive cells were gated. Calculation of median internalisation 
scores show an increase from 0.0939 at 0 hours to 1.244 at 2 hours, indicating that PE-labelled 
aDEC205 bound to the cell surface is being actively internalised over time (Figure 3.12B, C). 
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This can be visualised by a punctate staining pattern (Figure 3.12D, right) compared to the 
surface staining observed at 0 hours (Figure 3.12D, left). Although aDEC205 is labelled with 
phycoerythrin using unknown chemistry, the data shown in Figure 3.12 can be extrapolated to 
the aDEC205-peptide conjugate since I have shown binding of the antibody-peptide conjugate 
to the cell surface. It is therefore a reasonable assumption that the events which occur 









































Figure 3.11 Reduction in the amount of peptide at the cell surface 1 hour after pulsing with 
aDEC205-peptide conjugate. A depicts a schematic of the experimental strategy. EBV B cells 
were pulsed with activated aDEC205, peptide alone or aDEC205-peptide conjugate and 
stained with streptavidin-APC at specific time points following incubation at 37°C. B shows 
representative flow cytometry histograms illustrating the staining pattern with grey filled 
histograms denoting non-pulsed cells. Biotin MFI values across the four time points are plotted 

















Figure 3.12 Internalisation of aDEC205-PE. A depicts a schematic of the experimental strategy.  EBV B cells were pulsed with aDEC205-PE and 
the degree of internalisation measured using ImageStream X. Single focused and cells positive for PE were gated. Internalisation scores were 
calculated, reflecting the ratio of cytoplasmic to total brightness intensity. B and C show histogram plots of internalisation scores for cells 
immediately after pulsing and after incubation for 2 hours at 37°C, respectively. Representative cell images captured by the Amnis ImageStream 
Flow Cytometer are also provided (D). Selected cell images were chosen to be well above and below the median with the first column showing 
brightfield images (Ch01) and the second column showing images of fluorescence of aDEC205 (Ch03). Dotted green lines indicated in C 






















Figure 3.12 Internalisation of aDEC205-PE. A depicts a schematic of the experimental strategy.  EBV B 
cells were pulsed with aDEC205-PE and the degree of internalisation measured using ImageStream X. 
Single focused and cells positive for PE were gated. Internalisation scores were calculated, reflecting the 
ratio of cytoplasmic to total brightness intensity. B and C show histogram plots of internalisation scores 
for cells immediately after pulsing and after incubation for 2 hours at 37°C, respectively. Representative 
cell images captured by the Amnis ImageStream Flow Cytometer are also provided (D). Selected cell 
images were chosen to be well above and below the median with the first column showing brightfield 
images (Ch01) and the second column showing images of fluorescence of aDEC205 (Ch03). Dotted green 
lines indicated in C correspond to the location on the histogram where representative images were chosen. 
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3.10 Concluding remarks  
In summary, work presented in this chapter demonstrates that conjugation to PWM can be used 
for delivery of synthetic peptides into an APC for processing and epitope generation. Through 
a series of experiments, I show that the response to the PWM-based ADS is HLA-restricted and 
as a result of internalisation of PWM. Using a peptide-specific T cell hybridoma, I also establish 
that the optimal epitope density present on the cell surface occurs 16 hours after delivery of the 
ADS. A T cell response was not observed using an aDEC205 delivery system although binding 







CHAPTER 4: PULSING OF ANTIGEN-PRESENTING CELLS AND PEPTIDE 
ELUTION TO IDENTIFY NOVEL HYBRID EPITOPES 
4.1 Background to the Chapter 
The previous chapter established a system based on conjugation to PWM to efficiently deliver 
a 41-mer peptide containing a known HLA-DR4-restricted epitope into EBV B cells for 
processing and presentation. This approach benefits from being broadly applicable to any 
peptide containing a C-terminal cysteine residue, allowing it to be conjugated to PWM. This 
chapter will exploit this fact to deliver a hybrid polypeptide into EBV B cell lines homozygous 
for HLA-DR3/DQ2 and -DR4/DQ8. Analysis of the immunopeptidome will elucidate whether 
hybrid epitopes are generated from the polypeptide species. 
 
Co-elution of the natural BDC-2.5 ligand (WE14) with insulin C-peptide fragments was the 
prerequisite for identification of the first HIP within mouse β-cell granules, containing the 
DLQTLAL C-peptide sequence and the WSRM WE14 sequence (Delong et al., 2016). The 
longest possible species that this epitope could be derived from is the entire C-peptide sequence 
upstream of DLQTLAL and the WE14 sequence downstream of WSRM 
(EVEDPQVAQLELGGGPGAGDLQTLALWSRMDQLAKELTAE). The corresponding 
human sequence: EAEDLQVGQVELGGGPGAGSLQPLALWSKMDQLAKELTAE, is 
henceforth termed a C-peptide:WE14 polypeptide in the current study. T cell responses against 
a hybrid epitope (SLQPLALWSKMDQL) contained within the C-peptide:WE14 polypeptide 
have been reported in several T1D patients (Baker et al., 2019b). It is tantalising to speculate 
that this short hybrid epitope derived from APC-dependent processing of the long C-
peptide:WE14 polypeptide. The existence of a larger C-peptide:WE14 hybrid species has been 
further strengthened by identification of a deamidated polypeptide of insulin C-peptide fused 
to WE14 (EAEDLQVGQVELGGGPGAGSLQPLALWSK) in the human islet proteome 
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(Peakman & Purcell, unpublished). However, this sequence was cytoplasmic i.e. not HLA-
linked and the three amino acids WSK could quite possibly originate from many 
proteins/peptides besides chromogranin A.  
 
Delong and colleagues (2016) also reported reactivity to the DLQTLAL C-peptide region 
joined to the NAAR sequence from IAPP2. Although the presence of this HIP was confirmed 
in mouse islet cell extracts, the same antigenic fraction also contained numerous other peptides. 
Later studies by Wiles et al. (2016) correlated the abundance of this HIP with the magnitude of 
T cell response (BDC-9.3) providing evidence that this was indeed the antigenic component. T 
cell responses against the equivalent human sequence (SLQPLALNAVEVLK) are also detected 
in T1D patients (Baker et al., 2019b). These data induced me to have synthesised a C-
peptide:IAPP2 polypeptide (sequence detailed in Materials and Methods) in a similar manner 
described for the C-peptide:WE14 polypeptide. Preliminary evidence for the existence of a C-
peptide:WE14 polypeptide prompted an initial focus on this species for elution studies. For 
conjugation to PWM via a heterobifunctional crosslinker, a C-terminal cystine residue was 
added to the C-peptide:WE14 sequence and a N-terminal biotin moiety. The resulting sequence: 
Biotin-EAEDLQVGQVELGGGPGAGSLQPLALWSKMDQLAKELTAEC, was used for 
downstream pulsing experiments. 
 
4.2 Pulsing of B cell lines with hybrid polypeptide ADS 
EBV B cell lines WT51 and PF04015, homozygous for HLA-DR4/DQ8 and -DR3/DQ2 
respectively, were pulsed with PWM conjugated to C-peptide:WE14. A total of 1 × 109 cells/ 
cell line were pulsed in batches (100-150 × 106 cells/pulse) with an optimised ADS 
concentration (final peptide concentration 0.1 µM). After each pulsing experiment, an aliquot 
of cells was taken and stained with an anti-biotin antibody. FACS analysis showed that cells 
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pulsed with the ADS stained positive for biotin indicated by an increase in biotin MFI compared 
to the isotype and non-pulsed control (Figure 4.1A). Pulsed cells were incubated for 16 hours 
(optimal epitope density) at 37°C, 5% CO2 without washing and then harvested for 
immunoaffinity purification. Given the plan for downstream purification of HLA-DR and -DQ 
complexes, after harvesting cells were stained for cell surface expression of HLA-DR and 
HLA-DQ. Both cell lines co-express high levels of HLA-DR and -DQ with 99.9% of cells being 
double positive (Figure 4.1B).  The data confirms presence of the ADS at the cell surface after 









Figure 4.1 Biotin-labelled peptide is present on the cell surface after pulsing and cells express 
high levels of HLA-DR and -DQ. After pulsing with PWM conjugated to C-peptide:WE14 
polypeptide, cells were stained with an anti-biotin antibody (A) and class II HLA antibodies 
(B). A and B show representative staining from PF04015 and WT51 cells pulsed with the 
antigen delivery system, respectively. Isotype-control stained cells are shown in both cases (red, 
histogram; blue, dot plot). Values indicated in the table are the median fluorescence intensities. 
 
4.3 Building class II immunoaffinity columns for elution 
To purify HLA class II molecules from pulsed cell pellets, affinity columns containing 
immobilised anti-DR (clone: L243) and anti-DQ (clone: SPVL3) antibodies were generated. In 
order to first obtain milligram antibody quantities, L243 and SPVL3 were purified from mouse 
B A 
 107 
ascites. The ascites is conditioned to remove high molecular weight proteins such as transferrin 
and the conditioned ascites subsequently incubated with a non-IgG binding resin. Purified IgG 
is collected in the flow through with an identical protein band pattern to commercially available 
antibody by Coomassie staining (Figure 4.2); with bands corresponding to both heavy (50 kDa) 
and light chains (25 kDa). Bands at ~28-30 kDa were also observed and most likely represent 













Figure 4.2 Purification of antibody from mouse ascites. Representative Coomassie-stained 
SDS-PAGE gel (10%) of purification of anti-DR (L243) ascites. Raw ascites was conditioned 
to remove abundant proteins such as transferrin and then purified using a resin which binds to 
non-IgG proteins. Purified L243 purchased from BioLegend was also stained for comparison. 
M, molecular weight standard; kDa, kilodalton; HC, heavy chain; LC, light chain. 
 
Before proceeding to couple purified L243 and SPVL3 antibodies to Protein A Sepharose 
(PAS) beads, it was first important to eliminate the possibility that the purification process lead 
to a loss in the activity of the antibody. To test this, EBV B cells were stained with a titration 
of either purified L243 or SPVL3 antibody. A fluorescently labelled secondary antibody was 




performed with commercially available L243 and SPVL3 antibodies to allow comparison of 
MFI values. Data shows that similar MFI values were observed between purified antibodies 
and their commercially available counterparts (Figure 4.3B, D), indicating that at a given 
concentration the amount of anti-DR/DQ antibody binding to the cell surface was similar. These 
findings illustrate accurate quantification of purified L243 and SPVL3 antibodies and confirm 


















Figure 4.3 Purified antibodies bind HLA. An EBV B cell line was stained with a titration of 
purified or commercially available anti-DR (L243)/anti-DQ (SPVL3) antibodies. Binding to 
the cell surface was detected via a fluorescently labelled secondary antibody. A and C display 
representative histograms for each concentration of antibody relative to an isotype control (red 
histogram). The corresponding MFI values are shown in B and D. Data are representative for 





Whilst PAS beads have high affinity for the Fc region of IgG, dimethyl pimelimidate (DMP) 
was used to covalently link the Fc region of the antibody heavy chain to Protein A. To monitor 
the reaction, pre- and post-crosslinked beads were analysed by SDS-PAGE. A small-scale 
citrate buffer acid elution of the crosslinked beads was also performed. Pre-crosslinking, the 
antibody is not covalently bound to the beads, thus when the sample is boiled in reducing 
sample buffer the antibody comes off the beads and the heavy and light chains are visible 
(Figure 4.4). Successful crosslinking was indicated by the presence of the antibody heavy chain 
on the affinity bound beads but not on the post-crosslinked beads. The light chain, however, 
appears in both. Following incubation of antibody with PAS beads, the column flow through 
was depleted of antibody indicated by the reduced staining intensity compared with the purified 
antibody loaded on the column. Importantly, citric acid elution did not strip any antibody from 













Figure 4.4 Generation of MHC immunoaffinity columns. Representative Coomassie-stained 
SDS-PAGE gels (4-20%) monitoring crosslinking of SPVL3 (left) and L243 (right) antibodies 
to Protein A Sepharose beads. Lane 1: Pre-crosslinked beads. Lane 2: Post-crosslinked beads. 
Lane 3: Citrate buffer elution. Lane 4: Purified antibody. Lane 5: Flow through from bead-





4.4 Affinity purification of HLA-DR and -DQ complexes 
HLA-DR and -DQ molecules were purified from cell pellets pulsed with the ADS as previously 
described (Purcell et al., 2019a). In brief, cell pellets were homogenised using lysis buffer and 
sonication. The lysate was pre-cleared by centrifugation to remove the nuclei before loading 
the supernatant onto a protein A sepharose pre-column lacking crosslinked antibodies (Figure 
4.5). The flow through from this pre-column is then loaded directly onto the crosslinked 
monoclonal antibody columns (L243 and SPVL3) by gravity flow. For maximal yield, the 
lysate is run through the columns multiple times and the flow through collected at each stage. 
In western blotting, anti-HLA-DR antibody confirmed binding of class II molecules present in 
the lysate to the antibody column with each subsequent loading cycle (Figure 4.7A). Peptide-
HLA complexes are eluted from the column using 10% acetic acid, causing dissociation from 










Figure 4.5 Elution of pHLA complexes. The blank column contains protein A sepharose beads 
(without antibody crosslinking) and is used to remove nonspecific binding proteins from the 




4.5 Isolation of bound peptides and mass spectrometry 
To enrich peptides (separate them from the HLA class II molecules) the acid eluate was loaded 
onto a C18 column containing a hydrophobic surface of silica particles (Figure 4.6). Bound 
peptides were eluted using 30% acetonitrile (ACN) containing 0.1% trifluoroacetic acid (TFA) 
and analysed by liquid chromatography-tandem mass spectrometry (LC-MS/MS). As a quality 
control step the remaining proteins bound to the C18 column, which should include HLA, were 
eluted in 80% ACN:0.1% TFA. Western blot analysis revealed the presence of HLA-DR and -
DQ protein in the 80% ACN eluate (Figure 4.7B).  The flow through after loading of the acetic 
acid eluate onto the C18 column was also probed for HLA-DR and -DQ protein. DR but not 
DQ protein was detected in the flow through; this was, however, marginal compared to the 
amount of DR protein eluted from the C18 column with 80% ACN suggesting that the majority 











Figure 4.6 Peptide clean-up of MHC eluate by C18 column. Peptides eluted from the column 
were vacuum-concentrated to dryness before being re-constituted with 2% acetonitrile (ACN)-
0.1% formic acid (FA) prior to mass spectrometric analysis. HLA, human leukocyte antigen  













Figure 4.7 Depletion of flow through and presence of HLA-II in 80% acetonitrile eluate. 
Western blot analysis of HLA-DR protein in pulsed WT51 cell lysate and after each successive 
loading cycle (A). B shows analysis of flow through and 80% acetonitrile eluate from C18 
column using antibodies to detect HLA-DQA1 (left) and HLA-DR (right). Blots shown in B 
represent material obtained by peptide elution of pulsed PF04015 cells. FT, flow through; M, 
molecular weight standard; kDa, kilodalton; ACN, acetonitrile; ELU, eluate. 
 
HLA class II complexes were purified from whole cell lysate using 7 × 108 pulsed cells as the 
starting material. This reserved 3 × 108 cells for validation of targets should putative epitopes 
be identified. MS analysis was performed using two approaches: PD (ProteomDiscoverer 2.2) 
(conventional) and PEAKStudio 7.5 (Database Search and de novo sequencing). Peptides were 
first matched against the Uniprot Swiss-Prot human proteome database plus peptide sequences 
of interest, i.e. the C-peptide:WE14 polypeptide used for pulsing and PWM to identify any 
pokeweed-derived peptides. To accurately identify peptides, a false discovery rate (FDR) 
threshold of less than 1% was applied. The total number of identified peptides from HLA-DR4 
was 6376, with similar data for -DQ8 (Table 4.1). In comparison, fewer peptides were identified 
from -DR3 and -DQ2 with the least number of peptides from -DQ2 identified overall (3078 




Table 4.1 Number of unique peptides identified for each HLA allele with a threshold of peptide 







†HLA, human leukocyte antigen; FDR, false discovery rate. 
 
4.6 Length of eluted peptides and identification of nested sets 
Initial scanning of the complete dataset did not identify novel hybrid epitopes. To evaluate 
whether the elution was successful, downstream analysis was performed on a filtered dataset. 
Analysis was limited to peptides present at a peptide length frequency greater than 1%: at least 
eight (HLA-DR3 and -DQ2) or nine (HLA-DR4 and -DQ8) residues. Peptides not being part 
of nested sets were included as many non-nested peptides are predicted to bind their cognate 
class II molecule.  
 
The peptide length distribution of eluted peptides satisfying these criteria was characteristic of 
class II peptides (Lippolis et al., 2002), varying between 8 and 24 residues with a peak in 
distribution at 15 amino acids (Figure 4.8). For all HLA molecules, the next most common 
peptide length was 16 amino acids. For HLA-DQ8, -DR3 and -DQ2 14-mer long peptides 
represented the third most abundant length whereas for HLA-DR4, this was 17-mer peptides. 
An interesting peak of 9-mers was present in the HLA-DQ2 elution; closer analysis showed 
that these peptides lack a -DQ2 binding motif and did not form nested sets. This peak at 9 amino 
acids was, however, less pronounced for the other alleles suggesting that this may be associated 
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with fewer peptides being eluted from -DQ2 molecules. This finding is not surprising given 
identification of the unusually short PPI17-24 (8-mer) epitope from heterozygous HLA-DQ2/8 
expressing DCs (van Lummel et al., 2016b). This PPI epitope also does not fulfil the high-risk 
HLA-DQ binding motif. Most of the eluted peptides could be assigned to nested sets of 
sequences (Figure 4.9A, B, Table 4.2 and 4.3) in agreement with previous reports (Chicz et al., 
1993; Peakman et al., 1999; van Lummel et al., 2016b; Zhou et al., 2017b). Nested sets are 
groups of peptides with a consensus core binding motif but varying extended N- and/or C-






















Figure 4.8 Peptide length distribution. The peptide length distribution of peptides identified 
with a peptide FDR <1% is shown for peptides with a frequency greater than 1%. Each 
subsequent increment in length is shown until the frequency falls below 1%. Predominant 
peptide length is 14–17-mer with 15-mer being the most abundant length for all analysed HLA 
















Figure 4.9 Peptides are eluted in nested sets. Representative nested set peptides eluted from 
HLA-DQ8 (A) and -DR3 (B). Peptides derived from HLA class I and heat shock protein are 
shown by A and B, respectively. Core sequences are indicated with red boxes. 
 










†Nested sets were defined by the presence of at least two peptides which have a nested sequence. 
To identify a nested set, the following criterion was applied: the sequence of the shorter peptide 
is 100% represented in the longer peptide and the shorter peptide is at least nine amino acids in 
length. Data shown in the table is limited to the number of peptides represented by greater than 














†Nested sets were defined by the presence of at least two peptides which have a nested sequence. 
To identify a nested set, the following criterion was applied: the sequence of the shorter peptide 
is 100% represented in the longer peptide and the shorter peptide is at least nine amino acids in 
length. Data shown in the table is limited to the number of peptides represented by greater than 
20 proteins. Similar results were obtained for peptides eluted from HLA-DQ2. 
 
4.7 Binding motif 
Determination of the 9-mer core region of the most abundant peptide group (15-mer), reported 
to be essential for HLA-II binding (Madden, 1995; Rammensee et al., 1995), revealed allele-
specific amino acid preferences (Figure 4.10). In accordance with previous literature, four 
anchor residues were observed for binding HLA class II molecules locating to positions (P) 1, 
4, 6 and 9 (Sant'Angelo et al., 2002). For HLA-DR4, I identified a preference for a bulky 
aromatic (phenylalanine, tyrosine, tryptophan) or an aliphatic residue (leucine, isoleucine) at 
P1 and a preference for a negatively charged amino acid (aspartate and glutamate) at P4. P6 of 
core 9-mer -DR4 sequences displayed a preference for polar residues (threonine, serine and 
asparagine) while P9 showed an equal preference for polar (serine, glutamine) and hydrophobic 
residues (alanine, glycine). Similarly, the HLA-DR3 binding motif featured a preference for 
aliphatic residues (isoleucine, leucine and valine) at P1 and a strong preference for aspartate at 
P4. This is consistent with the observation that epitopes with a negatively charged residue in 
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position 4 of the binding motif bind more strongly to HLA-DR3 (Inaba et al., 2010). However, 
unlike HLA-DR4 9-mer core sequences, HLA-DR3 binding cores exhibited a basic residue 
(lysine or arginine) at P6 and P9.  
 
In line with previous literature on the -DQ8 binding motif (Moustakas et al., 2000), HLA-DQ8 
showed a distinct binding preference for negatively charged amino acids (aspartate and 
glutamate) at P1 and P9 and a non-bulky hydrophobic amino acid at P4 and P6 (alanine or 
valine). Strikingly, the -DQ2 binding motif was less clear although a strong preference for 
aspartate and particularly glutamate was found not only at the P6 and P9 anchor positions, but 
also at many positions in the binding core including the non-anchor positions P2, P5, P7 and 
P8, consistent with reported findings (Stepniak et al., 2008). The same analysis was also 
performed for the three most abundant peptide lengths and overall the binding motif appears 












Figure 4.10 Peptide binding motif of core sequences. Sequence Logo plots are shown as 
examples for the most frequent peptide group (15-mer) of each HLA allele with number of 
detected 15‐mer peptides indicated. The height of each letter within the column is proportional 
to its frequency at the given position. Predicted binding cores were identified using the 
NetMHCII 2.3 program and motifs visualised using iceLogo. HLA, human leucocyte antigen. 
 
4.8 Source protein of presented peptides  
To examine whether specific source proteins feature strongly in the elution dataset, the source 
proteins of the twenty most abundant peptides identified from each allele were identified. A list 
of source proteins identified from peptides eluted from HLA-DR4 is shown in Table 4.4. 
Similar results were obtained for HLA-DQ8, -DR3 and -DQ2 with CD74 (CLIP), 
immunoglobin, b2-microglobin, HLA class I and class II (DQA, DRA, and DRB) peptides 
being amongst the top twenty most abundant. The most abundant peptide eluted from HLA-
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DR3 was a peptide derived from the transferrin receptor. These findings are in agreement with 
previously reported source protein data of class II peptides (Bergseng et al., 2015; Wahlstrom 
et al., 2007). 
 
Table 4.4 Twenty most abundant peptides eluted from HLA-DR4.  
†High abundance peptides were identified by the number of peptide-to-spectrum matching 
(PSM) events. The source protein of each peptide is indicated. 
 
4.9 Overlap in the immunopeptidome between different elution studies  
To provide even stronger evidence that the inability to identify a hybrid epitope was not due to 
a technical failure within the elution, I sought to investigate whether peptides eluted in the 
current study have also been identified in pre-existing datasets. Bergseng et al. (2015) generated 
a single database containing HLA-DQ2-bound peptides eluted from three different EBV B cell 
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lines, including PF04015. As the choice of cell line impacts the peptide repertoire (Abelin et 
al., 2019), the use of a cell line identical to that used in the current study prompted an assessment 
of overlap between the two datasets (Figure 4.11A). In this case, overlap was defined as 
identification of a peptide with an identical sequence in both databases. Of the 3078 unique 
peptides identified in the current study, 1128 (36%) were also identified in the database 
generated by Bergseng et al. (2015). Considering that the database created by Bergseng and 
colleagues is larger (4266 unique peptides) and contains DQ2-eluted peptides not only from 
PF04015 but also two other HLA-DQ2-positive EBV B cell lines, this level of overlap is 
justifiable. Overall, these data indicate that a proportion of peptides eluted from HLA-DQ2 in 
the current study have been previously identified.  
 
To bolster this finding, the cellular localisation of the peptide source proteins eluted from HLA-
DR4 molecules in the current study was compared to data obtained from DCs homozygous for 
HLA-DR4 (Figure 4.11B). Comparing the subcellular location to that of the human proteome, 
epitopes from lysosomal, Golgi apparatus, endosomal membrane, endoplasmic reticulum and 
cytoplasmic proteins were enriched for both datasets. Similarly, a lower proportion of nuclear 
and mitochondrial proteins was observed. Interestingly, in DCs, epitopes were enriched for 
secreted source proteins (27% vs 12% in the human proteome), but this was absent in EBV B 
cells (14%). The data point toward enrichment of proteins derived from similar source 
locations, which in combination with an overlap of identified epitopes, undeniably 























Figure 4.11 Overlap of identified epitopes and source protein location with pre-existing 
datasets. Venn diagram showing overlap of peptides eluted from HLA-DQ2 molecules between 
the current study and Bergseng et al. (2015) (A). The number of unique peptides and those 
peptides common between the two databases are indicated. Dataset created by Bergseng et al. 
was derived from three cell lines expressing -DQ2.5: CD114 (obtained from a coeliac disease 
patient), STEINLIN and PF04015. Databases were searched for only identical peptide 
sequences. B shows the subcellular location of source proteins of peptides eluted from HLA-
DR4 molecules in the current study (EBV B cells) and dendritic cells homozygous for HLA-
DR4 (database courtesy of Menno van Lummel, Leiden University Medical Centre, 
unpublished). A graph of this for the human proteome is also shown. Data expressed as 
percentage of total identified proteins with subcellular location annotations (multiple protein 




4.10 Identification of epitopes derived from exogenously acquired proteins 
To reject the possibility that hybrid epitopes were not identified because of an incapacity of the 
cell line to process and present exogenous antigen under the pulsing conditions, I searched the 
mass spectrometry data for exogenously derived peptides. While a hybrid epitope was not 
identified, it is possible to envisage that epitopes derived from pokeweed mitogen may be 
generated. Crude PWM is heterogenous with multiple isoforms present (Yamaguchi et al., 
2004), any of which could be found within the elution sample. Protein sequences of Lectin-C, 
-D2, -B and -A are available in the UniProt database and were used for database searching. 
Identification of a peptide eluted from HLA-DQ8 (REASGKVCPDDL) that derived from 
Lectin-B provided reassurance at a technical level that the ADS was successful in delivery of 
the conjugate into the endocytic pathway for epitope generation.  
 
To confirm the identity of the natural pokeweed peptide in the sample, the synthetic peptide 
REASGKVCPDDL was analysed by MS/MS. Although the MS/MS fragment spectra varies in 
terms of the fragment ion intensities (Figure 4.12A), a spectrum is validated based on mapping 
of fragment ions between synthetic and natural samples. This is mainly because many factors 
might affect the intensity such as different types of instruments and matrix effects (Zhou et al., 
2017a), although the same fragmentation method was used in the analysis of both peptides. 
Figure 4.12B shows that the majority of fragment ions are overlapped with all the b ions being 
identified either as singly or doubly charged ions. Also important to consider is the retention 
time of both peptides, i.e. when they are eluted from the column. Both the natural and synthetic 
pokeweed peptide had a similar retention time of ~20 minutes. Taken together, the synthetic 
peptide is able to validate the same peptide present in the sample. Additionally, as cells were 
cultured in medium containing 10% FCS the main component of which is BSA, the elution 
dataset was also queried for peptides derived from BSA. Among the peptides eluted from HLA-
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DQ8, -DR4 and -DR3 molecules, overlapping peptides derived from BSA were indeed present. 
An example of a BSA peptide eluted from HLA-DR3 is shown in Figure 4.12C, where >85% 
of the b and y ions were identified (Figure 4.12D). Altogether, the data provide strong evidence 




















Figure 4.12 Exogenous proteins are processed and presented. A shows an inverse spectrum comparison of the MS/MS product ion spectra for 
REASGKVCPDDL peptide identified by elution of HLA-DQ8 (natural) and the synthetic version. Mass-to-charge (m/z) values for fragment ions of 
types b (blue) and y (red) are given for the natural and synthetic peptide in the ion table (B). Singly and doubly charged b and y ions are indicated. 





# b+ b2+ Seq y+ y2+ # # b+ b2+ Seq y+ y2+ #
1 157.10 79.05 R 12 1 157.11 79.05 R 12
2 286.15 143.58 E 1133.51 567.26 11 2 286.15 143.58 E 1133.51 567.26 11
3 357.19 179.09 A 1004.48 502.74 10 3 357.19 179.09 A 1004.47 502.74 10
4 444.22 222.61 S 933.43 467.22 9 4 444.22 222.61 S 933.43 467.22 9
5 501.24 251.12 G 846.40 423.70 8 5 501.24 251.12 G 846.40 423.70 8
6 629.34 315.17 K 789.38 395.19 7 6 629.34 315.17 K 789.38 395.19 7
7 728.41 364.70 V 661.29 331.14 6 7 728.40 364.71 V 661.29 331.14 6
8 831.41 416.21 C 562.22 281.61 5 8 831.41 416.21 C 562.22 281.61 5
9 928.46 464.73 P 459.21 230.10 4 9 928.47 464.73 P 459.21 230.12 4
10 1043.50 522.25 D 362.16 181.58 3 10 1043.49 522.25 D 362.16 181.58 3
11 1158.52 579.76 D 247.13 124.06 2 11 1158.52 579.76 D 247.13 124.06 2






Figure 4.12 Exogenous proteins are processed and presented. A representative MS/MS spectra and 
corresponding fragment ion table of a bovine serum albumin peptide identified by elution of HLA-DR3 
molecules is shown by C and D, respectively. Only singly charged b and y ions are shown in the ion table. 
Where the observed and predicted m/z values match, the fragment ions are coloured. 
 
C 
D # b Seq y #
1 116.03 D 21
2 231.06 D 2269.11 20
3 387.16 R 2154.08 19
4 458.20 A 1997.98 18
5 573.23 D 1926.95 17
6 686.31 L 1811.92 16
7 757.35 A 1698.83 15
8 885.44 K 1627.80 14
9 1048.50 Y 1499.70 13
10 1161.59 I 1336.64 12
11 1264.60 C 1223.56 11
12 1379.63 D 1120.55 10
13 1493.67 N 1005.52 9
14 1621.73 Q 891.48 8
15 1736.75 D 763.42 7
16 1837.79 T 648.39 6
17 1950.88 I 547.34 5
18 2037.92 S 434.26 4
19 2124.93 S 347.23 3
20 2253.04 K 260.20 2
21 L 132.10 1
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4.11 Possible reasons for the failure to identify a hybrid epitope   
4.11.1 The hybrid epitope is a non-binder 
One possible explanation for not eluting a hybrid epitope from polypeptide-pulsed BLCLs is 
that the epitope does not bind to T1D-associated class II HLA alleles (HLA-DR4, -DR3, -DQ8 
and -DQ2). To investigate this, the binding affinity of overlapping 15-mer peptides 
encompassing the C-peptide:WE14 polypeptide (termed peptides 1 to 27) were predicted using 
the NetMHCII 2.3 algorithm. The algorithm computes a percentile rank (% rank) for a peptide, 
generated by comparing its score against the scores of a set of 1 × 106 random natural peptides 
of the same length of the query peptide (Jensen et al., 2018). Because the peptide–MHC affinity 
may vary widely for different MHC molecules, % rank is considered a better measure to define 
binding peptides. MHC II peptides with a rank <2 are considered strong binders and those with 
a % rank <10 are considered weak binders, as described previously (Mason et al., 2019). A 
fragment of IA-2 comprising residues 709-732 has been previously identified as a naturally 
processed epitope shown to bind strongly to HLA-DR4 (Peakman et al., 1999); reassuringly 
this peptide was predicted to have high affinity for HLA-DR4 using the algorithm (% rank = 
0.3).  
 
Figure 4.13 indicates the % rank of each 15-mer peptide plotted for each of the T1D-risk class 
II alleles. Data shows the majority of overlapping peptides, including those where the core 
sequence contains the hybrid junction, have a predicted % rank greater than 10% suggesting 
that these peptides do not bind. However, overlapping peptides 1 and 2 are predicted to bind 
HLA-DQ8 with high affinity (% rank <1) while peptide 3 binds with weak affinity (% rank = 
2.5). Importantly, the amino acid sequence of peptides 1-3 contain only the C-peptide region, 
devoid of any hybrid component. In general, most overlapping peptides are not predicted to 
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bind with high affinity to the four analysed HLA molecules, supporting the notion that a hybrid 
epitope was not eluted due to a lack of binding capacity. 
 
Figure 4.13 Affinity of overlapping 15-mers spanning the C-peptide:WE14 polypeptide. 
Binding of twenty-seven overlapping 15-mer peptides (labelled 1-27; the first amino acid of 
the 15-mer is indicated directly below the peptide number) to HLA-DR4, -DQ8, -DR3 and -
DQ2 was predicted using the NetMHCII 2.3 algorithm to compute a percentile rank (% rank). 
Overlapping peptides were offset by one residue. The dotted lines on the graph at 2% and 10% 
indicate the threshold for a strong and weak binder, respectively. Bold indicates the first amino 
acid of the 15-mer where the core sequence contains the hybrid junction. For HLA-DR4, the 
binding affinity of R5 (IA-2 709-736; LAKEWQALCAYQAEPNTCATAQGEGNIK) was 
computed as a positive control. 
 
The above data suggested that a hybrid epitope capable of binding with sufficient affinity to 
the high-risk HLA class II alleles does not exist within the C-peptide:WE14 polypeptide. 
However, this observation depends on the algorithms ability to accurately predict peptide 
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binding. To determine this, the same algorithm was used to predict the binding affinity of eluted 
peptides for their corresponding HLA allele. A % rank was generated for each eluted peptide 
by rounding to the nearest integer and percentile rank plotted as a function of peptide frequency 
(Figure 4.14A). Eluted peptides were predicted to have a wide range of affinities indicating 
that the approach does not bias towards identifying peptides with only the highest affinity for 
HLA. However, the peptide frequency diminished with increasing percentile rank for all HLA 
alleles. Although, this was less pronounced for HLA-DQ2 where the median percentile rank 
(17%) was greater than that of HLA-DR4 (6.5%), -DQ8 (10%) and -DR3 (3.5%). These data 
also suggest that the HLA-DR-peptide repertoire is skewed toward a higher affinity than the 
DQ repertoire as a distinct peak in peptide frequency (>10%) is observed at a percentile rank 
of 1%. This, however, may be a feature of the binding algorithm in that larger datasets are 
available on DR-eluted peptides compared to DQ, permitting identification of more stringent 
binding rules and therefore more accurate binding prediction.  
 
The frequency of eluted peptides characterised as strong and weak binders was also analysed, 
with peptides considered to be non-binders (% rank ≥10) categorised further into four groups 
according to their % rank (Figure 4.14B). Overall, strong binder peptide frequencies ranged 
from 11% to 25% and weak peptide binder frequencies from 25% to 33%. For HLA-DR4, 58% 
of eluted peptides were predicted to be binders, having a % rank <10. Of these, 25% were 
predicted to be strong binders and 33% predicted to be weak binders. The greatest proportion 
of non-binders was represented by peptides with a % rank less than 25% and this was consistent 
across all the alleles. Similar data was obtained for HLA-DQ8 with approximately 50% of 
eluted peptides predicted to bind. 76% of peptides eluted from HLA-DR3 were predicted to 
bind with a near equal distribution of weak and strong binders. The lowest frequency of binders 
(36%) was seen by analysis of peptides eluted from HLA-DQ2, suggesting in silico prediction 
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of binding to -DQ2 is currently lacking. To summarise, these data indicate peptides that are 
predicted to bind and those that are eluted represent two different entities, as many eluted 
peptides are not predicted to bind their cognate class II molecule. The poor binding prediction 

























Figure 4.14 Affinity of eluted peptides. The % rank of eluted peptides was predicted using 
NetMHCII 2.3 and plotted against peptide frequency for each HLA molecule (A). B shows the 
percentage of peptides characterised as a strong binder (% rank <2), weak binder (% rank <10) 
or a non-binder (% rank ≥10; peptides falling into this category are divided into four groups 
indicated by patterned bars) to a given HLA allele. In this case, predictions were performed for 
the six most prevalent peptide lengths for each HLA molecule. HLA, human leukocyte antigen; 




4.11.2 The hybrid polypeptide is not efficiently processed 
A second plausible explanation for not eluting a hybrid epitope is that the polypeptide species 
cannot be processed to generate an epitope sequence containing the hybrid junction. Using the 
program SitePrediction (Verspurten et al., 2009) the susceptibility of the C-peptide:WE14 
polypeptide to proteolytic cleavage was assessed. Cathepsins S, B, D and L were chosen as 
putative enzymes as they represent lysosomal proteases involved in class II antigen processing 
expressed by Preiss EBV-transformed B cells (Wang et al., 2009). As a control, predicted 
cleavage sites within a sequence of amino acids from GAD65(200-300) containing the 
immunodominant 274-286 epitope (IAFTSEHSHFSLK) were also determined (Figure 4.15).  
 
The predicted cleavage sites within the GAD260-300 sequence occur around the 274-286 
epitope region but never within it. In the case of C-peptide:WE14, a predicted cleavage site for 
cathepsin D lies at the junction between the C-peptide and WE14 components, thus, cleavage 
at this position would likely destroy the hybrid epitope. Cleavage sites for cathepsins B, L and 
S lie exclusively in the C-peptide region of the hybrid polypeptide. Cleavage by any one of 
these enzymes at the site proximal to the intersection of the two peptide species, gives rise to 
peptides of between twenty-two and twenty-four residues derived from both C-peptide and 
WE14. Such peptides will still be linked at their C-terminus to PWM as cleavage sites within 
the WE14 sequence by cathepsins S, B, D and L are not predicted to exist. Therefore, it is 
reasonable to envisage that the cleavage products may require C-terminal trimming in order to 
be available for epitope generation. Such results do not exclude elution of a hybrid epitope as 
the DLQTLALWSRM sequence has been identified in granule-enriched fractions of mouse β-
cell extracts further processed by cleavage with an endoproteinase (Delong et al., 2016). 
Consequently, a cleavage or trimming site within WE14 must exist. It is feasible that an enzyme 
specific to the β-cell granule is capable of cleaving chromogranin A to generate WE14. It is 
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important to note, given the potential generation of peptide species >20 amino acids in length, 
that the full polypeptide sequence was used for PEAKS database searching allowing for any 
peptide derived from this sequence to be identified irrespective of length. Longer peptides are 
generally more difficult to identify by MS however, peptides up to 45 amino acids were 
detected in the current elution dataset. Overall, the data supports the idea that the hybrid 
polypeptide is not efficiently processed to generate a hybrid epitope, largely due to a lack of 
predicted cleavage sites within the WE14 sequence.    
 
Figure 4.15 Susceptibility of C-peptide:WE14 and GAD260-300 sequences to lysosomal 
degradation by cathepsins. Figure shows predicted cleavage sites by cathepsins B, D, L and S 
indicated by coloured vertical bars within the sequence using the program SitePrediction. Only 
cleavage sites with a specificity greater than 95% are shown. Specificity represents the 
probability that a site is a bona fide cleavage site. Amino acids displayed in bold indicate the 
WE14 component of C-peptide:WE14 (left) and the immunodominant 274-286 epitope (right; 
also underlined). PWM, pokeweed mitogen; GAD260-300, amino acids 260-300 from 
glutamic acid decarboxylase (GAD65). 
 
4.11.3 Immunological versus b-cell processing  
It is also possible that the polypeptide species does not require immunological processing but 
processing by the β-cell. Recently, β-cells have been described to have the capacity to secrete 
peptides into the periphery via exocytosis of crinophagic granules (Wan et al., 2018) which 
may or may not require further processing.  
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4.12 Concluding remarks  
In this chapter, novel hybrid epitopes could not be identified by elution of peptide-HLA 
complexes from EBV B cells pulsed with an ADS-delivered hybrid polypeptide. However, 
identification of a pokeweed-derived epitope, nested peptide sets and findings consistent with 
previously reported class II elution data, for example peptide length and binding motif, 
provided evidence of technical success. Later in the chapter, I discuss the possible reasons for 
not being able to elute a hybrid epitope. These include inefficient processing, binding and/or 
the existence of an alternative mechanism of hybrid peptide generation.   
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CHAPTER 5: IMMUNOGENICITY OF HYBRID POLYPEPTIDES  
5.1 Background to the Chapter 
One of the conclusions drawn from the previous chapter was that naturally processed and 
presented epitopes derived from the C-peptide:WE14 polypeptide are not identified by peptide 
elution of ADS-pulsed EBV B cells. Following this, one could hypothesise that hybrid 
polypeptides are not immunogenic. This chapter aims to explore the immunogenicity of hybrid 
polypeptides at the single-cell level by FluoroSpot. Previous literature describing HIP-reactive 
T cells to have a pro-inflammatory phenotype (Baker et al., 2019a; Baker et al., 2018; Baker 
et al., 2019b) prompted me to use a triple-colour assay format, permitting detection of three 
pro-inflammatory cytokines: IFN-g and the Th17 cytokines IL-17A and IL-22 (Liang et al., 
2006).  
 
Enzyme-linked immunospot (ELISpot) and FluoroSpot assays are instrumental technologies 
that have allowed detection of CD4+ T cell responses to native islet autoantigen peptides in 
peripheral blood; with the quality of immune response shown to be different in patients with 
T1D and in HLA-matched controls (Arif et al., 2004). In the case of hybrid peptides, Baker 
and colleagues (2019) demonstrated significantly elevated responses to several HIPs in the 
peripheral blood of T1D patients by IFN-g ELISpot. In contrast, nondiabetic controls did not 
show significantly increased responses to any HIPs, highlighting that T cell responses to hybrid 
peptides are disease-relevant. An assumption of both studies is that the length of the peptides 
tested are such that they bind externally to HLA molecules without processing. Since ADS 
labelling is not 100% efficient allowing for some free peptide to be present during pulsing, it 
is feasible to presume the C-peptide:WE14 polypeptide does not bind HLA directly or else this 
species (or fragments of the polypeptide) would have likely been identified by peptide elution. 
Thus, the main aim of the present study was to evaluate the ability of hybrid polypeptides to 
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be processed and presented by APCs present in cryopreserved peripheral blood mononuclear 
cell (PBMC) samples from newly diagnosed T1D patients (n=20). Control subjects were not 
tested as this piece of work aimed to address immunogenicity, not whether a difference 
between patients with T1D and healthy controls exists. Subjects included in this study are 
described in detail in Table 2.4 (Materials and Methods). 
 
5.2 Design of peptide panel 
Processing of the long C-peptide:WE14 polypeptide was investigated by comparing the 
response to that of a short (14-mer) pre-processed epitope (hEL:ChgA-WE14) shown in Table 
2.2 (Materials and Methods). Of note, the sequence of the hEL:ChgA-WE14 epitope is 
contained within the long C-peptide:WE14 polypeptide. A secondary aim was to consider the 
effect of reversing the orientation of the peptide species within the polypeptide, i.e. instead of 
C-peptide being present at the N-terminus of the polypeptide, it exists at the C-terminus 
(WE14:C-peptide). In this case, the short hEL:ChgA-WE14 epitope is absent from the reversed 
orientation polypeptide. A pre-processed epitope and reversed orientation polypeptide were 
also designed for the C-peptide:IAPP2 polypeptide (termed hEL:IAPP2 and IAPP2:C-peptide) 
and are indicated in Table 2.2.  
 
5.3 Overview of FluoroSpot analysis 
Figure 5.1A presents representative FluoroSpot well images of T cell responses to a long and 
short peptide shown for one patient. Using a cut-off (as defined in Materials and Methods), 
positive responses were identified with one patient (NDB121) found to elicit a response to all 
peptides within the panel with an unusually high magnitude (stimulation index, SI >100) for 
IFN-γ specifically (Figure 5.1B). This is suspected to be a spurious result as autoreactive 
responses do not occur to this level. Subsequently, this patient was excluded from downstream 
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analysis. An overview of the cytokine responses is provided (Figure 5.1C) with specific 
responses being teased out in the succeeding figures. The triple-colour assay determined the 
simultaneous production of IFN-g, IL-17A and IL-22, allowing for double- and triple-secreting 
cells to be enumerated. Dual-secreting cells were sparse following peptide stimulation with 
often only one individual eliciting a positive response to a given peptide. In these rare cases, 
the response was most commonly directed against a short hybrid epitope. Dual and triple-
secretors were present at a far greater frequency in cells stimulated with Infanrix-hexa and 














































Figure 5.1 T cell responses to hybrid (poly)peptides. A triple-colour FluoroSpot analysing the 
production of IFN-g (green spots), IL-17A (red spots) and IL-22 (yellow spots) from T1D-
derived PBMCs in response to peptide/polypeptide stimulation. Representative well images 
are shown for one patient (NDB118) following stimulation with Infanrix-hexa and Candida 
antigen, DMSO peptide diluent, hEL:IAPP2 and C-peptide:IAPP2 (A). The stimulation index 
(SI) for each peptide response per subject is plotted in B. Filled circles represent a positive 
response (SI ≥3; threshold indicated by dotted line) and open circles denote a negative 
response. Data shown for INF-hexa/Can (black) and hybrid (poly)peptides containing WE14 
(blue) or IAPP2 (red). Tringles indicate patient NDB121 considered to be an outlier. Excluding 
NDB121 from analysis, the frequency of IFN-g (red), IL-17A (blue) and IL-22 (green) 
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5.4 Processing of hybrid polypeptides 
To address the question whether hybrid polypeptides receive immunological processing, the 
magnitude and frequency of the polypeptide response was compared to that of the 
corresponding short pre-processed epitope. IFN-g responses to the short 14-mer epitopes 
exhibited a trend toward higher stimulation indices than the polypeptides, particularly 
discernible between C-peptide:WE14 and hEL:ChgA-WE14, although this was not statistically 
significant (Figure 5.2A). A greater prevalence of response to the short epitopes was also 
observed and this reached statistical significance for hEL:ChgA-WE14 (p=0.0463) where no 
patients elicited a positive IFN-g response to C-peptide:WE14 (Figure 5.2B). 16% (3/19) of 
individuals triggered a response characterised by IFN-g secretion against C-peptide:IAPP2 and 
this increased to 21% (4/19) following stimulation with the hEL:IAPP2 epitope. The same 
trends were not however, replicated in the case of IL-17A and IL-22 (Figure 1C). Altogether, 
these data indicate that the short epitopes are immunogenic since they do not require processing 
but bind HLA externally. The polypeptide which contains the short epitope, requires processing 
and this likely results in the generation of fewer peptides, thus providing an explanation for the 
reduced prevalence and magnitude of response. The lack of response to C-peptide:WE14 does 
however suggest either limited processing of this particular species and/or T cells are non-
responsive to the epitopes that are generated. In contrast, C-peptide:IAPP2 is seemingly more 
available for epitope generation although the response is not necessarily the result of T cells 















Figure 5.2 Pre-processed hybrid epitopes elicit a trend toward a greater prevalence and 
magnitude of response. The stimulation index (SI) of responses to the hybrid polypeptides and 
their corresponding 14-mer epitopes has been plotted for IFN-g (A). The dotted line on the 
graph indicates the threshold for a responder (SI ≥3). Paired data was tested for significance 
using Wilcoxon matched pairs test. The number of individuals eliciting a positive IFN-g 
response is indicated in B and a p-value calculated using Fisher's exact test. ns; not significant. 
 
5.5 Reversing the orientation of peptides within the hybrid polypeptide 
To next examine the effect of reversing the orientation of the hybrid polypeptide, the frequency 
of responders to the N-terminal C-peptide polypeptide was compared to that of the reversed 
orientation polypeptide (Figure 5.3). The data show that for IFN-g and IL-22, the number of 
individuals eliciting a positive response was greater following stimulation of PBMCs with 
WE14:C-peptide than with C-peptide:WE14 (Figure 5.3A). For IL-17A, stimulation with 
either the normal or reversed orientation polypeptide triggered an equal number of responders 
for both WE14- (2/19) and IAPP2- (3/19) containing polypeptides. Given that the three 
cytokines tested all represent pro-inflammatory cytokines, total responders can also be 
































































*Chi-square test with Yates correction
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cytokine (Figure 5.3B). In this case, 16% (3/19) of individuals elicited a cytokine response to 
C-peptide:WE14 and this frequency doubled following stimulation with WE14:C-peptide. An 
equal number of total responders (5/19) was observed for C-peptide:IAPP2 and IAPP2:C-
peptide. Taking all the cytokine responses together, the data provide evidence that long hybrid 
















Figure 5.3 Greater frequency of responders to WE14:C-peptide than to C-peptide:WE14. The stimulation index (SI) of responses to the normal 
and reversed orientation hybrid polypeptide has been plotted for all of the cytokines tested (A). The dotted line on the graph indicates the threshold 
for a responder (SI ≥3). The number of individuals eliciting a positive cytokine response is indicated in B and a p-value calculated using Fisher's 





5.6 Assessing T cell responses to left and right peptides 
The presence or absence of shared responses was used to evaluate whether T cell responses to 
the normal and reversed hybrid polypeptides were directed against common regions within the 
sequence e.g. C-peptide (Figure 5.4). In most individuals the response to either the normal or 
reversed orientation polypeptide was dominated by one cytokine, with the production of IFN-
g not necessarily accompanied by the production of IL-17A and/or IL-22. No shared responses 
were observed if the hybrid polypeptide contained WE14, however two individuals (G832 and 
NDB118) elicited a shared response to IAPP2-containing hybrid polypeptides. G832 mounts a 
positive IL-17A response to both the normal (C-peptide:IAPP2) and reversed (IAPP2:C-
peptide) polypeptide, whereas NDB118 responds to the N-terminal C-peptide polypeptide to 
produce IL-17A and IFN-g. In the reversed orientation, NDB118 elicited a positive response 
for all three cytokines. The rarity of shared responses between normal and reversed hybrid 
polypeptides, formally shown by a lack of statistical significance (C-peptide:WE14 versus 
WE14:C-peptide, p=0.5170; C-peptide:IAPP2 versus IAPP2-C-peptide, p=0.5696) suggests 
that the T cell response is not directed against the C-peptide or WE14/IAPP2 region but likely 
against peptides being exclusive to either of these hybrid polypeptides. It could therefore be 
speculated that in both cases responses are directed against an epitope that contains residues of 









Figure 5.4 Shared responses between N-terminal C-peptide and reversed orientation hybrid 
polypeptides are rare. PBMCs from nineteen T1D patients were stimulated with either a N-
terminal C-peptide or reversed orientation hybrid polypeptide. WE14- and IAPP2-containing 
polypeptides are indicated by blue and red, respectively. Filled rectangles represent a positive 
response (SI ≥3) measured through production of IFN-g, IL-17A and IL-22. A p-value was 
calculated (Fisher’s exact test) for comparing responses to the two long peptides using a 2x2 
contingency table containing a matrix of responders and non-responders. A responder was 
defined by a SI ≥3 for at least one of the cytokines. SI, stimulation index. 
 
5.7 Evaluating processing of a polypeptide as a mechanism of hybrid epitope generation 
Shared responses between the long hybrid polypeptide and the short hybrid epitope can be an 
indication of whether processing of the hybrid polypeptide generates the hybrid epitope (Figure 
5.5). If the hybrid epitope is indeed generated, where a response to the shortened peptide 
epitope is observed one would also expect to see a response to the long polypeptide. 60% (3/5) 
of patients responding to hEL:ChgA-WE14 elicit a cytokine response which is exclusive to the 
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short epitope i.e. they do not mount a response to C-peptide:WE14. Similarly, 63% (5/8) of 
individuals triggered a positive cytokine response to hEL:IAPP2 but this did not coincide with 
a response to C-peptide:IAPP2. The lack of statistical significance between the two groups (C-
peptide:WE14 versus hEL:ChgA-WE14, p=0.1548; C-peptide:IAPP2 versus hEL:IAPP2, 
p=0.6027) provides further confidence in deducing that a response to the hybrid polypeptide 
does not always parallel a response to the short hybrid epitope. A reasonable interpretation of 
this is that immunological processing and presentation of a hybrid polypeptide to generate the 
short hybrid epitope is insufficient which does not reach the threshold for T cell activation. 
Notably, a few patients (G732, G695 and G733) respond to the long polypeptide but not the 
short epitope. In this case, processing of the hybrid polypeptide may generate non-hybrid 
epitopes which are targeted or other epitopes wherein the hybrid contributes but in a different 









Figure 5.5 A response to the hybrid polypeptide does not always coincide with a response to 
the short hybrid epitope. PBMCs from nineteen T1D patients were stimulated with either a 
hybrid polypeptide or a short hybrid epitope. WE14- and IAPP2-containing peptides are 
indicated by blue and red, respectively. Filled rectangles represent a positive response (SI ≥3) 
measured through production of IFN-g, IL-17A and IL-22. A p-value was calculated (Fisher’s 
exact test) for comparing responses to the short and long peptide using a 2x2 contingency table 
containing a matrix of responders and non-responders. A responder was defined by a SI ≥3 for 
at least one of the cytokines. SI, stimulation index. 
 
5.8 HLA-unrestricted responses to hybrid species  
A tempting notion is that patients responding to the long polypeptide but not the short, bear a 
distinctive HLA haplotype. This was investigated by correlating the cytokine response to the 
hybrid polypeptide (normal and reversed) and the shorter hybrid epitope with the HLA 
haplotype of the patient cohort (Figure 5.6). The HLA genotype of patients eliciting a response 
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to the long but not the short hybrid epitope was also found to be present in individuals 
responding to both peptides. Similarly, no clear correlation with HLA haplotype was observed 
for individuals responding exclusively to either the normal or reversed hybrid polypeptide. The 
absence of any correlation is likely because the dataset is of insufficient size, making responses 
few and far between. Any possible HLA restriction could be more accurately determined using 
tetramers loaded with hybrid polypeptides. Bearing in mind that Delong et al. (2016) reported 
responses to hybrid peptides were HLA-DQ8-restricted, it was however interesting to find in 
the current study that responses also occurred in non-DQ8 individuals. For example, five 
patients responded to hEL:ChgA-WE14, three of which had -DQ2 haplotypes, which might be 
explained in part by the shared features of HLA-DQ2 and -DQ8 binding motifs (Godkin et al., 
1997). Overall, the data suggest the existence of additional factors bedsides HLA haplotype 




















Figure 5.6 Responses are not limited to individuals carrying the HLA-DQ8 haplotype. PBMCs 
from nineteen T1D patients were stimulated with either a N-terminal C-peptide polypeptide, 
reversed orientation polypeptide or a short hybrid epitope. WE14- and IAPP2-containing 
peptides are indicated by blue and red, respectively. Filled rectangles represent a positive 
cytokine response defined by a SI ≥3 for at least one of the cytokines: IFN-g, IL-17A and IL-
22. The HLA-DR and -DQ haplotype of each patient is indicated by the black squares. SI, 
stimulation index. 
 
5.9 Binding and core sequence prediction of reversed hybrid polypeptides 
A yet unexplored finding of the current study is the increased frequency of responders to the 
WE14:C-peptide polypeptide compared with the N-terminal C-peptide polypeptide (C-
peptide:WE14). To explore why this might be the case, overlapping 15-mers (offset by one 
residue) of the normal and reversed orientation polypeptides were designed and their binding 
affinity to HLA-DQ8 and -DQ2 assessed using the NetMHCII 2.3 algorithm. The algorithm 
identifies strong and weak binders with a percentile rank of <2 and <10, respectively. Non-
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binders are assigned a percentile rank of ≥10. Of the twenty-six overlapping peptides of C-
peptide:WE14, none were predicted to be strong binders to HLA-DQ2 whereas four 
overlapping peptides of WE14:C-peptide were predicted to bind with high affinity (Figure 5.7). 
Similarly, peptides spanning C-peptide:IAPP2 contained no strong binders to HLA-DQ2 while 
five of the IAPP2:C-peptide overlapping peptides were predicted to be strong binders. This 
observation was also true for binding to HLA-DQ8, where peptides overlapping the reversed 
orientation polypeptide contained a larger number of strong (and weak) binders than the N-
terminal C-peptide polypeptide. Altogether, the reversed hybrid polypeptides were predicted 
to harbour a greater number of candidate binders to T1D-associated HLA-DQ alleles than N-
terminal C-peptide hybrid polypeptides. These findings may, in part, explain the increased 
frequency of responders to the WE14:C-peptide polypeptide.  
Figure 5.7 Overlapping peptides spanning the reversed hybrid polypeptide sequence contain 
more candidate binders to HLA-DQ2/8. Binding of overlapping 15-mer peptides spanning N-
terminal C-peptide and reversed hybrid polypeptides to HLA-DQ8 (bottom) and -DQ2 (top). 
Binding affinity was predicted using the NetMHCII 2.3 algorithm to compute a percentile rank 
(% rank) and peptides characterised as strong (% rank <2, red), weak (% rank <10, blue) or 
non-binders (% rank ≥10, white). The pie chart reflects the relative number of peptides in each 
group. Overlapping peptides were offset by one residue.  
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To investigate whether the increased binding capacity of the reversed hybrid polypeptides is 
mediated by residues from both peptide species (i.e. C-peptide and WE14/IAPP2), the core 
binding sequence of each overlapping 15-mer was determined (Figure 5.8). The results show 
for HLA-DQ2, the core sequences of binders (strong and weak) exclusively contain the hybrid 
junction (Figure 5.8A, C). The binding core of strong binders to HLA-DQ8 incorporate only 
the C-peptide region however, the majority of weak -DQ8 binders were predicted to have a 
binding core containing residues of the hybrid junction (Figure 5.8B, D). These data indicate 
the enhanced binding capacity of the reversed polypeptides relative to the normal orientation, 
particularly for binding to HLA-DQ2, is due to the altered sequence of amino acids at the 










































Figure 5.8 Predicted binding cores of reversed polypeptides contain the intersection of the two 
granule peptides. Binding cores of overlapping 15-mer peptides spanning reversed polypeptide 
sequences (WE14:C-peptide, top; IAPP2:C-peptide, bottom) predicted to bind HLA-DQ8 (B 
and D) and -DQ2 (A and C). Binding affinity (% rank) and core sequences of 15-mer peptides 
were predicted using the NetMHCII 2.3 algorithm. Only overlapping peptides with core 
sequences predicted to bind with strong or weak affinity (% rank <10) are shown. Bold 
indicates the core sequence of overlapping peptides predicted to bind with high affinity (% 
rank <2). AA, amino acid. 
 
5.10 Concluding remarks  
The data presented in this chapter suggests that hybrid polypeptides can be immunogenic, 




explain why naturally processed hybrid peptides were not identified in the elution study 
(Chapter 4). The numerous APC populations present in PBMCs including 
monocytes/macrophages and DCs, may account for the discrepancy between the lack of 
epitopes identified by elution of polypeptide-pulsed B cells and the low-level reactivity 
observed in the FluoroSpot assay. Interestingly, reversing the orientation of peptides within the 
hybrid polypeptide renders the reversed sequence particularly immunogenic. Here I present 
evidence to suggest that this could be due to an enhancement of binding to HLA-DQ. It is 
noteworthy that not all cells following activation by their cognate peptide may release (the 
selected) cytokines and some may not become “functional cytokine secretors” but rather just 
proliferate. T cell assays based on proliferation (CFSE) or flow cytometric analysis of 
activation markers (e.g. CD154) may therefore provide additional information. Multimers 
could also be useful for characterisation of peptide-specific CD4+ T cells directly ex vivo 
(Holland et al., 2015). 
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CHAPTER 6: DISCUSSION  
6.1 Research question, methods employed and how this integrates into current knowledge 
In this thesis I have investigated whether natural processing of a long hybrid polypeptide within 
an antigen-presenting cell is required for generation of the C-peptide:WE14 hybrid epitope. To 
address this question, I explored: antigen delivery, whether the epitope is naturally processed 
and presented and whether hybrid polypeptides can elicit immune responses. This particular 
polypeptide species was selected as data available in the NOD mouse prior to commencing my 
PhD identified a C-peptide:WE14 epitope in fractions of b-cell tumour lysates (Delong et al., 
2016). T cell responses against the equivalent human epitope sequence are also present in T1D 
patients (Baker et al., 2019b). Moreover, unpublished data from a collaborator (Peakman & 
Purcell) identified a putative peptide in the human islet proteome containing C-peptide fused 
to WE14. I generate two lines of evidence, in an in vitro system and an ex vivo stimulation 
setting, to suggest that for this particular epitope a long hybrid polypeptide does not appear to 
be processed and presented in order to elicit a T cell response.  
 
The research question outlined above is important because the role of hybrid peptides in T1D 
has attracted considerable attention over recent years. However, much of the data currently 
available involves unsystematic generation of hybrid peptides and identification of a 
corresponding T cell response, for example the insulin-insulin hybrid peptide described by 
Wang et al. (2019). Like many other studies, information relating to such hybrids is functional 
and is not based on “hard” evidence such as elution from HLA or APCs. Evidence to indicate 
that antigen-presenting cells are necessary for the generation and presentation of hybrid 
epitopes is lacking as is the nature of the precise region of the epitope(s) involved in TCR 
recognition. To date, evidence suggesting that hybrid peptide specific T cell clones target the 
intersection of the two peptides is not conclusive. Thus, the question remains whether hybrid 
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peptides are key targets in the pathogenesis of T1D, either eliciting a different set of T cell 
responses or representing an amplification of the T cell response against conventional epitopes 
(Harbige et al., 2017). The latter is likely to be characterised by higher peptide-HLA binding 
affinity of hybrid peptides over native sequences. If this is the case, it is consistent with reports 
that T cell responses to hybrid peptides may be stronger (e.g. cytokine production) when 
compared with responses to the corresponding conventional epitope (Delong et al., 2016; Wang 
et al., 2019). 
 
6.2 Chapter 3: Lectin-based antigen delivery system 
In the first section of this thesis I established a working antigen delivery system to identify an 
optimal route of antigen delivery for a polypeptide into an antigen-presenting cell. Using this 
antigen delivery system, which is arguably not the natural method of antigen acquisition, I 
explored whether a polypeptide antigen could efficiently deliver peptide epitopes for 
presentation in a manner that enables T cell recognition and is amenable to upscaling. 
 
I generated two antigen delivery systems by conjugation of synthetic peptides to pokeweed 
mitogen or anti-DEC205 antibody. Data support that the pokeweed-based ADS method I have 
optimised is working as the method yielded successful delivery of the key epitope of a 
GAD65(274-286)-containing 41-mer peptide into EBV B cells for processing. The result is 
presentation of the GAD65(274-286) epitope shown using the T33 T cell hybridoma which 
recognises this epitope in the context of HLA-DR4 (Wicker et al., 1996). Similar experiments 
performed using pokeweed mitogen covalently linked to whole GAD65 antigen observed a T 
cell response comparable to my data and mass spectrometry also identified GAD65(274) 
peptides (Peakman, unpublished). Thus, the level of T cell response I observe would allow 
mass spectrometry to identify peptides. Delivery of the GAD65(274-286)-containing peptide 
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by targeting DEC205 did not yield a T cell response inconsistent with a previous report by 
Leung and colleagues (2013). In contrast to my study, the authors utilised whole EBV antigen 
which was not conjugated but rather fused to the anti-DEC05 antibody and this might explain 
the discrepancy. Had there been an experimental requirement, for example if pokeweed-based 
antigen delivery failed, it would have been useful to extend the studies with DEC205-mediated 
delivery further, for example by developing a system to generate a fusion antibody with the 
synthetic peptide attached at the C-terminus of the anti-DEC205 antibody, although such an 
approach would have been a challenge for upscaling.   
 
The antigen delivery routes of pokeweed mitogen are not clearly defined as yet but may be an 
important determinant of peptide presentation (Cohn et al., 2013). Since pokeweed mitogen 
targets cell surface receptors, most likely the epitopes which are presented derive from one 
specific antigen processing route and this route may not result in presentation of certain 
epitopes. There are multiple routes by which an APC can acquire antigen, namely; 
macropinocytosis, receptor-mediated endocytosis, phagocytosis and autophagy (Roche and 
Furuta, 2015). Evidence suggests that in DCs and macrophages, the mechanism of uptake of 
soluble hen egg-white lysozyme (HEL) favours rapid entry into late endosomes but antigen 
does not remain in early endosomes for sufficient time to allow processing and cross-
presentation (Belizaire and Unanue, 2009). This feature of trafficking also hindered MHC class 
II presentation of type B epitopes, which are generated exclusively in early endosomes (Lovitch 
and Unanue, 2005). These data suggest that the route of uptake can influence the epitope 
repertoire that is generated. Regarding the route employed by a pokeweed-based ADS, and 
how relevant the downstream peptide repertoire is compared to DCs (considered to be the most 
efficient professional APC (Guéry and Adorini, 1995)]) operating in the inflammatory 
environment of the pancreas or related lymph nodes is unknown.  
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As I have already alluded to, the mode of antigen delivery dictates trafficking through different 
intracellular compartments. Pokeweed mitogen binds preferentially to carbohydrate moieties 
on cell surface receptors with immunoglobulin-like domains (Chilson and Kelly-Chilson, 
1989), consequently binding a multitude of different membrane proteins on the APC. These 
membrane receptors enter the endocytic recycling pathway culminating in the movement of 
the cargo from the early endosome to the endocytic recycling compartment (ERC) (Grant and 
Donaldson, 2009). From the ERC the cargo is delivered back to the cell surface via recycling 
endosomes. Only some of the cargo is selected in the early endosome to be delivered onto late 
endosomes. Whereas, in the case of phagocytic uptake, a nascent phagosome sequentially fuses 
with early (sorting) endosomes, late endosomes, and eventually lysosomes to form a 
phagolysosome (Gordon, 2016). Despite the shared involvement of the late endosome in the 
receptor recycling and phagocytic pathways, in general cargos in the phagocytic pathway are 
trafficked to different organelles than normal receptor recycling. It is therefore possible that 
the ADS could be diverting some of the polypeptide cargo to other pathways and not entering 
the antigen presentation route.  
 
Restricting antigen delivery to a specific APC surface molecule can favour delivery into 
compartments equipped for processing and peptide loading. If one would have targeted only 
the BCR (Stevens and Peakman, 1998) this would have given confidence that the system is 
antigen specific however, it is known that following receptor ligation a proportion of BCRs are 
selectively retained at the cell surface (Hou et al., 2006) and do not feed into the same route 
which is favouring antigen presentation. Alternatively, complement receptor-targeted 
compartments also contain MHC II for peptide loading, albeit less than BCR-targeted 
compartments (Perrin-Cocon et al., 2004). Furthermore, efficient antigen presentation requires 
B cell activation (Kakiuchi et al., 1983) and although EBV infection induces expression of B 
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cell activation markers (Calender et al., 1987), it is not clear whether the activation status of 
EBV-immortalised B cells is optimal for presentation.  
 
6.3 Chapter 4: Identification of HLA-associated naturally processed and presented 
epitopes  
In chapter four I investigated whether epitopes from the C-peptide:WE14 polypeptide are 
naturally processed and presented by class II T1D-risk haplotypes. I did this by pulsing EBV 
B cells with pokeweed mitogen conjugated to the C-peptide:WE14 polypeptide (ADS 
established in chapter three) and used mass spectrometry to identify peptide epitopes.  
 
Uptake and processing of exogenous proteins was evident, but more important was the 
identification of a pokeweed-derived peptide presented by HLA-DQ8. This finding indicates 
that the ADS enters the class II presentation pathway but is also a target for presenting naturally 
processed epitopes derived from the ADS system. However, I was unable to identify a hybrid 
epitope bound to HLA and consequently, in my experimental setting I do not have evidence 
that the polypeptide species is naturally processed and presented to generate a minimal hybrid 
epitope. Nonetheless, one might be able to use other antigen deliveries or other methods to 
evaluate whether this epitope is presented naturally for example, targeting of DEC205. As 
mentioned previously, delivery of a GAD65(274-286)-containing 41-mer by targeting 
DEC205 did not result in peptide presentation but there is the possibility that this delivery 
method may have been successful for the hybrid polypeptide. Theoretically, it would also be 
conceivable to deliver the C-peptide:WE14 ADS to EBV B cells and co-culture with a T cell 
clone which recognises the SLQPLAL-WSKMDQL epitope to further evaluate whether this 
epitope can be naturally processed from the polypeptide species. A T cell clone against this 
particular insulin-WE14 hybrid epitope is currently unavailable and ideally, the T cell clone 
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used in the aforementioned experiment would be isolated from the pancreatic islets of T1D 
patients as described by (Michels et al., 2017) and (Babon et al., 2016).  
 
Currently, I conclude that the C-peptide:WE14 polypeptide is not naturally processed and 
presented but there are important caveats to contemplate. It might well be that it is processed 
and presented for example, taking into consideration that the amount of polypeptide present on 
the cell surface after pulsing may be lower than that of the ADS containing the GAD65(274-
286) epitope (Figure 3.6B and 4.1A). In this way, the assay may be limiting the amount of 
peptide available for processing. Therefore, despite the efficiency of the ADS, from the start 
the odds were stacked against identifying an epitope derived from the polypeptide because 
there was less peptide starting material being delivered into the APC. To illustrate this further, 
it is important to highlight the five steps of antigen processing: capture, internalisation, 
processing, loading and export of peptide-HLA complexes to the cell surface (Neefjes et al., 
2011). Using these five steps it is feasible to consider the differences between the GAD65(274-
286)-containing ADS, which I have data to show is working well and the hybrid polypeptide 
ADS. Internalisation and export of peptide-HLA complexes to the cell surface are likely the 
same whereas differences may theoretically arise in the amount of peptide captured at the cell 
surface, loading of the processed peptides onto HLA molecules due to HLA binding affinities 
and processing of the two peptide species. Regarding the latter, I have generated data in silico 
to suggest that the C-peptide:WE14 polypeptide lacks candidate protease cleavage sites which 
may be important in deriving a hybrid epitope. Furthermore, given previous emphasis on the 
route of uptake one cannot exclude that a naturally processed hybrid epitope may be generated 
if the hybrid polypeptide was taken up into the APC via an alternative route.    
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Consistent with my data, evidence from the literature also suggests the C-peptide:WE14 HIP 
may not exist in the immunopeptidome. Despite being previously identified by (Delong et al., 
2016) a recent publication by (Wan et al., 2020) could not identify the C-peptide:WE14 
(LQTLAL-WSRMD) HIP in the cell surface MHC II immunopeptidome of pancreatic islets of 
NOD mice. Notwithstanding that b-cells from NOD mice may express MHC class II (IA-g7) 
(Walter et al., 2003; Zhao et al., 2015), (Wan et al., 2020) claim not that the islets present these 
epitopes but that the species that are eluted derive from MHC class II molecules present on 
APCs (macrophages and dendritic cells) within the islet. Although the authors are unable to 
identify the C-peptide:WE14 HIP and state that it may below the detection threshold, they are 
able to identify a C-peptide:IAPP2 HIP (LQTLAL-NAARD) in the MHC II peptidome. This 
finding would suggest that the C-peptide:WE14 HIP may be difficult to generate either because 
this particular epitope is not processed in the APC and/or it is not very prevalent in the 
crinosome (a candidate organelle for HIP formation) so is not available as a substrate. Indeed, 
a previous report did not identify the C-peptide:WE14 HIP species in the crinosome of 
pancreatic b-cells of NOD mice (Wan et al., 2018). If the C-peptide:WE14 HIP is not being 
generated in the islets its identification by (Delong et al., 2016) may be exclusive to the 
insulinoma cell line in which it was discovered. Nevertheless, the findings of (Wan et al., 2020) 
lend support to the notion identifying a naturally processed WE14-containing hybrid epitope 
bound to HLA may be challenging for a number of reasons. Most probably, a lack of or limited 
presentation of the C-peptide:WE14 epitope in APCs would also reduce the likelihood of a T 
cell response being elicited.  
 
The identification of epitopes presented at the cell surface is to some extent determined by a 
hierarchy of available peptides. Evidence by (Wan et al., 2020) would suggest that hybrid 
peptides are present at very low abundance in the MHC II peptidome of islets and pancreatic 
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lymph nodes, representing less than 1% of the total peptidome in each case. This is in contrast 
to the initial findings of (Delong et al., 2016) in which the C-peptide:WE14 epitope is dominant 
in antigenic b-cell fractions, and it is suggested that molecular crowding within the b-cell might 
favour hybrid peptide generation. Knowing the former data, the C-peptide:WE14 peptide may 
not be ideal for use in the approaches I have been employing. The C-peptide:IAPP2 species 
however appears to be a strong HIP candidate as it has been identified both in the crinosome 
(Wan et al., 2018) and the class II immunopeptidome (Wan et al., 2020). It is possible that 
other HIPs are generated but because of their sequence motifs are rapidly cleaved/degraded, 
and hence are not very frequent in the class II immunopeptidome. The C-peptide:IAPP2 HIP 
may pose an exception, generating a hybrid intersection which is not targeted by other 
proteases. Similar experiments performed in chapter four could be employed for the C-
peptide:IAPP2 HIP to investigate whether a naturally processed epitope can be generated from 
APCs. Whole blood assays using overlapping peptides and the generation of T cell lines/clones 
could be an alternative approach to identifying NPPEs. However, this merely shows whether 
T cells capable of responding to a specified peptide exist but does not provide proof that a 
peptide is in fact naturally processed and presented. This information can only be obtained by 
direct elution from class II HLA molecules. 
 
6.4 Chapter 5: Peripheral blood reactivity to hybrid polypeptides 
Using triple-colour FluoroSpot I set out to investigate whether immune responses against 
hybrid polypeptides can be identified in T1D patients. The questions addressed by comparing 
responses between the short epitope and the long hybrid polypeptide were firstly, whether the 
hybrid epitope is generated by processing of the hybrid polypeptide and secondly, whether it 
elicits a T cell response as a result. Because the TCR repertoire within a PBMC culture is 
diverse (Warren et al., 2011), some of which may be pre-activated, it is difficult to argue that 
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a response against the short and long version in the same individual is due to the same TCR 
specificity which recognises both. To do so would require a T cell clone of single specificity 
to assess whether it responds to the long and short versions in the same way.  
 
I have generated data to show low-level reactivity against the C-peptide:WE14 polypeptide 
and in individuals which respond to the short hybrid epitope, not all of them elicit a response 
against the long polypeptide. This suggests that the short epitope is not easily generated from 
the long polypeptide. This finding was reproduced with another hybrid polypeptide, C-
peptide:IAPP2 albeit responses were more frequent and it is possible that this may be 
attributable to differences in the binding capacity of WE14 versus IAPP2. WE14 does not bind 
well into the MHC class II binding groove (Stadinski et al., 2010a) whereas peptides derived 
from IAPP might bind better (Baker et al., 2013). In this case it is important to refer back to 
the five steps of antigen processing; these data indicate uptake, processing or presentation of 
long hybrid polypeptides is limited and/or inefficient and does not lead to the same peptide 
binding as is the case for the shortened epitope. As uptake represents a key step, the route by 
which APCs acquire the polypeptide in the FluoroSpot system is likely the more 
physiologically relevant route compared with using an ADS. However, few patients elicited a 
positive cytokine response to the C-peptide:WE14 polypeptide and equally in the ADS system, 
which utilised a different route of uptake, a C-peptide:WE14 hybrid epitope was not eluted.  
 
Evidence exists suggesting that long peptides can potentially bypass the need for processing. 
Namely, (Wan et al., 2020) showed that 29-mer peptides can be eluted from APCs and do not 
require intracellular processing. While the hybrid polypeptides used in my FluoroSpot assays 
are longer than 29 amino acid residues, potentially an argument could be made that they bind 
the cell surface without needing processing. Although there is evidence to suggest that peptides 
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do not have to go through the internalisation processing pathway, data does not exist to exclude 
that this is still a crucial pathway operative within the assay. Indeed, the C-peptide:WE14 
polypeptide species needs processing to elicit a T cell response. This can be reasoned because 
conjugation of pokeweed mitogen to C-peptide:WE14 in the ADS is not 100% efficient, thus 
I would expect free unconjugated peptide to be present during pulsing. If unconjugated peptide 
was in fact available for direct binding to HLA, it is technically feasible that I would be able 
to detect these peptides (as the LC-MS/MS technique used detects peptides up to 45 amino 
acids long and the test polypeptide was 41 amino acids).  
 
I also found that the orientation of the hybrid polypeptide influences the immune response. 
Further, I was interested in understanding why changes in the orientation of the polypeptide 
lead to a greater prevalence of responses. Hybrid polypeptides comprise either the normal 
orientation (C-peptide:WE14) or the reversed orientation (WE14:C-peptide). Using a 
predictive algorithm, I generate data to show that the binding cores of reversed orientation 
polypeptides contain the intersection of the two granule peptides. Under natural circumstances, 
a natural cleavage product of ChgA is the WE14 sequence (WSKMDQLAKELTAE) (Orr et 
al., 2002). Consequently, the N-terminal region of this species is inevitably present and 
providing C-peptide is cleaved at the C-terminus, a reaction between the two species could 
potentially occur and a N-terminal C-peptide (SLQPLAL-WSKMDQL) epitope is generated. 
To generate an epitope in the reverse orientation (WSKMDQL-SLQPLAL) ChgA would need 
to be cleaved not at the natural cleavage site, but internally within the WE14 sequence and 
likewise the case for C-peptide. Cleavage within the WE14 and C-peptide sequence may not 
occur at the same rate as the conventional cleavage site (Muller et al., 2009). Therefore, the 
availability of both peptides at the same time for a reaction to occur would be lower. Unless 
such epitopes are generated at a later stage during degradation, it is then less likely that the 
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reversed orientation epitope is presented leading to reduced opportunity for tolerance 
induction. To further establish the region of the reversed hybrid polypeptide that is targeted, it 
would be necessary to also test the short-reversed hybrid epitopes by for example, IFN-g 
ELISpot. 
 
I have some evidence from my FluoroSpot data that the C-peptide:WE14 polypeptide is 
capable of eliciting a T cell response which suggests there is some degree of in vivo processing. 
Nevertheless, I have been unable to show the C-peptide:WE14 polypeptide is processed 
naturally in my setting. I generate data to indicate that T cells which recognise the C-
peptide:WE14 polypeptide are present in a few individuals, but it is possible that those T cells 
could also be specific for other unrelated targets, as a result of TCR promiscuity (Wooldridge 
et al., 2012). Sequences of both the normal and reversed orientation hybrid polypeptides could 
mimic the sequence of a pathogen, for example. However, no significant similarly to amino 
acid sequences present in the proteome of bacteria, archaea and viruses was identified using 
the National Centre for Biotechnology Information (NCBI) BLAST server and the Virus 
Pathogen Database and Analysis Resource (ViPR) (Pickett et al., 2012). 
 
Non-disease controls were not included in this study and therefore I do not have evidence to 
suggest the observed response is specific to disease. Accordingly, the data presented does not 
support the notion that the C-peptide:WE14 hybrid polypeptide is processed and presented and 
might therefore be disease-relevant. If one wanted to investigate whether responses to hybrid 
(poly)peptides are disease-relevant, a larger cohort of patients and matched controls would be 
required but this was beyond the scope of the project. Assuming 0% of responders in controls 
and 20% in patients (based on (Baker et al., 2019b); 2/11 respond to hEL:ChgA-WE14 
[SLQPLAL-WSKMDQL] epitope) a sample size of 32 in each group would be necessary to 
 166 
detect significant differences in the prevalence of responses with 80% power. Furthermore, 
from my data I cannot make conclusions regarding whether responses to hybrid (poly)peptides 
are more prevalent and/or of greater magnitude in T1D patients compared to other naturally 
processed epitopes restricted by the same HLA class II molecule.  
 
6.5 Implications of thesis findings on the disease model 
Overall the data would suggest that hybrid epitopes are not generated through conventional 
processing and presentation of a long hybrid polypeptide. It is possible that shorter fragments 
are being generated and then they are being fused, and this is likely happening within β-cells. 
Indeed, a model of unconventional epitope generation within the β-cell has been proposed 
based on the observation that the β-cell has the capacity to secrete peptides into the periphery 
which may or may not require further processing (Wan et al., 2018). The subcellular location 
within the β-cell where hybrid peptides are generated is still not clear but granular 
compartments such as the lysosome (Wang et al., 2019), crinosome (Wan et al., 2018) or 
insulin granule (Delong et al., 2016) are candidate organelles. Besides the proteasome, other 
proteases such as asparaginyl endoprotease (AEP) are known to catalyse transpeptidation, and 
in particular, the human homolog of AEP which is also involved in the generation of class II-
restricted epitopes (Manoury et al., 1998). Normal or stress-induced turnover of granules by 
crinophagy (Sandberg and Borg, 2006; Sobota et al., 2009) represents an attractive conduit to 
hybrid peptide formation as such crinosomes contain proteolytic enzymes derived from both 
lysosomes and aged insulin granules. How efficiently such proteases perform this reaction 
relative to the proteasome, which has several characteristics that favour catalysis of peptide 
splicing (Liepe et al., 2010) is not understood.  
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The question then remains how hybrid peptides are delivered into the class II pathway. Low 
binding affinity of CLIP to IA-g7, owing to the non–aspartic acid residue at position 57, 
permits spontaneous replacement of CLIP at the cell surface by extracellular peptides (Ito et 
al., 2018). In the context of HLA-DQ2 and -DQ8, both of which share the β57 polymorphism 
in the binding pocket with IA-g7 (Todd et al., 1987), low affinity binding of CLIP to these 
molecules has also been shown (Fallang et al., 2008; Reed et al., 1997; Wiesner et al., 2008). 
For this reason, extracellular replacement of CLIP bound to HLA-DQ2/8 molecules may also 
be operative. Together with the findings of (Wan et al., 2020) whereby use of an 
endocytic/processing inhibitor still lead to loading of long MHC II peptides on the cell surface, 
these studies suggest that there is pathway that allows for epitopes to access HLA class II 
molecules without the need for internalisation and processing.  
 
Using this knowledge, the model emerging is that within the b-cell processing is occurring, 
pre-processed peptides are secreted and can be directly loaded onto HLA molecules on the 
surface of APCs e.g. DCs (Figure 6.1A, B). Evidence in the NOD mouse suggests the 
concentration of epitopes within the peripheral lymph nodes draining the islet, is high enough 
to be presented by APCs and interact with T cells (Wan et al., 2018). Currently it is unclear 
whether this is also true for humans, but certainly within the lymph node itself close to the islet 
there is a high concentration of secreted peptides which may promote extracellular peptide 
displacement at the cell surface. Furthermore, the model implies that for cell surface 
displacement of HLA-DQ2 and -DQ8 molecules, extracellular peptides would need to possess 
a high binding affinity (Delong et al., 2016; Ito et al., 2018). This would suggest a selection 
process exists whereby only peptides with medium-to-high affinity will gain access to the HLA 










Figure 6.1 Different modes of antigen processing. Within an APC a polypeptide is taken up 
into endosomal compartments, processed into peptides and loaded onto HLA molecules (A). 
Peptide-HLA complexes are subsequently transported to the cell surface. The b-cell can 
process insulin peptides within the crinosome () formed by the fusion of lysosomes and aged 
insulin granules, but also within the secretory granule () (observation in Peakman lab). In 
either event, these peptides are released and can bind HLA molecules by extracellular 
displacement (B). APC, antigen-presenting cell; HLA, human leukocyte antigen. 
 
An attractive concept of the model is that there is disease relevance in HLA-DQ2 and -DQ8 
over other class II molecules. Specifically, the mode of antigen acquisition to HLA might 
distinguish where these hybrid peptides are more relevant. Although evidence exists that HIPs 
can be HLA-DR-restricted (Baker et al., 2019b), rapid CLIP dissociation has only been 
reported to occur for IA-g7 due to the b57 polymorphism (Ito et al., 2018) which is structurally 
similar to HLA-DQ8 and -DQ2 (Lee et al., 2001). Therefore, the acquisition of hybrid peptides 
into HLA-DR, or any other HLA class II molecule for that matter, is probably restricted by the 
notion that CLIP binds relatively strong (Amicosante et al., 2009; Hotzel and Koch, 1996) 
making peptide exchange difficult to accomplish. Thus, HLA-DQ is likely the most relevant 
HLA class II molecule to acquire hybrid peptides in the unconventional generation pathway. 
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6.6 Future outlook  
This thesis aimed to understand how a hybrid epitope can be derived and points toward an 
unconventional mechanism of generation. Immune responses against hybrid peptides have 
been described in the peripheral blood (Baker et al., 2019b), but in this thesis I do not have 
evidence to suggest that they are naturally processed and presented from a long polypeptide in 
an antigen-presenting cell. Therefore, the b-cell is the most likely origin of hybrid peptides and 
future discovery of hybrid epitopes should focus on the peptide repertoire on APCs under 
conditions where they have the opportunity to take up those hybrid peptides. Chapter four 
would suggest that further studies should utilise broader and more complex methodologies for 
example, different routes of antigen delivery into the APC and/or other APCs aside from B 
cells, to interrogate the HIP landscape more deeply. The jury is still out as to whether hybrid 
peptides are key drivers or initiators of disease. At least for the hybrid peptides identified so 
far, I would not predict that responses to hybrid peptides are a key driver of disease since they 
do not appear to elicit a higher prevalence or magnitude of response than that of other disease-
relevant epitopes (Peakman, unpublished). Studying at-risk individuals before any overt signs 
of autoimmunity and following its progression in parallel with measurement of immune 
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